var title_f12_51_13104="Vert collapse sickle cell";
var content_f12_51_13104=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F68218&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F68218&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 537px\">",
"   <div class=\"ttl\">",
"    Vertebral body collapse in sickle cell disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 517px; height: 248px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Posterior-anterior (left photo) and lateral chest radiographs (right photo) of a patient with sickle cell disease (Hb SS) demonstrate collapse of several vertebral bodies, with a typical biconcave shape to each collapsed vertebral body (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_51_13104=[""].join("\n");
var outline_f12_51_13104=null;
var title_f12_51_13105="Parotid gland sialectasis MRI";
var content_f12_51_13105=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F80648&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F80648&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Parotid enlargement in Sj&ouml;gren's syndrome on MRI",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 353px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    MRI coronal STIR sequence shows markedly enlarged parotids with irregular signal pattern. A number of globular high signal areas are seen bilaterally, particularly on the left (arrows), representing fluid-filled, sialectatic cavities.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Creamer, MD, MRCP.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_51_13105=[""].join("\n");
var outline_f12_51_13105=null;
var title_f12_51_13106="Dextro type of transposition of the great arteries";
var content_f12_51_13106=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F68589&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F68589&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Diagram of the dextro type of transposition of the great arteries",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 336px; height: 441px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Diagram of the dextro type of transposition of the great arteries showing the abnormal position of the aorta (Ao) and the pulmonary artery (PA).",
"    <div class=\"footnotes\">",
"     Ao: aorta; LA: left atrium; LV: left ventricle; PA: pulmonary artery; RA: right atrium; RV: right ventricle.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Multimedia Library of Congenital Heart Disease, Children's Hospital, Boston, editor Robert Geggel MD, www.childrenshospital.org/mml/cvp.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_51_13106=[""].join("\n");
var outline_f12_51_13106=null;
var title_f12_51_13107="Enchondroma malignant transformation";
var content_f12_51_13107=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F55316&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F55316&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Solitary enchondroma to chondrosarcoma: Malignant degeneration",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 420px; height: 549px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Observe the grossly expansile, primarily lytic lesion of the metaphysis and proximal diaphysis of the femur. There is characteristic stippled matrix calcification throughout the lesion (white arrows). There is disruption of the cortex with the presence of a soft tissue mass on the medial surface of the femur (yellow arrows). The radiographic signs of cortical disruption, a poor zone of transition surrounding the lesion, and a large soft tissue mass support the biopsy diagnosis of malignant degeneration of a pre-existing benign enchondroma to a secondary chondrosarcoma. Malignant degeneration of benign cartilaginous tumors occurs in bones closest to the axial skeleton and is much more common in the long tubular bones than in the small bones of the hands or feet.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Yochum TR, Rowe LJ. Yochum and Rowe's Essentials of Skeletal Radiology, Third Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2004. Copyright &copy; 2004 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_51_13107=[""].join("\n");
var outline_f12_51_13107=null;
var title_f12_51_13108="Diphenhydramine (topical): Pediatric drug information";
var content_f12_51_13108=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Diphenhydramine (topical): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?1/15/1269?source=see_link\">",
"    see \"Diphenhydramine (topical): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?4/10/4260?source=see_link\">",
"    see \"Diphenhydramine (topical): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8082068\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Banophen&trade; Anti-Itch [OTC];",
"     </li>",
"     <li>",
"      Benadryl&reg; Extra Strength Itch Stopping [OTC];",
"     </li>",
"     <li>",
"      Benadryl&reg; Itch Relief Extra Strength [OTC];",
"     </li>",
"     <li>",
"      Benadryl&reg; Itch Stopping Extra Strength [OTC];",
"     </li>",
"     <li>",
"      Benadryl&reg; Itch Stopping [OTC];",
"     </li>",
"     <li>",
"      Dermamycin&reg; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F8082069\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Benadryl&reg; Cream;",
"     </li>",
"     <li>",
"      Benadryl&reg; Itch Relief Stick;",
"     </li>",
"     <li>",
"      Benadryl&reg; Spray",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F10824332\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antihistamine",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F10824339\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?1/15/1269?source=see_link\">",
"      see \"Diphenhydramine (topical): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;display:inline\">",
"     Topical cream, gel, spray, or stick:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children &ge;2 to 12 years: Apply 1% concentration not more than 3-4 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children &ge;12 years and Adults: Apply 1% or 2% concentration not more than 3-4 times/day",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F8082187\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, topical, as hydrochloride: 2% (30 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Banophen&trade; Anti-Itch: 2% (28.4 g) [contains zinc acetate 0.1%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Benadryl&reg; Itch Stopping: 1% (14.2 g, 28.3 g) [contains zinc acetate 0.1%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Benadryl&reg; Itch Stopping Extra Strength: 2% (14.2 g) [contains zinc acetate 0.1%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermamycin&reg;: 2% (28 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gel, topical, as hydrochloride:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Benadryl&reg; Extra Strength Itch Stopping: 2% (120 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Liquid, topical, as hydrochloride [spray]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Benadryl&reg; Itch Stopping Extra Strength: 2% (59 mL) [contains ethanol; contains zinc acetate 0.1%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermamycin&reg;: 2% (60 mL) [contains menthol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Liquid, topical, as hydrochloride [stick]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Benadryl&reg; Itch Relief Extra Strength: 2% (14 mL) [contains ethanol; contains zinc acetate 0.1%]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F8082071\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes gel, liquid stick, spray",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F10824341\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Shake well (gel); apply thin coat to affected area",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F10824333\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Relief of pain and itching associated with insect bites, minor cuts and burns, or rashes",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F8082066\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       DiphenhydrAMINE may be confused with desipramine, dicyclomine, dimenhyDRINATE",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Benadryl&reg; may be confused with benazepril, Bentyl&reg;, Benylin&reg;, Caladryl&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Administration issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Institute for Safe Medication Practices (ISMP) has reported cases of patients mistakenly",
"       <i>",
"        swallowing",
"       </i>",
"       Benadryl&reg; Itch Stopping [OTC] gel intended for topical application. Unclear labeling and similar packaging of the topical gel in containers resembling an oral liquid are factors believed to be contributing to the administration errors. The topical gel contains camphor which can be toxic if swallowed. ISMP has requested the manufacturer to make the necessary changes to prevent further confusion.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F8082089\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Dermatologic: Photosensitivity, rash, urticaria",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F10824334\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to diphenhydramine or any component; breast-feeding (infants may be more sensitive to the effects of antihistamines)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F10824335\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Should not be used to treat chickenpox, poison ivy, or sunburn; on large areas of the body; or on blistered or oozing skin, due to potential for causing toxic psychosis, particularly in children.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F8082091\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F8082092\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): Anticholinergics may diminish the therapeutic effect of Acetylcholinesterase Inhibitors (Central). Acetylcholinesterase Inhibitors (Central) may diminish the therapeutic effect of Anticholinergics. If the anticholinergic action is a side effect of the agent, the result may be beneficial.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: May diminish the sedative effect of Antihistamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzylpenicilloyl Polylysine: Antihistamines may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Suspend systemic H1 antagonists for benzylpenicilloyl-polylysine skin testing and delay testing until systemic antihistaminic effects have dissipated. A histamine skin test may be used to assess persistent antihistaminic effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Betahistine: Antihistamines may diminish the therapeutic effect of Betahistine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Antihistamines may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving antihistamines (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F14445923\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     When administered orally, diphenhydramine crosses the placenta. Diphenhydramine can also be measurable in the serum following topical administration to large areas of the body. Refer to the diphenhydramine (systemic) monograph.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15969 Version 29.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-115.25.216.6-2972EEEA2C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_51_13108=[""].join("\n");
var outline_f12_51_13108=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8082068\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8082069\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10824332\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10824339\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8082187\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8082071\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10824341\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10824333\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8082066\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8082089\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10824334\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10824335\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8082091\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8082092\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14445923\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/15969\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/15969|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?7/33/7705?source=related_link\">",
"      Diphenhydramine (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?11/57/12182?source=related_link\">",
"      Diphenhydramine (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?18/48/19207?source=related_link\">",
"      Diphenhydramine (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?1/15/1269?source=related_link\">",
"      Diphenhydramine (topical): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?4/10/4260?source=related_link\">",
"      Diphenhydramine (topical): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_51_13109="Coal tar: Patient drug information";
var content_f12_51_13109=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Coal tar: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/43/44724?source=see_link\">",
"     see \"Coal tar: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/19/2356?source=see_link\">",
"     see \"Coal tar: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F154027\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Balnetar&reg; [OTC];",
"     </li>",
"     <li>",
"      Betatar Gel&reg; [OTC];",
"     </li>",
"     <li>",
"      Cutar&reg; [OTC];",
"     </li>",
"     <li>",
"      Denorex&reg; Therapeutic Protection 2-in-1 Shampoo + Conditioner [OTC];",
"     </li>",
"     <li>",
"      Denorex&reg; Therapeutic Protection [OTC];",
"     </li>",
"     <li>",
"      DHS&reg; Tar [OTC];",
"     </li>",
"     <li>",
"      DHS&trade; Tar Gel [OTC];",
"     </li>",
"     <li>",
"      Exorex&reg; Penetrating Emulsion #2 [OTC];",
"     </li>",
"     <li>",
"      Exorex&reg; Penetrating Emulsion [OTC];",
"     </li>",
"     <li>",
"      ionil-T&reg; Plus [OTC];",
"     </li>",
"     <li>",
"      ionil-T&reg; [OTC];",
"     </li>",
"     <li>",
"      MG217&reg; Medicated Tar Extra Strength [OTC];",
"     </li>",
"     <li>",
"      MG217&reg; Medicated Tar Intensive Strength [OTC];",
"     </li>",
"     <li>",
"      MG217&reg; Medicated Tar [OTC];",
"     </li>",
"     <li>",
"      Neutrogena&reg; T/Gel&reg; Extra Strength [OTC];",
"     </li>",
"     <li>",
"      Neutrogena&reg; T/Gel&reg; Stubborn Itch Control [OTC];",
"     </li>",
"     <li>",
"      Neutrogena&reg; T/Gel&reg; [OTC];",
"     </li>",
"     <li>",
"      Oxipor&reg; VHC [OTC];",
"     </li>",
"     <li>",
"      Pentrax&reg; [OTC];",
"     </li>",
"     <li>",
"      Scytera&trade; [OTC];",
"     </li>",
"     <li>",
"      Tera-Gel&trade; [OTC];",
"     </li>",
"     <li>",
"      Thera-Gel [OTC];",
"     </li>",
"     <li>",
"      Zetar&reg; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F154028\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Doak Oil Forte [OTC];",
"     </li>",
"     <li>",
"      Doak Oil [OTC];",
"     </li>",
"     <li>",
"      Emorex Gel [OTC];",
"     </li>",
"     <li>",
"      Neuotrogena T/Gel Therapeutic Shampoo [OTC];",
"     </li>",
"     <li>",
"      Odans Liquor Carbonis Detergens [OTC];",
"     </li>",
"     <li>",
"      Pentrax Gold Shampoo [OTC];",
"     </li>",
"     <li>",
"      Pentrax Tar Shampoo [OTC];",
"     </li>",
"     <li>",
"      Psoriasin [OTC];",
"     </li>",
"     <li>",
"      T/Gel Therapeutic Shampoo Extra Strength [OTC];",
"     </li>",
"     <li>",
"      Targel&reg; [OTC];",
"     </li>",
"     <li>",
"      Tersa Tar Shp [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10024929\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691803",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat dandruff.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat psoriasis.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691328",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to control seborrheic dermatitis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10024928\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701848",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to coal tar or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10024933\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697666",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may stain fingernails, hair, and skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697585",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect clothing and fabrics from staining.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697788",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may get sunburned more easily. Avoid sun, sunlamps, and tanning beds. Use sunscreen and wear clothing and eyewear that protects you from the sun.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696817",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use coverings (bandages, dressings, make-up) unless told to do so by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10024934\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698317",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Scalp irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10024936\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10024931\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705324",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         All products:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694772",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug by mouth. Use on your skin only. Keep out of your mouth, nose, and eyes (may burn).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Bath oil:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694383",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Add to bath water.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695650",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Soak for as long as you were told by your doctor, then pat dry.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705406",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Gel:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694440",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put a thin layer on the affected skin and rub in gently.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695292",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Leave it on your skin for as long as you were told, then pat with a clean tissue.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705450",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Lotion, solution:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694870",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow how to use as you have been told by your doctor or read the package insert.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705468",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Ointment:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694440",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put a thin layer on the affected skin and rub in gently.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705526",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shampoo:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696267",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wet hair and scalp.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694452",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put on enough shampoo to make a lather.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695277",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Lather well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695593",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Rinse and put on again, lather, and leave on for 5 minutes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695591",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Rinse and dry hair.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10024932\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696441",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put on a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696452",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not put on 2 doses or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10024937\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10024938\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699681",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Read the package insert for more details.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11612 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-27EA24A548-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_51_13109=[""].join("\n");
var outline_f12_51_13109=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154027\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154028\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024929\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024928\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024933\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024934\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024936\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024931\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024932\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024937\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024938\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?43/43/44724?source=related_link\">",
"      Coal tar: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/19/2356?source=related_link\">",
"      Coal tar: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_51_13110="Hypertrophic lichen planus";
var content_f12_51_13110=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F62561&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F62561&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hypertrophic lichen planus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 259px; height: 395px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Ridley, CM, Neill, SM (Eds), The Vulva, 2nd ed, Blackwell Science, Oxford 1999. Copyright &copy; 1999 Blackwell Science.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.blackwell-science.com\">",
"      file://www.blackwell-science.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_51_13110=[""].join("\n");
var outline_f12_51_13110=null;
var title_f12_51_13111="Gianotti Crosti";
var content_f12_51_13111=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F67780%7EPEDS%2F56024&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F67780%7EPEDS%2F56024&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Characteristic rash of Gianotti-Crosti syndrome (papular acrodermatitis)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAF6AfgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDwOSR97rubqe9RM79nb86SRiJG45yabuyQAK9JtEk9uZCwG5vzratC4UfM351mWUeccVswJgDiuGvK7OqjHS5aiZ+Pmb86uRb/AO8351BAlXY1rkZ0IkjLf3m/OrKM395vzqJV4qWMc0mWkWIy395vzqyhbH3m/OoYxgVMvSkMfvb+8fzoV2z94/nQopwXvSKSJkZsfeb86eHb+8fzqJTgU8UgH72J+8fzqaPcP4j+dQgVIrAdSKBMly394/nSgt6n86jEmfugmnhJG6cCgESByByx/Ol80AffP50iWrY+bJ+pqYQAD7tK47EIuAD95jQbpv4Vc/U1ZW1DdsVN9lQL0OfrRcOUofaLk8IMe/Wm/wCkv96VvoDWiIQM8ZFSLAMdDSuPlM2OBiM7mz9anSHjPP51eEJBzjFLswOKTY+UqCI+p/OnBCTgMfzqfApUHPTilcaiRmBuMSNinNZMy5V2/E1ZXOOmaepNIsoLE6YyamVGBzuOR61ZI9Rz2pjfL1qbisCu/wDeP50pySDkmkUjpgVInC9qLhaw1A2T8xqzCMjDEn8aYqfMeetSKuKLjIp4iDkE4+tPiQbMZJqTrwaaQU6LxSuPcp3MQ65IPbBqEFsA5PHvV44cHPXNQtFgk5BFA7FfLBsZOD71YRHdcA5x05qMxk/4VZh+UjpyKVxMRFboTUqpkjJOPrSkc9Kaw9TmlcmwyeMdVJ9+aRM84Y/nSnJzz/8AWp0agA5zntTZTQAsO5wfeht27gn6ZqTAA6U5QMgnkelSCRXIYfxE/jTH3AYy2e4q26gDuPQ1WxluRn2plRGgnPAPHvTwTxyc+5pFBHbFTiM4Gef5UDY1fu4JJpuTwM08IecDFBRl5Oc9KBWGkkdzn2prM23BJx6ZqQqefSo2+UkfzFFwIjuA4JwPekaRtmOx7g1IwOOMYqNscUXAqFWEnU8n1qdU5xuJ9Dmh4wwPynNSx4I5GTSQMiVGD43HFNJYHHOanZD1IGDTSoYnrimCGKx3gHP8qKcAu8Z4z70U0wZ8yyn9644zuNJEhZwKbKMTP9TV6yhyRX0M5Wjc8CKuy/Yx4ArWgj6VBaw4ArTgTAFedKV2d0VYkhjxVtFqNFqzGtRctCotTRrzQo9qlTrUlIei8VIopqnipYonc4VCaCkAFSDHerEWnzOMk7R7Cnrpwzy5Y+9S2h2KmVPTJPtVqK1mcZAVfqauRWYTGFq2tuwxj9KVwsZi2bkYkfj2qaKyX0/OtKOHLEkZNWUjUelK4WM+K2HZRU6wbeo49qvLGDj0p4XHG2i47FHy8dAMe9SLECfmWrZiyB60gj7UhkaQcYU0vkD+IHNP5Q+1PRxtzjmkUkyv5JX6UbCre1WQwJwaeFBHSi4WtuVDGfwp626t1BqyY84I6etKxKkcc1Ny0ynJaLklTSJCQatGRSfmGKccNjHSkNkKxYFHl9MDmpwgI+8B9aUDpQSV1TPWnNb55NWNnOeKnCZXjpSuUmZLQY5UEVLCMjOMHvV6eEY461W2EZApMp6oZ0PvUictzShRgGhcZ6cCkQShBu5qXywVqMEkDBNOVuoGB6UIEV5YgrAjGPao5o1PIGD3qzIue/51G68Y6GmWVCCBwKVQA2Tx9Kew544p8W3cN4O3PakJigZPHQ07bxRxuIXpng07djoDnFBJFsAOPX3p7KAoHGab3OQT9KkGAN3r2ouMYFxkk1JGM5PamMCT0wTUm7AA4FSwaB1BX3HSoGTrxye9WUGWyDTnUkA96aGiqvTpk1MFOzGaUrzx29KVAOmcmgGRMrYxTDuON3Qd8VoQIpYh/wCdR3EADZTOP5U7aApa2KW0/wD6qVwCOSRj3qR4ynJ6d6cYGfDAc0kFysVyD3PpUZC7sDPPXNWlCg85wOvFEqd/6UguVdgzs/Kk27GA7HrinNnjgZ96RssAScUBYdt7cjNMZMnrkVYj+bpn6UjxDGOfaqBFVQpf8aKfsJcFemaKaKZ8xbC07Z/vGtqwgwAcVStoiZmJ/vVu2seAOK9mvPojxaUdLlmBMAVdjFQwpkitO2sZZNp24B9a42dMUyOMVYQdK0LfSicb8mtSGwVYyAOfoKm6LUWYkcEj/dXrVyKwcnk/gK1o7ZVxxj6Vcig3cfzFS5GnKZdvYopzgA1fS3CgcY+lX4rcHqM1OtuMHipuOxRSBjjoOKlS0I6mr6xKqksTmlGOwwKVxryKscGB61OI8D2qYAHNBXHvRcViEoMjGKekeeSKeIhkECrUSDGO9NsCBoOMrTShyCPyq8OB71GUyc0hJldUOeakWLjIqQpk5A4py9O9SURNGCen1qPyQrc1eAyOBnNRtGCaBplcRArnHvSmL+6amCHd8vSn7NmM8igbZXQEYBGPpT9m7Ip0mM5ApEJznmlYpdyJoQRyKZt2njpVrBIBI4p3lgqOKTRdyqFOOBxS5GBU4G0bc8VGUGcZGT6UibArDGTwanjB/A1WK881YjfHFAmhXznB6VAxwxGKs53DHTFQkjJyOaQ0RKOORigrngdakLc896ao5GKQ7DMEHrSqOvQn1p7xMwyKZECDjBzQOwueeRnHrQy8cc5p8i9zUZBX8qAI3XPI5IqM89KsDkY4GKhKgnPf2pgNRuDnrnBqQ5PI5NNIOQWA29KsRgYBPJpWBkSqARkgZ9DT3VSPcdql8oFfp1pBGWOBzikTe4wKCOMj0pAuTjvT1B3gfjSuAGB7Z6UgCJSeOg6g1II2OCucehpYxkHbgDpwetWYOYm4BHQg0ILlQAYPHPekI5GOnU1OYSSdgyfSoipUkFcE8EHtTsMUYwAckjvUjc89D6CkjcrtO3nuDT2OCAMc8UIkilG9WOfb61HH8qENz2znrU00ZQ5JyO/NR7QSMg80+o+hFsbk8Y6/Wk2bx1IFSSKF+72oUbdpJ+X0qdmBVlt8AnbioVXgjv24rYuGDxgAAYrMZAJAR0pyVthp3Wo+2PIyBnvUjKWHTHp71EMo2Mde9TjkZz/XmhEjIIwxHYZ7UUuWWVSPWiri+43c+eNN0u5nkYxwsVyeSOK6ex0JsAzN+ArrIrFQ5VEwM1egtdmQFGa65VGzlhSSRhWekpEBtTPtjk1rwWDgZZdoPataGIBcADHU1OF4rNts0SRnJagdRj6VKlufTirQyD04p69elRexSi2QxQBRnAJqYRgnkYqTJySR1qRF3dRRcdmQpHjvgVMqDI2g/U08oCOO1OwVHH507kkbRZx3pDGPwqYDIxSYI6ilYpOxCvp+FKcZx0p7L3FN2kcnkUxDo8dqec9R1qIE/jUiuG6mlYRPEVZfm60FcHHWmAqOhzTickUIQ5cYoGAMkUnI5xTyoKj1oARjgACmqCScU0AgnjNAyp3UikiU/Ln1pSC4wTx7UwEHGehp47YzyaAsMCY6DinCPnI4NSdOe3vTlcFcY5HvSHqQkFcjqDQo456VIQSMmomfj6dKGWkEi5+pqB4nByOKtQt5mQQM1ZCBgwAGRU2uXfl3M4f6s78ZpEXnjpVpoMkjHNRxp1B7dfakDGDcMHr/AFpDhverCR4ODx2607y/mJOOvWkJMpSJ8wK5BPekXg7T1q+0ajGRk9qqOvzcY+pNJorcnQHaM4waiK7ZM9jUmDt96QKc4JPSmShD8/HU03GByRUigDnoRzxTiMDpk+lIXkUmGHPU4/lS43KPX+VSOPmGM4PH4Uw8kYGO1MojCgE4wQORmpIxxyeTyKUIR8tCoc8Y+tAifkKBkfN1pAxjYcc0wSbuOQ3vSv8Ad+bg0iUrbj5/ml3ABe/FQEgttHfpmpQdhb73TGT2pjKW6Dp39KGFhy527RnHQHNSxEqccc8moBweO/PWpRlsMBgHnp3FIC1bSFHzgMMFefQ1XnB83BPP8zTwCq7hgg0yVc5yQcHqetV0sNWuN55XPHt2oBHHJ5HpSl8qFAw3XNQk8ncD+FILE7vvjzxj1qPp0Pfg0kX3mBGdw7dc1IqFc98jjNPcNCMP8+0qP8DTD8wK9x0x+tPkGRtBJAPpSFeMkDPr9aQCo25clsdjk9aqzAkH1qwvy9csucEdqY+48AcHt60WGiFB5gA/zmpo1JTHpVeFxHLkjANaJHAwMeoJoiTLQrhsFdgGM5x6+1FPDHIQKDg52465oq0MwltxuIIxzVhIgo4+uameP5jgd6kRAQB0rYwIdpJ4FOETZGauRRqRjpipAoyKTY7lNIsnmp1hUYAFPbgg9qVSXPSpKTZH5Iz0p4iwvTAqQcEDmpT07e9A3JkGzIpwj3DFWFCkcUZCtnpQQVzHtFJ5Z2k8Zqc/O3SlKkZB/KmBRZRn5snPpSFQRx2qw6dz9MU1Ew3PWmUyqeeMc0cAcH8Knljz0GKQQ8c/nTuQyFQT7fSpjkKCRx05p4jwMgUjgFSBmkFxVJPU+9PUY6n6VGgwOeKkjA6txzSYDgBnvSGPAI6jsakH3jxxUmDgnHBpDK6x7RyRzTgPyNOLkHHGPelRwwAPXNBdmMKfNy3U9KeqgD5utSeWCR7dvSlIKvzSHe44gbNuMY61XaLbkjmrCkhh1p7RqQABgY5/rSHHQoDHmD9cVbU/JkDjvUTxjJA59PWnq+ACDg9PakVJXHbuQcZFNKDnAH1pynJOBg+5pCCwOO3NISGFc9+nBpSclcdelK0Lghl5+lMDFgccUrDt2JM9vXrULRgnOD7Gp4xwBg4xSt909x709xcxWHpQUzz2Hp3qRlycYOeh+tOIVfpSAixg7tucc03nILcjtipiVJwB1psiHHzLgg45oBEJXOO/0pPJ+XJHAODmnx5V+fTpUxGcEc5pA9CsEAAPP4VHIDk8lask8EEcDtTkRA5ZgCuOvWhdgT7mcH5wevU1aYAqOucc49alvbWNELREsy8kelQJ80ZxxtGT9KbVmNtPVDU4UA8N7j8qeXPU8gc/jTXxlT8oPQgd6QjeAM8Z/CgVrijOW+ZTz26GnqpbKA5/ofambSOuPQj0/wA809R1UEc/Tg0MTJIyXQjJyOOKc6FzuHJPNRQsFnBXgMKsOoTockHdQgvZjFG1SAORzg9vaopVO0DBAqUrgnI465q3HsMLKQHIx+HqKdr6CbsZafLtkI4HB96tbOQT3GRUKBA7grksPlGasxZ8gZA44yD1pIUmRlVxk9T/ADquxAf/AGT146VcCtsI64Oc/jUV1EoAIJLHOaGroEyJY8gjrz2qZYT5ZchtnYikGDGrAfMOuR1q6swW2RQpxnI7545qopMG2YNym1jkc9atWkqFcONx4Iz096bdhnYqRz9OlRRZj2lgDioejLauicqBOj4yAxGMY7cGipHG/a/G3jJOenSiqWhBUZOW+tKEp/BZvrSYAHTJrYmw3djAqZckCkWPcd3epo0GO2aTHoMCZxzQEODipShz9KVFwfSgRCvJyePSjdg55x3qd0BHambcqCOaW5SAtwMUg+alCc461IIznOKYWRGEK8g8VJkDOep9acFzkHinsnGDkUxESIXB6Z/pTSCGGQatxAof5Glkj3L0yxoFfUq7N2cAUm3CE4GanVSDnH1ofBHI6UCKcnABFCKSMgVYMYx1IB7UxFK0gsRSxtt3DgUkYOOBgn9auYIA4HB+tHlgMMde/pQPoNiVd2Dge5odSTxgCpFGT7n1qeOLOSM59MUhJ2M+aJl4yDkdqjCEsRtII9K1Djc2VVj29qgYBiCuM9yOM0rGykJAQYQHPzA808r1yMUohAycdT3qQ4I60bmb30EiHPI6etT+WDxjPeq68e+emO9Socn5GxzxQISaEFRjGCACaoMHjfJTK1q5DLjPTn8ainHmQ4CHdnt+NDVy4SfUorznaO/HtUkQDfdAweSPXFMIwvUGnYBw8fDd/XI71JdiRy0mQmMLzmqrA/e9eCMdKtLjBC8ZHbv7VFKpChsde49aBoRdwXHYYp4UkZyD61EC3CkEqfQ1IudnAGO9IGhkrY5BFROzkBh36fSpSitgHr+lOtdm7y3KlM/pSHsikWaNgwxj0q3AwdcjgHHNOubYLkYwQO/H+f8A61V4GKnB4HtSejE7SWhdvtsnlnYoK/KcdP8APeq5JyExn0FTodwAxzk4xyDUcoIYim9dSEuhFJt5CAfL0/z9KSPHl4J4HUex/wDr1MqFgfpnBpu3acbST6Dv/nNAeQ+fJhG1uWUhxjGfQ1nuCchcZx1A/wA/5FXVVpIgFIJIxjue4/lVcp+7JGMgnjocAf1BNVuNaFZ0+YEAqCRk+lPRG2kEjcafLnYF2g46Z6Yz/wDrpjMQA2MgcjtSGPG4g8MMjP8An8RTHO1xksFz09qntRvcruwR0B7jr/n61ZntwIyrKd5PU9KEroltIzlJUI+4ZDYPtWpCAwIkwCnGDxwe9Y4XDYYgds1ehkyFLcnoc/lUp6ikXZpEe2+6hOASQMVQhbdgE4XODzip0ALNGzZDfxd8+n8qrHr0yOD9eat66hG2wif6zaADnoTVm3kZUbAGScfh34qq+QH2556Z9Klt3DFkzhcgnPap2YSRMWwvX5gQBz2NRMS5Xgk8jOfyqcqEjBCgj7u71561VcBi3Y5yT71QoiREHGB1z1OKcBgE/wAPRvanOBsUqcEEnGPu9O/epNoYI3fBGD1//XQkO5XlRiQu0Ajtj0qNlEaIDty2CMenvVkL0cn5u+OtVnBHOCRyCf8AP4UMa1FiKBCCC2GABPv2opibBIRuwGGR9fSihbA0MyQ57c05Tz7VI6DccDPNR4ZW56elbWJWpPHnB9zxUg6YHWokbOD2PpTi3zA4yD0xSYrE444NKeMc0wH5+OtSdc454pNDSIiGLEg0ke4tg8GpPL7/AMqkWMAjI59amxeiQm0enNSdsdv5UpjHYcU4KU4bBU9MVSM9xq84zgCpY1VshuKaEwv1qeBQeppoTG7cjgYHtQq84I4qcgA7c/gRQ6A8chfzxQQVJUAJ5BpnlHOOtWJEOeP/ANdTKmVzjOPSgq9kUFQ8kjODnOKcE3ZwAPrV2ZCMtg9M5qFEGASc/wBKLXC99SsEHbIPc054yRk8j6Yq0Y/mJ6g8U444K8Z4yaBXKbpj1z/nipIWK5B5zQzAjt8vFKh3AHsOMe/vQO2g5ygxtGcnv2FKygvuJGfvDioZIy0Z5AYHggU/aVQIRjGSM/rSKtZEgAxgsOP88UMh6bfrj/P1oDDaoIxtPB9KkYF1AUYI5PvRYhlZkBTIGcHqOKRD8xGwZGcgdqlYjGGAyMEehqvKGjlGeMgfl/nFFkUlcsrycouMnjtmkBG05AxkEjvTEIJAOTnrjvkf4ipeGUk44yfwP/1+aLBsVpIm+YBchjgHtmqaAhwCcDqMmtV2byGjbgoCv454/wD11TaIkocZ78f59zUuJtGQ+EdA3DLkfQ5qdIcttxnBzj1/z/WmxKoYBuB3I/LP8jUy7xLuUDcp6e2P/wBdIhsqXEIQcNjA547kUy2TzSgwMnrgZqe4RsHOSp4+mKZAChUYY4O4Y4JHoP1qWtS09CS4tcpvj2jg4/D/ABFUlZQfnX2IHGcf/WP6VfuWGECnIVcYPTjrVPaSnAzjr7n1pyHHbUkYq6YZs47/AJ/5/GqMS/vGx9Of8+lXFQh1+8QeDt447/0qMIAcL8xzk/l/+uk1cNESRk+XkDDe3+faicBWyy/McZGegNEBI5Oeudw6j/PH60rDC4OPlzke4/8A1mgjqNUAkAcsxIx/KmOjDDjCjPXHTqOn0zS/L5jDkev8/wDP0p7fcdeMPg4I6H/9fFKwndDDwV4yRxz7H/DNJMIyJFAGfvD6A5/qf0oTBQZYZHIH4j/P4U6ZWRFZ1HBKkbv7vB/SqWwupGYV3FH+8MryevoR/ntUcFqJUZHfBVuvqD/9fNPRiNrY5XHze3TpRlApzn5f7p5x/wDr/lT0K1KzZgk2bfnVj/8AqrSurzzo23gYCjGO+M4P61QaB5FMn3RnA/z+FQM2+Ibxkjrz0xxS1iHKmQT5B38HJP1HSrMRKCVd3zcEZHUVXlUqpycgnkCnQ5IUnGCCMZ54qbDkjQMm5VcgnOMenpUKExzgjtkHPQZpsRHlMAcDB49ef/r0yQgOAAMEAc1XQSXQsXTr5aKqjcowx/HioLRv9IxjG7qBUckjEc8AD9RSKwEiHnIODipkwtZGkW+XpwMZA6cVEyFZJegI6U75iAjNnGc7T+PFMblc8kE8889KomIDoQBwx6nrmgOOMjJ6ih8iJQuQO9QSNsc/XOKTdirXLfBTheOv4Gq82BICQSOh+verKL5kO8fdPp6Zpt1HE0Xyn94Ccj09OardEp6lP/WIgwq7eNxzRTrcLvyQce3qKKSVxt22JiACRjqeKYBux0xUx+Zzjk00pjqce4rZISIgoBPXP8qEU7sjtU6gbeeT705E2HIUUWKTsRkEHJ4FTgEryOO3vTvLO8E59sVKgxgEDFJk3GQxZfPrU5hyeRz15qRE7AdRmnBQy88MOxNKwnIrsPXBI/CngHrjHrUjBuD6+lG0hh3xQIVUwo4Iz7daeVU+xA4NSjbwAc5557U7au0Z7jmmS2MjAGCw57cUu0Zxz/hUgUKoOcH+lV2D7yVbG0Zx/hQJK7Dgn3HNIvy4Iz/jT1Us4OPxzjNPODgHp2NA7DQCc47dj3qNUKtwO/BqcKUbPVeRn1+tNKryTnOM4oEMlG0jv29/xqNkyoIXAPOfp/WpmfAAwPy60pQhQBz+PFMNiFAI5A6gZ7gjIIxTXjUc4wfYcVLhtp5O3AB/A8VJGmcggcnt6+v9fwpjvYzm3LL0+XOAfX2qwoLAHPH8LH+v6VK6lkAY8bunYH/IpUUBQxJ3KRnA5xz/APXqRuWhHgKTxgcfL6j/AD/OlUYAwQW9R+n5inOu37+MDoQfp+mOaCOxG5Qedv8An6/nTsRcjMZwQ2R2+g7/AJUxocoxcgjOfqeh/OpcMWzksVPzf4/lQx2gZOeRyO2COlIpNkCxqyMwJ47d8YJ/TH60rw5cNxjHT/P1oRtoU+2Mdc55/wAfyp2NqH++PTpS3KuxqKGBAJCngn/P4UqE4wcAg5I+h/8A108cSZHI6AjuKTI2FdvA5JPYf5/lSuFxgxt4+8CDn9P5j9aIcgg428Z/D1/I/pSphi+cfMMD/Co0faV6HoP8/jn86RRK7YyMc9/5f0/Wo2BBJ4z0I9KcuAq5XlTkZ7//AFjio9x+fDfKeg9uP8KTGiSTDgbdxxk8nr1/XpVZS6uynIJG70qcfJvIGAQc57c//W/nVWYOZgJMjaNvB/AUM0j2JmIBZhgEsT/n2/wqNsbmAXp+B9KeSqqOMKRnH54/Q1EQOQcjnA569qRKQKwTGWByD36jI/z+dP42McZ+YHnGM44+vIP51HcxoipNG2ATnae/b/GkV96DJ+U4GW7DPFN6Ba+o68KG5X7OSVZQcN1zj/8AXSMEIkO7JxkfT/HofxqORc7WVenJ479aBztTOSAQAPx/+tU9bg1oNG1WIUE5JB9u3FOLuSzleuD8p6YwCQPw/WmM3dec7Tn3FSLtC4zgrzkemef5/pTEOTMZ8zKtGeCuOdp71CoIVgxX5jg89uop+eVcHJzxx+v51DMA0h6HHGRx/n/61FwSFWRliYKTjlT/AJ/OoI/lIPBByvP+fap3zwFOd/Ht/n/GogDgbeoIP+NIZExbYScEg/jTEO0g4wobJP4VIwGcHBDYzkdCKYqlVwM4I5/CkxkqZMrxj+8OBSSo5BHbsaRSFc7uWwCM+1ST3J8sqAAvUVSfcWvQj2h4mbnaOuPyqHIKsPbikaThlHrzimFscgdP1qGOzNCOYoqOgHHTPNNRiWAP4E1CjZQbTjAGPanwuN/zkcHNNMkviMbW5DZHGO1UrnHAA57kCpTON3yLgkD8/Wqcz5UZbkU5aoEmSQXEgjMYbC91ppZjlQxx/OqiyAOxB4qVmOQehqU9Btal/T4lklXe3Q8gjoMfWis0T7SvPJNFawkkiZRb6m1swxx0zwaEUkkZOOtShCJM9iealx83OAfbvWlxEJT0OQB0p8a/d5x/n0qYRjccjJpm1wQWAI/WkG5KE3cD6inhcHoOv5VJFg45we1PbAOAcqR1oM7kIX5iB/jUgyMBcE4p6plkyepp7AFlz6YOOKAuRKOVPp1OOlCgBjt4IqV8kjtg84FNVSM7fpx3oAdsAIAOM457c+9SbsegwO1NQfICuCuc47A+1P43/eGMjtTEwXoM/eHy5pjKECk85GAf6VMY8qQR83HHtioihYAMSecnnimhIbIFRgDkJ1BHX/OagkcbSMYI5q7MhKoN3zNwQfTtUK26PAQ+FfGRnoR9aTRpFrdkAl3gKxAHX2NSMGJRgdxHB55//VVN1IUHBJ4xx0qxHyV4OOPu+lSipRtsPBCswONvUCo2Yhhtbjpg1YWNHABZNu7q4wD2/p+tVbpFSRvKyF5GD2NNkqz0Jo2B3BT3Dfh3/EU5g+NxI4AyPUZ6/rVWNiVznGcn9Ks7i6KowMdQOgyBTTJkrD8ADbn6E0DGGwOeTn2700YABz3BzmkJwgY/KACOPUHB/Q0iGNGNoyOAeSB7/wCNA3YDBgPp9f6GmOWDsARtwOenfGacCxbeowc7uO2R/wDWouMMAuxBOccY+nWo5SWHQe/GP89alADKACACMj68/wBMU2ThgRjkj8KQJlZCA4Lkgg9KkY7VHLZzyevr+dMYDOBnGOc9xg5/z7U0Al8ODtxyM9+9Jmm5PuC8fUnn86TaN3zZ7/XmiMbQMjtk5+vIpjqc4OeOB34zSBIdLuUsQOCckDjHX+tQ5HmArjbk8+uKeOUJ+UE+g/lUbgZbGeh/lSLQrcxnnp0yf8+lMB2+aAvXOMHPXPSpC2Fx90jjn6//AFqiQ/MdrBWz/SgaHAsSPfrn6DNExdUGBw3I+lO3ZbORkf0/z+lQTXG2F40JO4fd/wA/55pJopaiKRImMDA7mkP3Av4H+X+fpUFqWbGT2yKuHbgjIGcYPpUoJaMqSRHJJyABn8cUqhgCoJ2EHHH5fyqfduA/ugYH+H86jUELx6cf1phcGbJO3knkHPHTP+FQmTJOOoORj/PrQ0nltkcDj8s5FNKnPB5GQBTuFh3yZwBx169fWl35YKQMdPrTfMGSeCBjH+foKSRgC20Akcj2qbiJN22N1HGfT1zTG3IyuwIjc4Jxk+9DEEE9OM7fpVeYkLjnB+bPtRcETElhjBBx0pjnY2BycZP0prHCKe+MH86jVic5GeSSR9KLhYkIAAJY85BaowCXBx8vU0/I27QeGPftUWepBzikArqUfKtnHTNI/Knnn2FBIAYEc5/WmlhgquCfWgZHKuFDc4P602QOUJ6e3tUiHLLls4qa5ChccYHpVdBtkVoxkRQOuMUrfLMQR0qC2nMcrYwRTnl3Sbj3PQVHQnqTO/QYxkVTll+YgHj3p8xJ4yarSL3z9Md6oqKF8wBiFPGKkL4XHftxVXhRgdaUOXb3pDZMG5HU/MKKr5OQcgYOaKpCO1YZfpgZ6invuVFzu6/WrEaqJCjgjnINEi4BI9ef8a2MU1exBHIxIBQg+9WISrgqeGzkCoZEKrkDIHepbVSRh+x6ds0upUkrXHEYcgYHOeKmPyxle+Of8aRUGFOeG/SnKvzEc7h0707GTETJVhjHtUgCsjc5IxyO9LlMFR2H5jsaeFDM2AASMKMU7aEtjXCktyc4yMfrSNGV6sMEY4796eqFuo4xjHTmiIBsEcADGMc8daAGYEYOBhe+D2z1oBIXcB8xPGO1PY70AIOAce9Jwi5OPm6/40DJiHXZhsEnBAHapGQNkr0BzwOOaiDgHnqD68CngfMxTseDngA/5FMhiXCgOOuNpyM54qC6lPlbN6sozhfXPf2+lTAgr85IHB459jUMkayShsfMTncDjJpO5cX3KbAn5SeSe3fmrEQAjcjPQAj6c/zBpJY13HCgc96dtxuIOBjOM9f881K3LlK6G4IbKk43ZI7gUyWMA8ISF68cGpFxwSeAACP8/WlPyqdrbuetURcrKAFwfu+vf2pYepI5xjHr/nrS8Bj1znb/APXppbacn5ec+uc0h7jsjBXk44Pv3qN2wrEtkAjr9KEfH6YHXvTZCDlWOA36UiRMgDk/OcjIHWkWUljxnHXHT1/xqMn7208/pS7wGOP8/wD66VyidH2ncOnTPoCMUwuPLIPUGmq/yncflJ7im8Fc5wAeppCsJK/B64Ht6f8A1qamF5Xt1/oaUgKCGOG7D+hpFChecGkWTAgtxzk+vWkc5OfyI9ajC7m7AnnNKWwScc449j0pMdhQeAOh7+3Uf1psu1Mkfe6g5z6immbnnHPOMdD3x/ntVWebMpYDb26ev+TRc0jG5ZVxnJAA700suQOhwR/n86jjY7zk8kZPvSXJCouTjPYfU80D5dbEu75QAee/r3qCReBg9c81EkgI54J75pWctHxnOSQMUhpND7cFT0OO1T53scgc1DFwQTwD7/pT2z5hOeD/AJz+lImTuwcYw2T0GeKb5mcYAB/lTncBvmGf64qEEbSSBwM0ARbsI2cZOBilyHYqTtIGck9+v64qNmyD3qJzkYzihMpIcjAgk4K5I561JxkH7p/karQ5ViCPl5BPvUwkQKMf/q5pIJbjnyFz2wQBUbnJGTkAHrxSueCBzkU1gp4PTv3wKNyQaTAIxkjj60xSDwBx1zTGxwec0g4OAee+RTHYezEjB9sYFMbIBwPbp700uTtIbkdKcDhR25zSAYZd0p2jHHNNBOfUjrTX4+bJ6dqbuwfr1pDHrIEf61HNccEZqN+vNV5Bz1OadxpIsW7bmbPToakbHXFV42CPtB4zSmXIODwaLCZOxDnr2zSNhck8cY6VXQjIJP5U9jmPPOBVCsRSSAZAPWmBsfd49OOtMkk+YgcAU3cTn6cZpFWJMgt1NFVw2ZAF9smiqQNHqRUFyVI68CjA5DAj+tStHlwcnPY+1P2beWyADgfTFbWOS4xgQARg4HT1+ooCKGUhSOORnGaUFgU6Y6EYzmnvuUmPdnHGR0z2phcjTHQgHPpwfb8adErLJk7TkAgk9KVFPJA4AwQTmpQg2kMvGAeOf896QmyFVClTkA54zyKlJHmnBOe5/r/9akYgEAcqDxxxjNNUgu24nA4IxnpxTEIqtx/e9KenTIJGRx6A5pqPgHpyPX0pzgDaxOFJOCD0H+eaQxRzuGP9/HfmmTuBGuByuRkHg+9PMhVVbj1475qvIwyHKjBzxjoKY4kZkIl2ZDDs1W45Ad3BwRiqAUDJPBHPT+tWIXVlbscipW5UkrFwncjHkg5z/jUTH5wGySB0IquZ9pURkjnke/SnZLbTkDjjPbvTepHLYkfBTOeg7daYF2k9DkGnPMhJBBwSee9Rs2Iic4GM47GlcauOJ5ycDaD071WZw3A4xTPO3AgZ9qYMkh+c9qVyuWwjlgMEk45qJnyqg5z0zU0pLLjOe/1qsCBhSThsc0bjRMvdgcAjOKYZC2ASecU0HDD2FNdgGxt568UhWJipcsc8nnioMHrz75NEbn1wOn+f0pWfJ45OO/rmkC0JN+UA6kjtQG4ILcjn6/5zUJyOPx/z+dAcEZHXHagdiUFSOTzwTSxjhsjqOfamI3Kg4x06dhUikv8AcGcdcGktSkhGK8qCQuc4/KmnLjOdvfmqkkpEm0EnrkmnLIdo5+tSynCxO0e7kdv0quFAO4888/j2qdCABkdMZxUYIGd34UDTaGn7wKg5/n1prIH5cgnqPzpZGw3sc9KRzxlccYFA7kDcHHA+tKGAAHGe596WRdwOMEdxUL5U8gAAH86ClqTq+Rg8Y71OWGzHXHQ/jVWJsIefyqRGAGM9e3TNIVriM4zjv054qGeRo3Kg/KOfrTJzsz82TyCPxqsrZ3bjzxSehfKTlic7WI9qbtyMg8cH6VGrktl+QfTvTZ5Sec8+5oRJJ5gBUZHXHNAZAvfOKrocHJ5PYVPuJHT5ep96Y7EvKgHGRTGbI46gY/GmPIYwc9SOaYHDZOf/AK1S9BW6jpCD16+1NLAr1GR6fyoYknjGDxUZUxtjrj9adxBuJbKmpQRjLfhUK4OeetTIAyZJ6dB3oSuOxFIQckduKqyNt5FNmnIkKg0x3GOTzSC1h8h3KWPT61WaTB+X05p0jtyByKgyec+lNAh7OWbg4pwPyjeOP51APu5zznNSIwK/MeKY2S5JxgUySXC4ZulNYnHynioWXdjOT/SmCaHiXC46e9SLgJnnPXmq4Hz8kAelTbgCOSeKBSYkYG4DPJI7UU5fvqQSB7UU0S2etMcMWbI549/WgDdkZ2q3Iz+lIUMhdsgHr17VIFUZzxnjGO341uchGvzIu4hQCM+5/wDrVGXyFDc7h3YdalkJPfHYjt9ajcHzPmOHyecA89DQNCxOAA/U46e1SlwvHQ4447VAhzuyNgU8Y/lSA7WGM4xlWzjNANFgAg7sEggggHqPaoQxRwQfmGRnp/ninNJhck9flOKY7DO4ZPv0yOn50CQ+MLuB/gIIPHIpJQNpUn/61IhxwByR+FNldWXJ4/pSH1GpKNgB6juKazMRk4yetMyTI47EU1927jpjtSuXYkOcHyyGB5P+NN+7zyTmmbysmBjBWkc5fJOCOOKGMkz84bg5PP1qUudu0kY9DVYtgHB69cd6QHcSecZ4JpXFYeZGGSBnbzSSXOUbI7ZwR/n3pM8cEZ6Y71XuFPUE/Sk2y1ZjUffIvAI6VaL7AQM9c4qso2DJ5xjGKl3DGc596lCk7jJGJcAZGfwzUcvzZPA57UhZvMY9TnpTWJ8ws+MYxVCQhkIQgde3vTHYq5xnpgUZIOetIVL8E8jpQMegxk55/TFLjnIOBnNNByQM8jtT3y2STj2pCY0E5AzwBximDJzxxn1px4ycjjtTSTlsd+OKVxon28kdPeo55mRRtcrxxj0pm4/KCe/WkYAk9MUio6blHcTJnPA4zViOTdjjnHQ0OFLFdvGeAPShX+bJxz7YpWNW7k+CF7k/zpC+QMfXHanD5xnrn1NDL97IPPPpQZ3IznJPoMc0g55Io4znPP8AOmAgNz+FA7idD645qA428k88Y/Kpn5Pb0qF8HPzYHbNA0xQ2N2Ohpnn4Byc9s0wv0GevBxTQAw5/KpLWhFPJu/nUYb0z70SD5zzTGIAOKC2yV5F2AkmoxluB90c1A7Zx0xT4mzwOnamRsTgEEEnp3qxCS5PXiqu4DgcexqI3GwnbnFK40rk91IFPAJxVaCQ4YjsarzXDtnj8aajFV9+5pN3KeiLwlYZJpok3AdQM+tQ78Djp9KC2eRgY9aLGY8zLuIB4PpSGchDyAenSoYzhj8vGKcu12Oc5ApotWK0jkPk9KXfuHzHpTrggDjB/DpVTzPmHWhjepO5GOD+FNJG3J6+9ORuemRUcg2kg5BHJqiLCoCeh59qkEar346VGjEkcc1ZcYj9j3PWkkJlWRiThentSDccFu/rUXnEN1wOlO3sxXJLCgHoOPysf0PSlJB+XGT65pjYyM44Pr1oQ/PjjHvTEWIxuKkcGilTO4HPf8qKaIep62oKlW3AjOCB2pSwZVLYOOOR61XSQF2UhgAcE/jUjE5wcEZx9K3uczQHOBglSOOR15pC+4ljgd8dhSMeVXGCDyBzmoZJeydOmOv8AntQNK4+dwykcgEY6jt0/rUUbEjuWHrSZBU8knHQetOT7uAAR1BoK2QrktkHcB057UgOAo49+OaBnzDxgY/GmNkNhjn29TSBDi2ANpPHGemaRmG3BZuP50i4IwR2xUUv+sAyPT0FTcEKJCOAefX1p5YH5c/KD9TnvVQNtbp9KkViw6cdDSKaAsu/bgDPFMkkxkdMUyRs5GcH1JqqzyO+SeB3xSbNIq5fVhgk8CnbyeRg1TLHdg84qSKRRnnJ6/wD1qBOPUtbsZ64qB5CSQQMDnJpjzbnwCf8AGn98hulBFrDWYhckj3pAx5x1PamsMg4GO1NCnnnt39aAHFxjk8Y7Hmmudzc+nU9qbkcHGMdjTJHwvWmCQ52HO3p6GjeOvBzVctuBJPTrnrTlIJC5znkGgqxKuMdADTzJngL17e1MLAdCcihmHTpUkh94sCevNKzbTnjFRK579ev1prOFGCM46/WkOw+eUcDv9M8U0sX5LY5qNnG4HnA4Hp6UAg8dup9KGWkIxZeMUkSsZMsKmJUAE8nr1qNjggEAdyaRSkWEYDoc47YpCSSc/TBPtVcyegzmlVyByM4oJsOJIGAO3UVCWIzggnNG8kuOv0phXnK9PSgqw7DEc9R1qKWTjA5HbFPDZHPTuKryuSxJGMmhgB44OM4H8qVeSSx5xUROTluD3+tJlgDyc0hiyuMEDOfWqUhy2KnmkPbv3qr1zj60FR0GyZDVIrBVUg9QM1E4z3x70wvx64oGyy0mR1yKiZhnjmoA/wCIpFYlRigFoSOTzSbywAGc0jAkAdaUjjk0CbBpDnjBxzxTRJzySKHyoBAx2qFmA6UhFgNzz09aaZlU4BqJW7d6cUB6igadiKecetMgI2/N1/lVho1VckY71UL5Ygc0ym7rQl3BDuB/CmvcALkgk00DI5NRzKBwOlBN0SRzFW5pZ7olfeoMjApjIMnOTihBdCK5LZPJ7e9ToWYgEZ+hqCNMY4qwhwwxgD2qloJskXlT83PfNPj68D8etMG3quT2wamjYr1H50EkiAh1/iGewop6uMANgcj8aKaQNHo8sipOwjcupOQxHNTlgcHJJH5GqZR2OTgNz+FTRKVj64I5P1q0YySJnI3cA9MYz1qDeRyRggY9/wAamXOB2PWo5mzxkgA+tO5CITIQSCMkHqDU8fAcKQVHrVDftb5h36VKkoOM8jvigtonMgIA7gY/GkLbTjgnPSol6Btx9KHYck+nNIEgaUIzbegNIGEgweo9aqyTHJ/ujgU2CY8ccj1qL6mjgWJscDjjr70zf5YwDwf5VGXzyPoKdn5QWBxnpVCsS8MMgHn+dN2gJ8wyR3z1oSQEEAU4kOB6fypE6oilBJA5Bx06UyJNrHJ5NTfKQc9OlNXaMevahoq7sKBk54wfUU4nORnjrzTWYBcgVA7HOcj60iNyZpNvU1GXyTnPJ6mo2PPJ4x+VInygHPsKodhWOC39ajzyeR360rnkg9e1R53OKBoGPynHPrSBiSAvTpmhpR1UAVD5o3jB4zz7UrlpE5bYW65zgf1pTIFY856Eehqv52OAarSytv8Al4zz9Km5Shfc0BIHYknmmOxJP5YxVWCTCjPQU8PyOee9IhqzJRICpHX/AOtUIdgQeTn9KkyNg6ZH60w4yB2pjTsWFYHg/eBpWwckZz71X3cjHOKlV1JOCc9BmkIZu+b2qQvldvr1x6VCTnk/n+NMYjjnvjNAydMIuc8E01m+X0AqFiccHpTGnJ2g5x3oKSuPdgF6mqzvuAPYUySYmTg9KiY8cmlcpqxJvxwTnHpTnk3d+KqB8NgZxSvIVIHr1oEx8jjeB1FNDDPXimM4ppfDc4xSEJMQSecVXcAc8gdqJ3+f6VEzjZz1qkUtCVPc5FSAqfug8VVD7QBzmno5zzwKQmWQcYwcEUxyCT2oG3HJJpvFIkR2OMelV5JODjr1qWTAH3qqSN83WmNE6sTjtT5JCoGDjFVVZievFSN83JxmiwDZLgtwATnqaZHkA5zTjlAeeBTM45BFDRTemhLkYpjMMn1PWmuTxTGJ+lNEDyP8ihEG85/DNNVgO9SDuR0piuOAwwxj6U4cEAEfTFAwAM8nvTwuGIIoAUnjk/gKQyDOSacVwR2/nVec7vaixURZZWMqbGAANFVViYupLcE0Uym0eyumXyec0qnjsR3psrcgDnJxnvUM0hiC7scjPJ5q2cqTZMZeABULOSRuFMU7wSPz9aRsensBmkFrETEK249OufemA9Mn6ipAgU89Peq8mTjGMiquUncsBweM84pJWwvTmoIvvL1BqR/mXrg/SpY9mV5XL4CqRn9akSP5Sp7DJp42/wAXOOKjmfr659aVrF3voSZCg4POO3amBtwAB5J+8aqvJkc9T6UyVsEhm6c4pNlKJMsmZCATzU6H5RzjFZ8MhyeDmpyCCeenQUkJ7lqWZRnk7qrmX5gRyeozVZywJOTioTLlyFOB6UNlxgjSWXcuSf1pzZKnsfUms8SkMvb2q0sm8Elu3rQjKUbAzkE8kA+lA7ZY471Ezs4+93yc9KZuxnBzkZ4qhNEzkKDz16VA0g3Nt/OkZt3JNRKwGQetA4kh+bBJ/GomfAJONpPapW28A9Mc1VkZAfl69Oak0QNJgDHFQ8kknoKenXkkUjDn1zRuDlbQd8ygHPA6VKpAHXANQHlsE8A9qeCFPPIPWghsuB02jI544qIt8xBqBpC24joefpRkg/WgSRNG+GJ5yaCwHzE/nVUswY5OMehprN8w+bnNFh2LzSgIMVX/AIc549KiMvGKTee/SkCVifJC89T2puc5yag83BByKa0vGQRj0oLiLPtReDnNRBweveq1xMTwKakmF5pFS2JWfaaa7knGPxqJmJ6DrTS/IHemQSiTJ+tNaTg1FkDOTUPmHmgW49j8xIyajY47U057UhY5oHcdu96fv9M1XclT+FN3+9JgaUTAg0kjheKpR3A289RURuPMfA6DmmOxamkA4JOKqSSKTwaju5lAC55quGyc5osLYuI/TAIq0p3ADpWchxnBqxFJ3xzQkBNIiA8MT9ai81clcfjUM0w5GcGoIX3k02insXN3XJ4qMuc8c0yZ1ROetVln3HNOxBfUgDce9TbgRgHn9KoxvkjjNTRsCe4osSXo3xkE5NTblwOn4VSH3eDzTHmKqQDg0FRVy5I4yDkZzVaaXDdc1UkmJ6HmiKNmbLUFtJFuL5nXHFFSQJhl57iiqSMWep3DHJI654Gaz5FYsSTxVt3y/NIyjp3+tDVyYT5Qhcbce1KZOMLyfWoCm3vjNNDfw5x70ITs9SZ25OSfSowoYbu9BJBz60hYBfrQLYikbDcU4ucc5qOUgtzimhjjPt1oKJN2BnPI6VWlckElvmFSHJHXiqzLuyc8fWk0XFkXmncMdBTl+c85xilEZ28d+tPQ7QoIzilYpyJEKxgED8KUyNt6D61EAcA5PPXNK04Uc/TNBG5HJJkYzx/KolVS2Tkgd6cW3Hpx7VXZWOSDSNYyJWl3sACak3kICO1U0Vhxg/jU0gYKU49eDQkEmgknz1JJNETHrkDNQBMHLN9KkH3QRzmmkS5E20nv15pWYbuOg5qISnBBpdwNMzu0NlkPr1qvje2c0sg5IOfwoReCcnPvU2NObTQkL9Oe3OKXjBOePSo9yjAJ5700sCMA/hTIHg557ZyfekbGTu5pjNjqTTA/foaQ0TgkDIFIzfMOuKaJOgFDMCcAHFAXBiAueuagJ+bA59abKeMDiohwM55plItKwBUntTjjkmqqS7cE9KJrrIzmpYWYrkZOOlRM2OhOelRtK2CQKheY8cdaCr2HtyeTTc8fSmkkkEZ96cpIyO9GxLkBf5SDmg4Iz39aikemA/Mck0APYkdTkU0kDJHpQzYHQH61AznmhCuSM/J5pvmZJHaoGk6e/NMZ++adgJ3YEc1Az84HSonlyKg83B5pWBFlnyDVdnAzUTOTz61GWGKaQ0yXfhuKeHPQ1W3Y570qycU9guXlfBFS7sKT61RjfIz2qVpQqe4ppCGXMhzx0702Kbyx8uSaqXM5fjkCkiJNFimy1JI8p+bpT0B4GOKjQ9MVMuMUIi5PGxxU6HANVlanh8HAosItb+OKikG71NNQ447mpAM8ClYadhioMjHFWFAqEkimNJjpTKWpdWUKyAnPNFZXmfvVbcevSimU0euNJySDyDU3mrtBPU9apAgEnNAfII/I02czRO7MRn1FRA855pA5AOPzoDDaSTSC5KHAHNRySH6D2prMCBg85yaQEbcUWAjYtlQ3A9KFJBOSTmkY4HfNQ+YS3y5FFy1qW2ztwDwR0qPdjANRrNjIPU01hkEk4pXFsK0nUN0piyg8jBqvOeoU57UR/KO2SOvWkXpYtlyvT07VVkQ7txPynmgP0z2pZXOzFG5N7DowSM5z6UrPngg0xAQBnimENkg8jtTC5JIwboMComyRwOKYvzM3NDMAvtQCGSHseCaI2J5BAHrUDzKzEY/+vToz6Dg9qCnoWomBz3pzsqrwarhtp44z0pksnODyB+VBn1HO55wc5P5UwzELhRyfemO2QdvSmBwOGzkdKCkxFJLHJ4HrUyMB9TUO5e3Sjf3x09anYbdyZmG3I6imKcA8GopH9CcUnmY75oGT7/mz+VK8uCTjmq3mYz0pry56ZosA+RgCM5pmQRzwahZzj2phfbTGTO2Rgc1EwBPPT0qIOSx9qC/vSsF2SSMNuBxjtUDHJpsjcdahZ8c5oAsNJjH0pvm7e/NVDIQeKbvyDmiwFoy5OSKTfwOKqNJgYzQJgMAcUWEWjKcGq8kg/GoTcYAyKgkk3EkdPSiw0iwZQOQeaieT86rl+KiaQ9uadgLDS4HFQNJmomYk80xmVVyxwB1JOKaAmMvrSeYMH9KyLzWbS3YqrGRh2X/Gsa71+5lJEKiNfzNJtIpQb2OreYICXIA9ziqUur2UT4e4TPfHNcbNLPcHMkjt9TTRaM3alzIv2TO3GsWaLu+1oB161kX3jCFG2W8TSD+8eKwRpckn3UJ/CnHQrk8iJvypqcSHBo7DTb+HUIhJG3zd19K0lUiuDsbDULOdXhSQEdsda7WwupJIh9piaN+5I4p3T2IkrF9MVMM7eDUK9ODTwPemSTIPWpQR1qFcgcGnq+ODQBYXHepFZQQOgqtu5pD83vSBeZK8ozjOTUb8mmhQp4FJnnPWmO/YQKDInHcUUqn51PQ5opicj08MctzTCcYxnPfNCOBnJ57VC74PHXNMnqS7zgDOTSIxZqqtKAfenxyg/wBaQFkEg4PSnFsHg81CrjPNP3jBOaQA5AU55OKgeQlsD9KjlmCKcGqhkJcEnrSKUepdzwMmlaQgAkA1WMn0pry5BGRigklaQN7ZpiPnr+GKjRwxAGBUrMqgdqY2yRmG3jrUMjFj1pryEkY4qIuM+1FhItLLxzycU1pipOByahWRQDg5Y+1QyyksMDNIXUl8wjB9aZIQQOaiOSx/SovMwSG60WHfsP6ZA4XrzS+dt4HP41CzLuPOfamEgDI600O5aVi/JOKYzqSe9QK5IwOKjLHI7UhdS28pAwMCoDJk9c/WoZJM5zzUXmfNz27UDRc8wDg0gfPGRxVQyGjdg8ZpFJFgsccmgsAQSeag3cnFO6HgZouMsBunpTWfIK9Kiy2M9AKY77e4zSYiQtzULsBxTPMxUUj8UDJCdvSmF6geQGmsxx7UAWN+c1WeTkimGRiMA8VF93vQA/zMHPGKjeTbTZH4PvUW8d+aoZIXOeTik3ccVEWGehNRmQgcUAT5ycd6jZwAageQKNzEAepOKy7zXLSEkKxlf0Xp+dA0rmsWJNVbu8t7YZnlVfbvXMXmt3dzlYyIkPGF6/nVBYpJWy2WPvUuSRrGk3ubd74hOStpF/wNqyJ7i5umJmkZge3ar9jo9xcsAkbH8K6jTfBk8m1pRtBqLylsi7whucRDZu54UnNatroFzPjZE35V6tpHg+2gVS6hiK6W306CFV2RLx7VoqLfxMwliv5UeS6b4IuJSPNXbmunsfBNvFjzRuNd6sI7DFO8sA8c1apRRhKtOW7Odt/DlnEPlhX8qsjSLYYHlL+VbQTj2o2D86q5k7sw5NKt15ES/lVebS4XUgxrj6VuyQMe9MWE55quawWOE1DQpYSXtDx12msh3eF9s6Mh9+lemzW4I/pVC502CdSsqA1DSexpGVtzh0fPQ0/zPWtW+8O7G3WrFT6dqxbuOe0YiaJuO61L03NFaWxLv4609JgvBrIbUY1PJI/CmnU4G6vikpIrkZstKMVG0oxxxWT9vgPSQU030R/5aD86OYOU1RN86/Wislb2LeuZF6jvRTTQnFnr8ku1iM8Z6VG0h4PpVaaUoxyRUZm6FTkVSJsWGfJyTQs2GycY9qqs/filLjGD9RTEXVmIJ+lRNccHJOarLN+lRvJkdahocWPe43ZWkEuPvcfSq7EE+n9aYz7STQkU3cuLIc5xhe3rSPIOOuarI4xzzTGcueKZJejkOQe+OKlLAkFvyqijn15xTzMuMNwKQupPLKDwM47VHuyDgVTluF/h4PbmkSc55NFxtWLm8jvQX+XIOcVV8wseBTt3yYNBmOLkDvmofMLE02ScKn1qq04J4FCKLRbBOO9I0pAx19Kq+YM8HmmGT5utAi4sh647c02SXJznk1VD89TTWbuemaQE7S8YHLdzTRkDOeTUO8buO9KHAPLUMq5OHwOaeGOwVAHB5BpTLtFTcZaVgeD1pWwOQapLOc/LzUEtySTyT7UFpFqSY561EZS3JxVMTA9aa0wx1oSEy08ozxUbSbveq7TjoB165pol564FMCyuDmldiAajSZV6kVBNdpg+vpRYErj3ftmo2cnAziollc/MDt96pXV/bW+TLOoPpmiw7F13561GW5wDXOXXiaJcrbxFz6twKz5NcvZshNiD2FDdi1TbOour+G1U+dIq+2eaxrzxCoBW0Qk/3m6VipBLPJucszHuea17Dw9dXONkLEfSpc+iNPZxjrJmTc3F1eNmWRiPTtT7bT5ZSAiEk+1egaL4Hkdgbldq13ul+GbKzQHylJHcinGnOW+hnPEQhpHU8m0nwjd3RGYyq+prtdI8DRR7WnwxrvUtERQEQAVNFFgY7VqqUV5nPKvORmWOi21oB5cajHtVsRoP4RVxhjqKhZCfWrv2M1ruIigDIqTBFJFHnPGKkPPy0rjsKmM80piJbgcU0kZAqRGNK4mhBGBUMykc1aBPcVHJ7ilcEVVyPvUwn56mfDHpwKruSDx09aC0hzrkE1Vccmpy5A5qNtoOaNASISgIzVWe2jl4dQa0GXIxUEiEH2ouOxz93oNpIxJiX8qy5vC9pIeExXYleuRxULqAelKyfQalJdTiZPB0DA7Mis+bwcM/K5r0bAA6dagkQFs0uSPYFUn3PNm8IypIpDZGRRXo6oCwyO9FL2cGDrTIZmYu2fWmq59O9LN94getQsSMVaDmJXl55x0ppkPrVcyDJz+dIjMxJAJ9KYFrfwRmkA4zmmPhTwc460wuCcUhXFdiRgVHvPfikdsYx0qGR8dTQO5YEo6U8SL9DVHzACDmnGXcuc9KQi35uDUUr5HWq7zDPNQtNnp2oauK5O7KpBzzTllBWqRcsST2p3mDFFgbLom25x+dD3Sr9481QaY7QuflzmoWlGcbqLCTLUlzvb5R7ZpDKSB2HtVN5cHANRmY9qEht3LrSgUhlFUt/GT1pPMxQFi+JCTQZASaomdumeB2pnnH1pDsaJcBT0qEynseOtU2n7ZzSbzjrSKSsXxP780j3A6Z4qgZcd+aZ5gJ5NIdjSFwig89ary3IIITv3qkWU+9QyXMMed8safVhTKLvmHJyacGB6kVjPq1ggOblcjsKzrvxNFHkW0ZdvVulFgOod8fd5qrLcRpkyzIgHq1cLd63fXJO6UqvovFZxZ3bLsSfc07Advc+IbGLhWaU/7IrLn8USZP2a3RfdjmsCOIt2q3badNMQEQn8KVylF9R9xq99dk+ZO4U9l4FVkidzk5JPrXS6f4Tvrgj90QPeuo0vwNIJF+0Yx6UmpPZFqcIdThLDSZrlgI0JNddo/gi4nw0o2rXpGk+HrazQBYxn1xW1HbqnCjAq40l9oyniW/hOU0nwbZ2+0um5h611VvYQwKFjjUfhVyKPC8mk4bgda0SUdjmbctxyQr6CpY0G7BpqdMYzTs7ecc07isOc9sYFIpBpgbfnPNOwQMgcUrjsNcnOR0peBj1NA4XJprtgetIdhSfSo2PJ7U1XJPPSnMOOlDKSG7jnBFOErA4x0pwUMOOtM2Hcc9aRWhOshJ5FMlbNBB2+9MU5JzSJsN5IOaibgYqUnnFIwGaBkDDIOKj2noRUh4NKORzSHsMYYFNwGHNSkfLkioicCgCFgAetRSIG5HWpXG6oiMUARsPeoW4NTtz0qNhkYqQIo3+cY9aKVEAYfWii4mijJKTIRkdTVaV+CAcGq8kpV2ye9RPPk81aJZO7cj9aUykINvaqKysW5xilklJGKYFoykjJNIsvPbFUjIPWo/MyevWkBoyTrjqM1Xebk96psB1NIHC9DSG2i0X9TjNIZQq9aqNLjpURkJJzTFuWmkYjORTDJzk1UeYscE5x2pjT7etMdy8ZewOaYZj0qi142wqMBe+BTDcFhgtx6UWJL7TZGKhMpJqoZwB8xqN7jJwoxSGi+8ufujA+tIHBHWs8zgZ5phuO2TQOxpl/TOKaZgOM1mmdiOTge5qCbULeD/AFsyg/XJoY0jVabJ4NM8z3rnpvEVumRFHJIfXoKoT+ILlz+7VIx+ZpFpHY+YACc1Wn1O2i/1lxGp9M5riLnULm4XbJK2OuM1Uxk80WHY7GbxFaJkIWc/TArPuvE87cW8aKAOpGa58LT1jJ6ChtFKLLM+q3s3+snbn04qmSzHLEn61YW3Y9jWjZ6RPcEbYyfwqedFeztuY6pmpkgZu1dnYeDrmYjcmB9K63S/A8KAGfk00pS2JlUhE8og0+WQ/KhP4VrWHhi7ujhYmx9K9lsvDlnbkbYh+VbEFjDF91FH0FUqXdmTxP8AKjzTRPA20KbofhXbab4csrZFxEufpWyUAPFSKMDNaJKOyMpSlPdjIbSKPG1QKnWNck4GKQEsfY1Mo2pTZKVhUHoKkVOc4oiYAc9fSl34JqShzYA571CU6kVJuBNOXAB9aCthsYbqKe4JHtSHjvgUxc5IFIY5Pk6VNvwnJqBRzzUhIFMTQ1+ah+bP+FWHbK8DmmhcLk8Ug2GFOPekYjoTT8juTTDES3tTsAoBbpThwMk0q4Qc44pGYZz2qWG4kj56VCzZ68Yp24ButD4YdOaBjGwOhzTGbkZFPKYHFAjbHY5pDuQSqWwV60DIXk809vlqIuSSKTY0rjy4IIziogCc0w05Se1K47WIXUgnFMOe9TsfUUxyGUjvSAqM+DjtTCCeQeKc6nPtQMbcZo8hiK3zD60UBfmA96KEiXY5SaQB27jNQGXcSDiopn+YnPc8VXaQkgLkmtTFFlmCjrTfPxwSKoySHOTTHnG3HA/nSGW2lHmcYIpolIPY59qotMO1NNwo7fnTAvmdicZ4pDIM1mi6647jFIbnA5PPtSAvs/PUfjUDzEd+KpzXOcHgZ6AVXM3ftQNF9pgO/NQvL61SeY+uPrUL3EaHMswUe3NFhpF9pxTBOPp+FZE2owq37pWcep4qE6mck+UPzoHY3GlLNwOPeo57uKFiZHRPRQc1z89/PJwG2D0Wqb5JySSfehDsb02tQrkRozn1PFUpNcnIOxEQ9BjtWWfemmgCWW6nlz5krt+NRZz1pMZp6pmgpJsZilxU8cLN0FXINPllIwhNQ5GqpmcqGpo7dmPArptN8M3Fw4yhArs9G8GxqQZhn60JSlsDnCB5vaaRPMQEjJz7V0mleD7icguuBXqVpodtbjCxrxWnb26Rj5VFWqS6syeIb+FHCab4KhjwZgCa6uw0O1tlG1F/KtQIc9KmEeB1qklHYylJy3ZCltGuNoFSCPHFTRqB2pxI3GquTYjCd6CeOaV27jikxkZpBYacZqTgLTMe1SlMge9MqwyIKPc1Y6jPFNjiGM55qUKFFIljAT2HNKqkk56VIoHBxRKcEAUFJkarzmnhSTSbwo9zT1zn0FIoTaT1oHyDBp4PXbTZB8uTSAOOuaUfdqONsHpxTjIMe1JhYGOB/Wm7s4GaVsMOOnvTCQoxkU0gSB/an7jt55FQLuL9eKfkqMdqBtBuxnNAbORikJzkdKI1xnPWgLAsfU96UttX5utDNg+9I439xSCw0Hd0pNxUYB4pUixn5qAoHBNSw0GPyMmoX2jpUshxxmqznJ5oGkOK5XKmmn5cjFAbaKC29c0hkTy84xUDnmnsMtgUqrmgexDwQRUePmxUrJhuKQgYzSE2ITgrnnmioiSHAPrRRa4rHms1yRIx9CaiNzkHBA71kT3Q8x8t3NV2u+eCa1sY2NZ7rk55qFrrr0rIlvAv33C/jVR7+L+JmYf7NFh6Lc2WuvfimG5yev61hNqLHO1Bj3Oahe6lb+Mge1VYXMjoJLrA+Zgv1NVpb5FP3y30rEBJOSST708dOaLDuaP9plT8kY+pNQyX9xJ1kwPReKqd6MUikSGRicliT7mkJzUZzml7UikOB9aQnmkzSgZNIpK4Ckbk1YSIsOBU8OnyyMNqE/hU3K5e5nhSakSEs3ArqdP8Mzz4ypFdNpng9UYGUZppSexDlBHntvpk0p+RCa3dO8LTz43LivULLQra3QYQZrRjtUjOVUAVfs11Yvbt7I4jTvBscePNGTXSWPh+1hxiMflW4qDr0qQAY96pJLYhuUt2VIbKOMfKoFXoY1UelKqEdacQeop3FYdjPTpT41GMGkhOeKkA+apbGOC0YyTjtU4TjpUbDaSBUiTGgEUxven/AKUjDJ4poYFRtxQeAAKADjmlOM80yRoX3qRPu03bu5FOQbuAcCgroSAntSlxkYqMjaMA5pFcE8igViwGwOlA3E5qIMeMVYQ8Y4pDRGU+annjpSHlsDmkyFb60upSHRjA4qRumGqJTg4Jp7njjmgGLuUDGKryMN3AxU6jI5GKYUXdzzS3BaEajP3ulRuFzyKnIPpx6UxoyxxkUx3BCFHSmyE84FSKu0HNNyQcYzigCkZHDgEVYRsjB61MUVuSBmgAeg+tSyrjTzyTTMDqDUpAP0qExEHrx0oEPUEgkmkkPHGKGyDxTZDge9ICN8HGabIoxkDmg0M+enBpDIHx3qE9OKssMiojHtGaB3I+QMimZKng8mnscA5qNwDgg80gEdzjpUSscnvTyxxg1GHAJzxQAqje4z60U3d842+tFNEM+dLrUnaRwiADcevNVHupn4aQ49BxV6SKPzX+Rep7Uwxp/cX8q6bHJzNmexycnk+9C9K0fLT+4v5UqxpgfIv5UAUVpc1oLGmfuL+VK0aZ+4v5Ui0Z6nmng81e8tOPkX8qcI0/uL+VSaIpindqvCNP7i/lT1jT+4v5VDNUjNxQFzWssaZ+4v5VLHFHn7i/lU3NFFGQkDORtGa1tN0aa4YAKea3NLhiyP3af98iu50aGIBcRp/3yKqMeYic+XY5rS/CnAMq10tnoUEIHyCuliRdg+VfyqREXP3R+VaqCRzObe5n21rGgwFAq0qAcAVb2Ln7o/Kl2ruPA/KqEkQooPWhh6VajVeeB+VCqv8AdH5VJoiAfdxQi8+1XI1XH3R+VKFXP3R+VSMrM/pSg8AGpio54H5U5FX+6Pyo8xjUwuMU5WGfepto2ngflTYFG88ClYRKkg2+9Ru4Ddafgc8Cmsox0HWkCQwnJpm4An3q0FGOg/Ko2UZ6D8qew7FdnIzjrTUYk5PWp9oyeBT0Vf7o/KmBEXwvHFJE2CcGpHUZ6CpUVdn3R+VA7aELEsaAvHPBq0FGOg/KnFV44H5UhXKygsBipAfbpVpFXA+UflUcqjngUhIh3elNIJBJqzEq7l4H5VYdV9B+VBV7Geo4FP3lQAamZRnoPyoKjB4H5UmURg5pB96rcSrs6D8qR1G4cD8qZNyuDzTmx1HNPAG8cCggYPApiK+exOKUgYypoYDHQVMijb0FKxRVwcZFOX681a2rs6D8qYVGOgqWguQZAPSmSMcc9Ksqoz0FNkUbegpICrvBP9abJzUgUeg6+lPCj0FBRS+YZ9KYCQTkVoOox0H5VEyrg/KPypWAo7iTS7+xHFWkVeflH5UyVV44H5UhlKVc9KrjJbBrQZR6CmMq5+6PyoY7lMiq8gBY1p7Vx90flVZlXf8AdH5UWFcrR8Ecd6Ktoq5Hyjr6UUiWz//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The characteristic rash of Gianotti-Crosti syndrome consists of symmetric pink-brown papular or papulovesicular lesions that are flat-topped and range from 1 to 10 mm in diameter. The face, buttocks, extensor aspects of forearms and legs, and feet are predominantly affected.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Moise L Levy, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Gianotti-Crosti syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 288px; height: 410px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Symmetrically distributed papules involving buttocks and extensor aspects of upper and lower extremities.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Brandt, O, Abeck, D, Gianotti, R, Burgdorf, W. Gianotti-Crosti syndrome. J Am Acad Dermatol 2006; 54:136. Copyright &copy;2006 The American Academy of Dermatology, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_51_13111=[""].join("\n");
var outline_f12_51_13111=null;
var title_f12_51_13112="Ampicillin: Drug information";
var content_f12_51_13112=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ampicillin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?11/26/11685?source=see_link\">",
"    see \"Ampicillin: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/38/38503?source=see_link\">",
"    see \"Ampicillin: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F134956\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Ampicillin for Injection;",
"     </li>",
"     <li>",
"      Apo-Ampi&reg;;",
"     </li>",
"     <li>",
"      Novo-Ampicillin;",
"     </li>",
"     <li>",
"      Nu-Ampi",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F135006\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antibiotic, Penicillin",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F134960\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Usual dosage range:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: 250-500 mg every 6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M., I.V.: 1-2 g every 4-6 hours or 50-250 mg/kg/day in divided doses (maximum: 12 g/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Cholangitis (acute):",
"     </b>",
"     I.V.: 2 g every 4 hours with gentamicin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Diverticulitis:",
"     </b>",
"     I.M., I.V.: 2 g every 6 hours with metronidazole",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Endocarditis:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Infective:",
"     </i>",
"     I.V.: 12 g/day via continuous infusion or divided every 4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Prophylaxis: Dental, oral, or respiratory tract procedures:",
"     </i>",
"     I.M., I.V.: 2 g within 30-60 minutes prior to procedure in patients not allergic to penicillin and unable to take oral amoxicillin. Intramuscular injections should be avoided in patients who are receiving anticoagulant therapy. In these circumstances, orally administered regimens should be given whenever possible. Intravenously administered antibiotics should be used for patients who are unable to tolerate or absorb oral medications.",
"     <b>",
"      Note:",
"     </b>",
"     American Heart Association (AHA) guidelines now recommend prophylaxis only in patients undergoing invasive procedures and in whom underlying cardiac conditions may predispose to a higher risk of adverse outcomes should infection occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Prophylaxis in total joint replacement patient:",
"     </i>",
"     I.M., I.V.: 2 g 1 hour prior to the procedure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Genitourinary and gastrointestinal tract procedures:",
"     </i>",
"     I.M., I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     High-risk patients: 2 g within 30 minutes prior to procedure, followed by ampicillin 1 g (or amoxicillin 1 g orally) 6 hours later; must be used in combination with gentamicin.",
"     <b>",
"      Note:",
"     </b>",
"     As of April 2007, routine prophylaxis for GI/GU procedures is no longer recommended by the AHA.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Moderate-risk patients: 2 g within 30 minutes prior to procedure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Group B streptococcus (neonatal prophylaxis):",
"     </b>",
"     I.V.: 2 g initial dose, then 1 g every 4 hours until delivery (CDC, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Listeria",
"      </i>",
"     </b>",
"     <b>",
"      infections:",
"     </b>",
"     I.V.: 2 g every 4 hours (consider addition of aminoglycoside)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Mild-to-moderate infections:",
"     </b>",
"     Oral: 250-500 mg every 6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Prosthetic joint infection,",
"      <b>",
"       <i>",
"        Enterococcus",
"       </i>",
"      </b>",
"      spp (penicillin-susceptible):",
"     </b>",
"     I.V.: 12 g continuous infusion every 24 hours",
"     <b>",
"      or",
"     </b>",
"     2 g every 4 hours for 4-6 weeks; consider addition of aminoglycoside (Osmon, 2013)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Sepsis/meningitis:",
"     </b>",
"     I.M., I.V.: 150-250 mg/kg/day divided every 3-4 hours (range: 6-12 g/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Urinary tract infections (",
"      <i>",
"       Enterococcus",
"      </i>",
"      suspected):",
"     </b>",
"     I.V.: 1-2 g every 6 hours with gentamicin",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F134982\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/38/38503?source=see_link\">",
"      see \"Ampicillin: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Usual dosage range:",
"     </b>",
"     Infants and Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: 50-100 mg/kg/day in doses divided every 6 hours (maximum: 2-4 g/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M., I.V.: 100-400 mg/kg/day in divided doses every 6 hours (maximum: 12 g/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Community-acquired pneumonia (CAP) (IDSA/PIDS, 2011):",
"     </b>",
"     Infants &gt;3 months and Children: I.V.:",
"     <b>",
"      Note:",
"     </b>",
"     May consider addition of vancomycin or clindamycin to empiric therapy if community-acquired MRSA suspected. In children &ge; 5 years, a macrolide antibiotic should be added if atypical pneumonia cannot be ruled out.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Empiric treatment or",
"     <i>",
"      S. pneumoniae",
"     </i>",
"     (moderate-to-severe; MICs to penicillin &le;2.0 mcg/mL) or",
"     <i>",
"      H. influenzae",
"     </i>",
"     (beta-lactamase negative) (preferred): 150-200 mg/kg/day divided every 6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Group A",
"     <i>",
"      Streptococcus",
"     </i>",
"     (moderate-to-severe) (preferred): 200 mg/kg/day divided every 6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      S. pneumoniae",
"     </i>",
"     (moderate-to-severe; MICs to penicillin &ge;4.0 mcg/mL) (alternative to ceftriaxone): 300-400 mg/kg/day divided every 6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Endocarditis prophylaxis:",
"     </b>",
"     Infants and Children: I.M., I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Dental, oral, or respiratory tract procedures:",
"     </i>",
"     50 mg/kg within 30-60 minutes prior to procedure in patients not allergic to penicillin and unable to take oral amoxicillin. Intramuscular injections should be avoided in patients who are receiving anticoagulant therapy. In these circumstances, orally administered regimens should be given whenever possible. Intravenously administered antibiotics should be used for patients who are unable to tolerate or absorb oral medications.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     American Heart Association (AHA) guidelines now recommend prophylaxis only in patients undergoing invasive procedures and in whom underlying cardiac conditions may predispose to a higher risk of adverse outcomes should infection occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Genitourinary and gastrointestinal tract procedures:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     High-risk patients: 50 mg/kg (maximum: 2 g) within 30 minutes prior to procedure, followed by ampicillin 25 mg/kg (or amoxicillin 25 mg/kg orally) 6 hours later; must be used in combination with gentamicin.",
"     <b>",
"      Note:",
"     </b>",
"     As of April 2007, routine prophylaxis for GI/GU procedures is no longer recommended by the AHA.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Moderate-risk patients: 50 mg/kg within 30 minutes prior to procedure.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Mild-to-moderate infections:",
"     </b>",
"     Infants and Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: 50-100 mg/kg/day in doses divided every 6 hours (maximum: 2-4 g/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M., I.V.: 100-150 mg/kg/day in divided doses every 6 hours (maximum: 2-4 g/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Severe infections/meningitis:",
"     </b>",
"     Infants and Children: I.M., I.V.: 200-400 mg/kg/day in divided doses every 6 hours (maximum: 6-12 g/day)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F134961\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F134962\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;50 mL/minute: Administer every 6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-50 mL/minute: Administer every 6-12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: Administer every 12-24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Intermittent hemodialysis (IHD) (administer after hemodialysis on dialysis days): Dialyzable (20% to 50%): I.V.: 1-2 g every 12-24 hours (Heintz, 2009).",
"     <b>",
"      Note:",
"     </b>",
"     Dosing dependent on the assumption of 3 times/week, complete IHD sessions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Peritoneal dialysis (PD): 250 mg every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Continuous renal replacement therapy (CRRT) (Heintz, 2009): Drug clearance is highly dependent on the method of renal replacement, filter type, and flow rate. Appropriate dosing requires close monitoring of pharmacologic response, signs of adverse reactions due to drug accumulation, as well as drug concentrations in relation to target trough (if appropriate). The following are general recommendations only (based on dialysate flow/ultrafiltration rates of 1-2 L/hour and minimal residual renal function) and should not supersede clinical judgment:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     CVVH: Loading dose of 2 g followed by 1-2 g every 8-12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     CVVHD: Loading dose of 2 g followed by 1-2 g every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     CVVHDF: Loading dose of 2 g followed by 1-2 g every 6-8 hours",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15673180\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F134931\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral: 250 mg, 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution, as sodium [strength expressed as base]: 125 mg, 250 mg, 500 mg, 1 g, 2 g, 10 g",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder for suspension, oral: 125 mg/5 mL (100 mL, 200 mL); 250 mg/5 mL (100 mL, 200 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F134915\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F134935\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer around-the-clock to promote less variation in peak and trough serum levels.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Oral: Administer on an empty stomach (ie, 1 hour prior to, or 2 hours after meals) to increase total absorption.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.V.: Administer over 3-5 minutes (125-500 mg) or over 10-15 minutes (1-2 g). More rapid infusion may cause seizures. Ampicillin and gentamicin should not be mixed in the same I.V. tubing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Some penicillins (eg, carbenicillin, ticarcillin, and piperacillin) have been shown to inactivate aminoglycosides",
"     <i>",
"      in vitro",
"     </i>",
"     . This has been observed to a greater extent with tobramycin and gentamicin, while amikacin has shown greater stability against inactivation. Concurrent use of these agents may pose a risk of reduced antibacterial efficacy",
"     <i>",
"      in vivo",
"     </i>",
"     , particularly in the setting of profound renal impairment. However, definitive clinical evidence is lacking. If combination penicillin/aminoglycoside therapy is desired in a patient with renal dysfunction, separation of doses (if feasible), and routine monitoring of aminoglycoside levels, CBC, and clinical response should be considered.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F135012\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Incompatible",
"     </b>",
"     in D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      10",
"     </sub>",
"     W, fat emulsion 10%, hetastarch 6%, LR;",
"     <b>",
"      variable stability (consult detailed reference)",
"     </b>",
"     in NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Acyclovir, allopurinol, alprostadil, amifostine, anidulafungin, aztreonam, bivalirudin, cyclophosphamide, cyclosporine, dexmedetomidine, docetaxel, doxorubicin liposome, enalaprilat, esmolol, etoposide phosphate, famotidine, fentanyl, filgrastim, fludarabine, foscarnet, gemcitabine, granisetron, heparin, hydrocortisone sodium succinate, insulin (regular), labetalol, levofloxacin, linezolid, magnesium sulfate, melphalan, meperidine, milrinone, morphine, multivitamins, oxytocin, pantoprazole, pemetrexed, phytonadione, potassium chloride, propofol, remifentanil, tacrolimus, teniposide, theophylline, thiotepa, tolazoline, vitamin B complex with C.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Amphotericin B cholesteryl sulfate complex, caspofungin, ciprofloxacin,  epinephrine, fenoldopam, fluconazole, hydralazine, midazolam, nicardipine, ondansetron, sargramostim, verapamil, vinorelbine.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Calcium gluconate, cisatracurium, diltiazem, doxapram, hetastarch in lactate electrolyte injection (Hextend&reg;), hydromorphone, vancomycin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Chloramphenicol, colistimethate, dimenhydrinate, heparin, iohexol, iopamidol, iothalamate meglumine 60%, ioxaglate meglumine 39.3%, ioxaglate 19.6%, pantoprazole, procaine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Erythromycin lactobionate, gentamicin, hydromorphone, kanamycin, lincomycin, metoclopramide.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Lidocaine, polymyxin B sulfate, streptomycin.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F134934\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of susceptible bacterial infections (nonbeta-lactamase-producing organisms); treatment or prophylaxis of infective endocarditis; susceptible bacterial infections caused by streptococci, pneumococci, nonpenicillinase-producing staphylococci,",
"     <i>",
"      Listeria",
"     </i>",
"     , meningococci; some strains of",
"     <i>",
"      H. influenzae",
"     </i>",
"     ,",
"     <i>",
"      Salmonella",
"     </i>",
"     ,",
"     <i>",
"      Shigella",
"     </i>",
"     ,",
"     <i>",
"      E. coli",
"     </i>",
"     ,",
"     <i>",
"      Enterobacter",
"     </i>",
"     , and",
"     <i>",
"      Klebsiella",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F135014\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Ampicillin may be confused with aminophylline",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F135004\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Fever, penicillin encephalopathy, seizure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Erythema multiforme, exfoliative dermatitis, rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Appearance of a rash should be carefully evaluated to differentiate (if possible) nonallergic ampicillin rash from hypersensitivity reaction. Incidence is higher in patients with viral infection,",
"     <i>",
"      Salmonella",
"     </i>",
"     infection, lymphocytic leukemia, or patients that have hyperuricemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Black hairy tongue, diarrhea, enterocolitis, glossitis, nausea, pseudomembranous colitis, sore mouth or tongue, stomatitis, vomiting, oral candidiasis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Agranulocytosis, anemia, hemolytic anemia, eosinophilia, leukopenia, thrombocytopenia purpura",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: AST increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Interstitial nephritis (rare)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Laryngeal stridor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylaxis, serum sickness-like reaction",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F134938\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to ampicillin, any component of the formulation, or other penicillins",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F134919\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylactoid/hypersensitivity reactions: Serious and occasionally severe or fatal hypersensitivity (anaphylactoid) reactions have been reported in patients on penicillin therapy, especially with a history of beta-lactam hypersensitivity, history of sensitivity to multiple allergens, or previous IgE-mediated reactions (eg, anaphylaxis, angioedema, urticaria). Use with caution in asthmatic patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Rash: Appearance of a rash should be carefully evaluated to differentiate a nonallergic ampicillin rash from a hypersensitivity reaction; rash occurs in 5% to 10% of children and is a generalized dull red, maculopapular rash, generally appearing 3-14 days after the start of therapy. It normally begins on the trunk and spreads over most of the body. It may be most intense at pressure areas, elbows, and knees.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including",
"     <i>",
"      C. difficile",
"     </i>",
"     -associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Infectious mononucleosis: A high percentage of patients with infectious mononucleosis have developed rash during therapy; ampicillin-class antibiotics not recommended in these patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; dosage adjustment recommended.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298748\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F134924\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Allopurinol: May enhance the potential for allergic or hypersensitivity reactions to Ampicillin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atenolol: Ampicillin may decrease the bioavailability of Atenolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Chloroquine: May decrease the serum concentration of Ampicillin. Management: Chloroquine prescribing information recommends separating administration of ampicillin and chloroquine by at least 2 hours to minimize any potential negative impact of chloroquine on ampicillin bioavailability.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fusidic Acid: May diminish the therapeutic effect of Penicillins.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lanthanum: May decrease the serum concentration of Ampicillin. Management: Administer oral ampicillin at least two hours before or after lanthanum.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrexate: Penicillins may increase the serum concentration of Methotrexate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mycophenolate: Penicillins may decrease serum concentrations of the active metabolite(s) of Mycophenolate. This effect appears to be the result of impaired enterohepatic recirculation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase the serum concentration of Penicillins.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetracycline Derivatives: May diminish the therapeutic effect of Penicillins.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 24 hours after cessation of antibacterial agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Penicillins may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F134951\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food: Food decreases ampicillin absorption rate; may decrease ampicillin serum concentration. Management: Take at equal intervals around-the-clock, preferably on an empty stomach (1 hour before or 2 hours after meals). Maintain adequate hydration, unless instructed to restrict fluid intake.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F134927\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F134941\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have not been observed in animal reproduction studies. Ampicillin crosses the placenta, providing detectable concentrations in the cord serum and amniotic fluid. Maternal use of ampicillin has generally not resulted in an increased risk of birth defects. Ampicillin is recommended for use in pregnant women for the management of preterm premature rupture of membranes (PPROM) and for the prevention of early-onset group B streptococcal (GBS) disease in newborns. Ampicillin may also be used in certain situations prior to vaginal delivery in women at high risk for endocarditis.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     The volume of distribution of ampicillin is increased during pregnancy and the half-life is decreased.  As a result, serum concentrations in pregnant patients are approximately 50% of those in nonpregnant patients receiving the same dose.  Higher doses may be needed during pregnancy.  Although oral absorption is not altered during pregnancy, oral ampicillin is poorly absorbed during labor.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F134967\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F5673664\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ampicillin is excreted in breast milk. The manufacturer recommends that caution be exercised when administering ampicillin to nursing women. Due to the low concentrations in human milk, minimal toxicity would be expected in the nursing infant.  Nondose-related effects could include modification of bowel flora and allergic sensitization.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F134942\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Take on an empty stomach 1 hour before or 2 hours after meals. Some products may contain sodium.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F3422187\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Ampicillin Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250 mg (100): $23.46",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (100): $39.88",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Ampicillin Sodium Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 g (1): $6.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 g (1): $13.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 g (1): $78.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     125 mg (1): $5.22",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250 mg (1): $2.70",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (1): $2.95",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Ampicillin Sodium Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 g (1): $17.91",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 g (1): $34.75",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 g (1): $107.77",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension (reconstituted)",
"     </b>",
"     (Ampicillin Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     125 mg/5 mL (100 mL): $9.54",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250 mg/5 mL (100 mL): $14.08",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F134929\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     With prolonged therapy, monitor renal, hepatic, and hematologic function periodically; observe signs and symptoms of anaphylaxis during first dose",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F134943\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Alphacin (NZ);",
"     </li>",
"     <li>",
"      Alphapen (MX);",
"     </li>",
"     <li>",
"      Ambiopi (ID);",
"     </li>",
"     <li>",
"      Amcillin (KP);",
"     </li>",
"     <li>",
"      Amcopen (PK);",
"     </li>",
"     <li>",
"      Amfipen (AE, BH, CY, EG, GB, IE, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Amipenix (JP);",
"     </li>",
"     <li>",
"      Ampecu (EC);",
"     </li>",
"     <li>",
"      Ampen (VE);",
"     </li>",
"     <li>",
"      Ampibex (EC);",
"     </li>",
"     <li>",
"      Ampiblan (CO);",
"     </li>",
"     <li>",
"      Ampicil (BR);",
"     </li>",
"     <li>",
"      Ampicilina (EC);",
"     </li>",
"     <li>",
"      Ampicillin (PL);",
"     </li>",
"     <li>",
"      Ampicin (PH);",
"     </li>",
"     <li>",
"      Ampiclin (PH);",
"     </li>",
"     <li>",
"      Ampiclox (SG);",
"     </li>",
"     <li>",
"      Ampicyn (AU);",
"     </li>",
"     <li>",
"      Ampidar (AE, BH, CY, EG, IL, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Ampiger (BR);",
"     </li>",
"     <li>",
"      Ampilag (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);",
"     </li>",
"     <li>",
"      Ampilin (IN);",
"     </li>",
"     <li>",
"      Ampillin (MY);",
"     </li>",
"     <li>",
"      Ampimedin (PY);",
"     </li>",
"     <li>",
"      Ampipen (IN, ZA);",
"     </li>",
"     <li>",
"      Ampitenk (AR);",
"     </li>",
"     <li>",
"      Ampitrex (PH);",
"     </li>",
"     <li>",
"      Ampivral (CO);",
"     </li>",
"     <li>",
"      Ampliblan (CO);",
"     </li>",
"     <li>",
"      Ampolin (TW);",
"     </li>",
"     <li>",
"      Amsapen (MX);",
"     </li>",
"     <li>",
"      Ancillin (TW);",
"     </li>",
"     <li>",
"      Austrapen (AU);",
"     </li>",
"     <li>",
"      Binotal (AT, BR, CO, MX, UY);",
"     </li>",
"     <li>",
"      Biocil (MY);",
"     </li>",
"     <li>",
"      Bridopen (PH);",
"     </li>",
"     <li>",
"      Brupen (MX);",
"     </li>",
"     <li>",
"      Camicil (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);",
"     </li>",
"     <li>",
"      Cilisod (TW);",
"     </li>",
"     <li>",
"      Citicil (IT);",
"     </li>",
"     <li>",
"      Clovillin (PH);",
"     </li>",
"     <li>",
"      Dhacillin (HK, MY);",
"     </li>",
"     <li>",
"      Dibacilina (MX);",
"     </li>",
"     <li>",
"      Dinpen (PH);",
"     </li>",
"     <li>",
"      Doktacillin (SE);",
"     </li>",
"     <li>",
"      Duacillin (MY);",
"     </li>",
"     <li>",
"      Eurocin (PH);",
"     </li>",
"     <li>",
"      Excillin (PH);",
"     </li>",
"     <li>",
"      Extrapen (AE, BF, BH, BJ, CI, CY, EG, ET, GH, GM, GN, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, OM, QA, SA, SC, SD, SL, SN, SY, TN, TZ, UG, YE, ZM, ZW);",
"     </li>",
"     <li>",
"      Flamicina (MX);",
"     </li>",
"     <li>",
"      Gramcil (PH);",
"     </li>",
"     <li>",
"      Ibimycin (AU);",
"     </li>",
"     <li>",
"      Intramed (ZA);",
"     </li>",
"     <li>",
"      Iwacillin (JP);",
"     </li>",
"     <li>",
"      Magnapen (PE);",
"     </li>",
"     <li>",
"      Marovilina (MX);",
"     </li>",
"     <li>",
"      Maxipen (CO);",
"     </li>",
"     <li>",
"      Microcilin (PH);",
"     </li>",
"     <li>",
"      Omnipen (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, MX, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Pamecil (BF, BJ, CI, ET, GH, GM, GN, HK, KE, LR, MA, ML, MR, MU, MW, MY, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);",
"     </li>",
"     <li>",
"      Panacta (PH);",
"     </li>",
"     <li>",
"      Pelitin (TW);",
"     </li>",
"     <li>",
"      Penbritin (AE, BF, BH, BJ, CI, CY, EG, ET, GH, GM, GN, HK, IE, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, MX, MY, NE, NG, OM, PE, QA, SA, SC, SD, SL, SN, SY, TN, TZ, UG, YE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Penibrin (IL);",
"     </li>",
"     <li>",
"      Pentrexyl (BE, BF, BJ, CI, DK, ET, GB, GH, GM, GN, GR, IT, KE, LR, MA, ML, MR, MU, MW, MX, NE, NG, NO, SC, SD, SL, SN, TH, TN, TZ, UG, ZM, ZW);",
"     </li>",
"     <li>",
"      Petercillin (ZA);",
"     </li>",
"     <li>",
"      Polypen (PH);",
"     </li>",
"     <li>",
"      Primapen (ID);",
"     </li>",
"     <li>",
"      Promecilina (MX);",
"     </li>",
"     <li>",
"      Radiocillina (AE, BF, BH, BJ, CI, CY, EG, ET, GH, GM, GN, IL, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, OM, QA, SA, SC, SD, SL, SN, SY, TN, TZ, UG, YE, ZM, ZW);",
"     </li>",
"     <li>",
"      Rimacillin (AE, BB, BF, BH, BJ, BM, BS, BZ, CI, CY, EG, ET, GH, GM, GN, GY, IQ, IR, JM, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, NL, OM, PR, QA, SA, SC, SD, SL, SN, SR, SY, TN, TT, TZ, UG, YE, ZM, ZW);",
"     </li>",
"     <li>",
"      Roscillin (IN);",
"     </li>",
"     <li>",
"      Sanpicillin (ID);",
"     </li>",
"     <li>",
"      Semicillin (HN);",
"     </li>",
"     <li>",
"      Shacillin (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Standacillin (AE, BG, BH, CY, EE, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Standcillin (MY);",
"     </li>",
"     <li>",
"      Synthocilin (IN);",
"     </li>",
"     <li>",
"      Totapen (FR);",
"     </li>",
"     <li>",
"      Tricil (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);",
"     </li>",
"     <li>",
"      Trifalicina (AR);",
"     </li>",
"     <li>",
"      Trilaxin (PH);",
"     </li>",
"     <li>",
"      Vacillin (TH);",
"     </li>",
"     <li>",
"      Viccillin (ID);",
"     </li>",
"     <li>",
"      Vidopen (GB, IE);",
"     </li>",
"     <li>",
"      Virucil (CO);",
"     </li>",
"     <li>",
"      Winpicillin (TW)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F134918\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins (PBPs) which in turn inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thus inhibiting cell wall biosynthesis. Bacteria eventually lyse due to ongoing activity of cell wall autolytic enzymes (autolysins and murein hydrolases) while cell wall assembly is arrested.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F134937\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: 50%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Bile, blister, and tissue fluids; penetration into CSF occurs with inflamed meninges only, good only with inflammation (exceeds usual MICs)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Normal meninges: Nil; Inflamed meninges: 5% to 10%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 15% to 25%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children and Adults: 1-1.8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Anuria/end-stage renal disease: 7-20 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: Oral: Within 1-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (&sim;90% as unchanged drug) within 24 hours",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Baddour LM, Wilson WR, Bayer AS, et al, &ldquo;Infective Endocarditis. Diagnosis, Antimicrobial Therapy, and Management of Complications: A Statement for Healthcare Professionals From the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association - Executive Summary:",
"      <i>",
"       Endorsed by the Infectious Diseases Society of America",
"      </i>",
"      ,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2005, 111(23):3167-184.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/51/13112/abstract-text/15956145/pubmed\" id=\"15956145\" target=\"_blank\">",
"        15956145",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Boguniewicz M and Leung DY, &ldquo;Hypersensitivity Reactions to Antibiotics Commonly Used in Children,&rdquo;",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 1995, 14(3):221-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/51/13112/abstract-text/7761188/pubmed\" id=\"7761188\" target=\"_blank\">",
"        7761188",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bradley JS, Byington CL, Shah SS, et al.  &ldquo;The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America&rdquo;,",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2011, 53(7):e25-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/51/13112/abstract-text/21880587/pubmed\" id=\"21880587\" target=\"_blank\">",
"        21880587",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bratzler DW, Dellinger EP, Olsen KM, et al, &ldquo;Clinical Practice Guidelines for Antimicrobial Prophylaxis in Surgery,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 2013, 70(3):195-283.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/51/13112/abstract-text/23327981/pubmed\" id=\"23327981\" target=\"_blank\">",
"        23327981",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Brown RD and Campoli-Richards DM, &ldquo;Antimicrobial Therapy in Neonates, Infants, and Children,&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1989, 17(Suppl 1):105-15.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/51/13112/abstract-text/2692934/pubmed\" id=\"2692934\" target=\"_blank\">",
"        2692934",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Prevention of Perinatal Group B Streptococcal Disease, Revised Guidelines from CDC, 2010,\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2010, 59(RR-10):1-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/51/13112/abstract-text/21088663/pubmed\" id=\"21088663\" target=\"_blank\">",
"        21088663",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chow MS, Quintiliani R, and Nightingale CH, \"",
"      <i>",
"       In Vivo",
"      </i>",
"      Inactivation of Tobramycin by Ticarcillin. A Case Report,\"",
"      <i>",
"       JAMA",
"      </i>",
"      , 1982, 247(5):658-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/51/13112/abstract-text/6798229/pubmed\" id=\"6798229\" target=\"_blank\">",
"        6798229",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dajani AS, Taubert KA, Wilson W, et al, &ldquo;Prevention of Bacterial Endocarditis Recommendations by the American Heart Association,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1997, 277(22):1794-801.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/51/13112/abstract-text/9178793/pubmed\" id=\"9178793\" target=\"_blank\">",
"        9178793",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Daly JS, Dodge RA, Glew RH, et al, \"Effect of Time and Temperature on Inactivation of Aminoglycosides by Ampicillin at Neonatal Dosages,\"",
"      <i>",
"       J Perinatol",
"      </i>",
"      , 1997, 17(1):42-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/51/13112/abstract-text/9069064/pubmed\" id=\"9069064\" target=\"_blank\">",
"        9069064",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Donowitz GR and Mandell GL, &ldquo;Beta-Lactam Antibiotics,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1988, 318(7):419-26 and 318(8):490-500.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/51/13112/abstract-text/3277054/pubmed\" id=\"3277054\" target=\"_blank\">",
"        3277054",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dowell JA, Korth-Bradley J, Milisci M, et al, \"Evaluating Possible Pharmacokinetic Interactions Between Tobramycin, Piperacillin, and a Combination of Piperacillin and Tazobactam in Patients With Various Degrees of Renal Impairment,\"",
"      <i>",
"       J Clin Pharmacol",
"      </i>",
"      , 2001, 41:979-86.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/51/13112/abstract-text/11549103/pubmed\" id=\"11549103\" target=\"_blank\">",
"        11549103",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Farchione LA, \"Inactivation of Aminoglycosides by Penicillins,\"",
"      <i>",
"       J Antimicrob Chemother",
"      </i>",
"      , 1982, 8(Suppl A):27-36.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fuchs PC, Stickel S, Anderson PH, et al, \"",
"      <i>",
"       In Vitro",
"      </i>",
"      Inactivation of Aminoglycosides by Sulbactam, Other Beta-Lactams, and Sulbactam-Beta-Lactam Combinations,\"",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 1991, 35(1):182-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/51/13112/abstract-text/2014975/pubmed\" id=\"2014975\" target=\"_blank\">",
"        2014975",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Halstenson CE, Wong MO, Herman CS, et al, \"Effect of Concomitant Administration of Piperacillin on the Dispositions on Isepamicin and Gentamicin in Patients With End-Stage Renal Disease,\"",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 1992, 36(9):1832-36.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/51/13112/abstract-text/1416875/pubmed\" id=\"1416875\" target=\"_blank\">",
"        1416875",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Heintz BH, Matzke GR, Dager WE, &ldquo;Antimicrobial Dosing Concepts and Recommendations for Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy or Intermittent Hemodialysis,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2009, 29(5):562-77.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/51/13112/abstract-text/19397464/pubmed\" id=\"19397464\" target=\"_blank\">",
"        19397464",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hitt CM, Patel KB, Nicolau DP, et al, \"Influence of Piperacillin-Tazobactam on Pharmacokinetics of Gentamicin Given Once Daily,\"",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 1997, 54(23):2704-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/51/13112/abstract-text/9408514/pubmed\" id=\"9408514\" target=\"_blank\">",
"        9408514",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Konishi H, Goto M, Nakamoto Y, et al, \"Tobramycin Inactivation by Carbenicillin, Ticarcillin, and Piperacillin,\"",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 1983, 23(5):653-57.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/51/13112/abstract-text/6223576/pubmed\" id=\"6223576\" target=\"_blank\">",
"        6223576",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lau A, Lee M, Flascha S, et al, \"Effect of Piperacillin on Tobramycin Pharmacokinetics in Patients With Normal Renal Function,\"",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 1983, 24(4):533-37.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/51/13112/abstract-text/6651279/pubmed\" id=\"6651279\" target=\"_blank\">",
"        6651279",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Osmon DR, Berbari EF, Berendt AR, et al, &ldquo;Diagnosis and Management of Prosthetic Joint Infection: Clinical Practice Guideline by the Infectious Diseases Society of America,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2013, 56(1):e1-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/51/13112/abstract-text/23223583/pubmed\" id=\"23223583\" target=\"_blank\">",
"        23223583",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Russoe ME and Atkins-Thor E, \"Gentamicin and Ticarcillin in Subjects With End-Stage Renal Disease. Comparison of Two Assay Methods and Evaluation of Inactivation Rate,\"",
"      <i>",
"       Clin Nephrol",
"      </i>",
"      , 1981, 15(4):175-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/51/13112/abstract-text/7237864/pubmed\" id=\"7237864\" target=\"_blank\">",
"        7237864",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tenenbein M, Cohen S, and Sitar DS, &ldquo;Whole Bowel Irrigation as a Decontamination Procedure After Acute Drug Overdose,&rdquo;",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 1987, 147(5):905-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/51/13112/abstract-text/3579442/pubmed\" id=\"3579442\" target=\"_blank\">",
"        3579442",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Thompson MIB, Russo ME, Saxon BJ, et al, \"Gentamicin Inactivation by Piperacillin or Carbenicillin in Patients With End-Stage Renal Disease,\"",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 1982, 21(2):268-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/51/13112/abstract-text/6462107/pubmed\" id=\"6462107\" target=\"_blank\">",
"        6462107",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Triggs EJ, Johnson JM, and Learoyd B, &ldquo;Absorption and Disposition of Ampicillin in the Elderly,&rdquo;",
"      <i>",
"       Eur J Clin Pharmacol",
"      </i>",
"      , 1980, 18(2):195-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/51/13112/abstract-text/7428803/pubmed\" id=\"7428803\" target=\"_blank\">",
"        7428803",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tunkel AR, Hartman BJ, Kaplan SL, et al, &ldquo;Practice Guidelines for the Management of Bacterial Meningitis,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2004, 39(9):1267-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/51/13112/abstract-text/15494903/pubmed\" id=\"15494903\" target=\"_blank\">",
"        15494903",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Viollier AF, Standiford HC, Drusano GL, et al, \"Comparative Pharmacokinetics and Serum Bactericidal Activity of Mezlocillin, Ticarcillin and Piperacillin, With and Without Gentamicin,\"",
"      <i>",
"       J Antimicrob Chemother",
"      </i>",
"      , 1985, 15(5):597-606.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/51/13112/abstract-text/4008387/pubmed\" id=\"4008387\" target=\"_blank\">",
"        4008387",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Walterspiel JN, Feldman S, Van R, et al, \"Comparative Inactivation of Isepamicin, Amikacin, and Gentamicin by Nine Beta-Lactams and Two Beta-Lactamase Inhibitors, Cilastatin and Heparin,\"",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 1991, 35(9):1875-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/51/13112/abstract-text/1952861/pubmed\" id=\"1952861\" target=\"_blank\">",
"        1952861",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wilson W, Taubert KA, Gewitz M, et al, &ldquo;Prevention of Infective Endocarditis. Guidelines From the American Heart Association. A Guideline From the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2007, 115.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/51/13112/abstract-text/17446442/pubmed\" id=\"17446442\" target=\"_blank\">",
"        17446442",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wright AJ, &ldquo;The Penicillins,&rdquo;",
"      <i>",
"       Mayo Clin Proc",
"      </i>",
"      , 1999, 74(3):290-307.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/51/13112/abstract-text/10090000/pubmed\" id=\"10090000\" target=\"_blank\">",
"        10090000",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8737 Version 46.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-89.32.226.102-5846377118-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_51_13112=[""].join("\n");
var outline_f12_51_13112=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134956\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135006\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134960\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134982\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134961\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134962\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15673180\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134931\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134915\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134935\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135012\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134934\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135014\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135004\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134938\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134919\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298748\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134924\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134951\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134927\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134941\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134967\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5673664\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134942\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3422187\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134929\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134943\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134918\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134937\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8737\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8737|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?11/26/11685?source=related_link\">",
"      Ampicillin: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/38/38503?source=related_link\">",
"      Ampicillin: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_51_13113="Strategies to reduce postoperative pulmonary complications";
var content_f12_51_13113=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Strategies to reduce postoperative pulmonary complications",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/51/13113/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/51/13113/contributors\">",
"     Gerald W Smetana, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/51/13113/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/51/13113/contributors\">",
"     Talmadge E King, Jr, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/51/13113/contributors\">",
"     Mark D Aronson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/51/13113/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/51/13113/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/51/13113/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postoperative pulmonary complications are common and a major cause of overall perioperative morbidity and mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?12/51/13113/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The major categories of clinically significant complications include [",
"    <a class=\"abstract\" href=\"UTD.htm?12/51/13113/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Atelectasis",
"     </li>",
"     <li>",
"      Infection, including bronchitis and pneumonia",
"     </li>",
"     <li>",
"      Prolonged mechanical ventilation and respiratory failure",
"     </li>",
"     <li>",
"      Exacerbation of underlying chronic lung disease",
"     </li>",
"     <li>",
"      Bronchospasm",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Strategies to reduce the risk of postoperative pulmonary complications in high risk patients will be reviewed here. The evaluation of preoperative pulmonary risk and the management of patients undergoing lung resection are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/8/1162?source=see_link\">",
"     \"Evaluation of preoperative pulmonary risk\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/2/15400?source=see_link\">",
"     \"Preoperative evaluation for lung resection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of factors increase the risk of developing postoperative pulmonary complications [",
"    <a class=\"abstract\" href=\"UTD.htm?12/51/13113/abstract/3,6,7\">",
"     3,6,7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/8/1162?source=see_link\">",
"     \"Evaluation of preoperative pulmonary risk\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Definite risk factors include [",
"    <a class=\"abstract\" href=\"UTD.htm?12/51/13113/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Upper abdominal, thoracic, aortic, head and neck, neurosurgical, and abdominal aortic aneurysm surgery",
"     </li>",
"     <li>",
"      Emergency surgery",
"     </li>",
"     <li>",
"      Age &gt;50 years",
"     </li>",
"     <li>",
"      Surgery lasting greater than three hours",
"     </li>",
"     <li>",
"      Poor general health status as defined by ASA class &gt;2",
"     </li>",
"     <li>",
"      Heart failure",
"     </li>",
"     <li>",
"      Serum albumin &lt;35",
"      <span class=\"nowrap\">",
"       g/L",
"      </span>",
"     </li>",
"     <li>",
"      Chronic obstructive lung disease",
"     </li>",
"     <li>",
"      Use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/33/19990?source=see_link\">",
"       pancuronium",
"      </a>",
"      as a neuromuscular blocker",
"     </li>",
"     <li>",
"      Functional dependence",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Probable risk factors include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      General anesthesia (compared to spinal or epidural anesthesia)",
"     </li>",
"     <li>",
"      PaCO",
"      <sub>",
"       2",
"      </sub>",
"      &gt;45 mmHg",
"     </li>",
"     <li>",
"      Abnormal chest radiograph",
"     </li>",
"     <li>",
"      Cigarette use within the previous eight weeks",
"     </li>",
"     <li>",
"      Current upper respiratory tract infection",
"     </li>",
"     <li>",
"      Postoperative nasogastric tube placement",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Strategies to reduce postoperative pulmonary complications should generally be reserved for those at higher than average risk. As an example, patients undergoing upper abdominal or thoracic surgery with at least one other risk factor are at high risk. Patients undergoing other types of surgical procedures are at lower risk; these individuals are candidates for risk reduction strategies if multiple other risk factors are present.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PREOPERATIVE STRATEGIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment to reduce the risk of postoperative pulmonary complications begins prior to surgery. Potential preoperative strategies include cigarette cessation, optimization of underlying chronic lung disease, antibiotics, and patient education.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Smoking cessation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The preoperative evaluation provides an opportunity to discuss the benefits of smoking cessation [",
"    <a class=\"abstract\" href=\"UTD.htm?12/51/13113/abstract/8\">",
"     8",
"    </a>",
"    ]. Current cigarette smokers have an increased risk for postoperative pulmonary complications, although the incremental risk is small in the absence of chronic lung disease [",
"    <a class=\"abstract\" href=\"UTD.htm?12/51/13113/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/8/1162?source=see_link\">",
"     \"Evaluation of preoperative pulmonary risk\"",
"    </a>",
"    .) Suggested methods for smoking cessation are reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/3/23609?source=see_link\">",
"     \"Overview of smoking cessation management in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Smoking cessation prior to elective surgery appears to improve a number of outcomes such as wound healing and long-term smoking cessation [",
"    <a class=\"abstract\" href=\"UTD.htm?12/51/13113/abstract/10-13\">",
"     10-13",
"    </a>",
"    ]. The duration of abstinence from smoking necessary for a reduction in pulmonary complications is not well-established, although more than eight weeks may be preferable [",
"    <a class=\"abstract\" href=\"UTD.htm?12/51/13113/abstract/10,11,13-18\">",
"     10,11,13-18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An important clinical question is whether postoperative pulmonary complications could actually be increased by quitting smoking less than eight weeks prior to surgery. This concern was first raised by a prospective study of 200 patients undergoing coronary artery bypass surgery in which patients who had stopped smoking for two months or less had a pulmonary complication rate almost four times that of patients who had stopped for more than two months (57.1 versus 14.5 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/51/13113/abstract/19\">",
"     19",
"    </a>",
"    ]. Since this report, subsequent studies have yielded conflicting results.",
"   </p>",
"   <p>",
"    Two meta-analyses addressed the question of the optimal duration of surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?12/51/13113/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. In one systematic review, there was no difference in total postoperative or pulmonary complications between current smokers and recent quitters (less than eight weeks) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/51/13113/abstract/12\">",
"     12",
"    </a>",
"    ]. While they identified no increase in risk for recent quitters, they also found no benefit of a brief duration of cessation. In a separate analysis of a larger number of eligible trials (six randomized trials and 15 observational studies), the data supported different conclusions [",
"    <a class=\"abstract\" href=\"UTD.htm?12/51/13113/abstract/13\">",
"     13",
"    </a>",
"    ]. They found a reduction in both total (RR 0.76, CI 0.69-0.84) and pulmonary (RR 0.81, CI 0.70-0.93) complications for past smokers as compared to current smokers. There was no difference between early and late quitters. Each week of cessation increased the beneficial effects of cessation.",
"   </p>",
"   <p>",
"    As there is no evidence of harm related to a short duration of cigarette abstinence, we advise all patients anticipating elective surgery to quit smoking as soon as possible, regardless of the anticipated date of surgery. When time allows, a longer duration (at least eight weeks) of cessation is optimal.",
"   </p>",
"   <p>",
"    The potential benefits of preoperative smoking cessation counseling and nicotine replacement were demonstrated in a prospective, randomized trial of 120 smokers awaiting major orthopedic surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?12/51/13113/abstract/20\">",
"     20",
"    </a>",
"    ]. Patients who underwent counseling and replacement six to eight weeks prior to surgery had a lower rate of overall postoperative complications compared with patients in the control group (18 versus 52 percent). However, most of these complications involved wound healing; the study was underpowered to show a difference in pulmonary complication rates.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Chronic obstructive lung disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Known chronic lung disease is an important patient-related risk factor for postoperative pulmonary complications [",
"    <a class=\"abstract\" href=\"UTD.htm?12/51/13113/abstract/9,21\">",
"     9,21",
"    </a>",
"    ]. Patients with chronic obstructive pulmonary disease (COPD) should be aggressively treated in order to achieve their best possible baseline level of function. In general, the indications for specific treatments are the same as those for patients not preparing for surgery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/26/39338?source=see_link\">",
"     \"Management of stable chronic obstructive pulmonary disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A retrospective study of patients with COPD undergoing general anesthesia illustrated the importance of optimizing preoperative function [",
"    <a class=\"abstract\" href=\"UTD.htm?12/51/13113/abstract/16\">",
"     16",
"    </a>",
"    ]. In this report, 227 of 464 patients underwent some sort of preoperative preparation, including various combinations of bronchodilators, antibiotics, and systemic glucocorticoids. The incidence of pulmonary complications was lower in the prepared group compared to those receiving no preoperative preparation (23 versus 35 percent). These results were confirmed by a second study which noted a reduction in the incidence of pulmonary complications from 60 to 22 percent in a group of high risk patients prepared with bronchodilators, smoking cessation, antibiotics, and chest physical therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/51/13113/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    All patients with symptomatic COPD should receive daily inhaled",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/37/33360?source=see_link\">",
"     ipratropium",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/34/27173?source=see_link\">",
"     tiotropium",
"    </a>",
"    . Inhaled beta-agonists should be used as needed for symptoms and wheezing in patients with COPD in the perioperative period; they may be administered by nebulizer in the immediate perioperative period.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     Theophylline",
"    </a>",
"    should not be added to the regimen of a stable patient in preparation for surgery unless it would be used in the nonoperative setting. Patients with COPD and persistent wheezes or functional limitations despite bronchodilator therapy should be treated with perioperative glucocorticoids [",
"    <a class=\"abstract\" href=\"UTD.htm?12/51/13113/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Asthma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Poorly controlled asthma is a risk factor for the development of postoperative pulmonary complications [",
"    <a class=\"abstract\" href=\"UTD.htm?12/51/13113/abstract/24,25\">",
"     24,25",
"    </a>",
"    ], but well controlled asthma appears to confer little additional risk [",
"    <a class=\"abstract\" href=\"UTD.htm?12/51/13113/abstract/26\">",
"     26",
"    </a>",
"    ]. The National Asthma Education Program consensus statement recommends that patients with asthma undergo a preoperative evaluation to assess asthma control (",
"    <a class=\"graphic graphic_table graphicRef53233 \" href=\"UTD.htm?38/33/39453\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/51/13113/abstract/25\">",
"     25",
"    </a>",
"    ]. Patients whose asthma is not well-controlled should receive a step-up in asthma therapy; this may include a brief course of systemic glucocorticoids in patients whose forced expiratory volume in one second (FEV",
"    <sub>",
"     1",
"    </sub>",
"    ) or peak expiratory flow rate (PEFR) are below their predicted values or personal best (",
"    <a class=\"graphic graphic_figure graphicRef56729 \" href=\"UTD.htm?43/33/44563\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In patients with asthma who require endotracheal intubation, we suggest inhaled rapid-acting beta agonist two to four puffs or a nebulizer treatment within 30 minutes of intubation. Inhaled beta agonists may be continued by nebulizer in the perioperative period; they also can be used in the circuit of anesthesia tubing for prolonged procedures, and for patients still intubated immediately after surgery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/26/8618?source=see_link\">",
"     \"Beta agonists in asthma: Acute administration and prophylactic use\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some authors recommend routine administration of one to two doses of systemic glucocorticoid in the 12 hours prior to surgery to prevent bronchoconstriction at the time of intubation, however evidence for this is lacking [",
"    <a class=\"abstract\" href=\"UTD.htm?12/51/13113/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. In the absence of clinical trial data, we suggest that preoperative systemic glucocorticoid be reserved for patients with a history of poorly-controlled, brittle, severe, or glucocorticoid dependent asthma. The safety of perioperative systemic glucocorticoid use in asthmatic patients has been demonstrated in numerous studies [",
"    <a class=\"abstract\" href=\"UTD.htm?12/51/13113/abstract/26-28\">",
"     26-28",
"    </a>",
"    ]. In one retrospective series, for example, the incidence of infection in 71 asthmatics who had received glucocorticoids prior to undergoing 89 procedures was no different than that in nonasthmatic patients [",
"    <a class=\"abstract\" href=\"UTD.htm?12/51/13113/abstract/26\">",
"     26",
"    </a>",
"    ]. Similarly, a review of the postoperative course of 68 patients with glucocorticoid-dependent asthma undergoing 92 surgical procedures reported three cases of pneumonia, but no fatalities or clinical occurrences of adrenal insufficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?12/51/13113/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients who have received greater than 20 mg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    per day for more than three weeks in the past six months should be assumed to have suppression of hypothalamic-pituitary-adrenal function. Patients who have taken any dose of glucocorticoids for less than three weeks or those on long term treatment with glucocorticoids at a dose of less than 5",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    of prednisone or its equivalent do not have hypothalamic-pituitary-adrenal suppression. Patients with a history of intermediate dose and duration of glucocorticoid use have unknown integrity of the adrenal axis and may require further study before surgery. Occasionally, patients using high-dose inhaled glucocorticoids have developed hypothalamic-pituitary-adrenal suppression [",
"    <a class=\"abstract\" href=\"UTD.htm?12/51/13113/abstract/29\">",
"     29",
"    </a>",
"    ]. However, routine use of stress dose glucocorticoids in these patients is not recommended. Details of this evaluation and perioperative glucocorticoid coverage are provided separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/62/17384?source=see_link\">",
"     \"The surgical patient taking glucocorticoids\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preoperative antibiotics are not useful for prevention of pneumonia in patients with stable COPD or asthma, unless other disorders such as acute bronchitis, bronchiectasis, or immunodeficiency are present. They should be administered prior to surgery only in patients with a clinically apparent respiratory infection, manifest by purulent sputum or a change in the character of sputum [",
"    <a class=\"abstract\" href=\"UTD.htm?12/51/13113/abstract/23\">",
"     23",
"    </a>",
"    ]. Elective surgery should be cancelled until such treatment is completed. The use of perioperative antibiotics to prevent surgical site infection is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/35/31290?source=see_link\">",
"     \"Overview of control measures to prevent surgical site infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Upper respiratory infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of anesthesia and surgery in the setting of a viral upper respiratory tract infection (URI) is unknown; the sparse literature has focused upon the pediatric population. One study of 489 children undergoing myringotomy showed no difference in the incidence of pulmonary complications between those with URIs at the time of surgery and those free of upper respiratory symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?12/51/13113/abstract/30\">",
"     30",
"    </a>",
"    ]. However, myringotomy is a very low risk procedure not commonly associated with postoperative pulmonary complications. No studies have addressed the issue of risk in adults undergoing high risk upper abdominal or thoracic surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?12/51/13113/abstract/31\">",
"     31",
"    </a>",
"    ]. Nevertheless, pending pertinent data, it is reasonable to delay elective surgery in the presence of a viral URI.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H94581694\">",
"    <span class=\"h2\">",
"     Inspiratory muscle training",
"    </span>",
"    &nbsp;&mdash;&nbsp;A program of preoperative inspiratory muscle training may reduce the risk of postoperative pulmonary complications. This was evaluated in a randomized study of 279 \"high-risk\" patients undergoing coronary bypass surgery who received either usual care or a program of at least two weeks of preoperative inspiratory muscle training [",
"    <a class=\"abstract\" href=\"UTD.htm?12/51/13113/abstract/32\">",
"     32",
"    </a>",
"    ]. The program was intensive and involved breathing exercises, incentive spirometry, and education in active breathing and forced expiration techniques. Postoperative pulmonary complication rates for experimental and control groups were 18 and 35 percent, respectively, OR 0.52 [95% CI 0.30-0.92]. Median length of stay was one day shorter for the group receiving inspiratory muscle training.",
"   </p>",
"   <p>",
"    Similar findings were reported in a systematic review that included four eligible studies of preoperative inspiratory muscle training [",
"    <a class=\"abstract\" href=\"UTD.htm?12/51/13113/abstract/33\">",
"     33",
"    </a>",
"    ]. The summary risk ratio estimate was 0.40 (95% CI 0.23-0.72). While time intensive and potentially expensive, this strategy appears to have no risk and offers an additional approach to the preoperative preparation of high-risk patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H94581765\">",
"    <span class=\"h2\">",
"     Chest physical therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preoperative chest physical therapy, including activities such as aerobic exercises, breathing exercises, and inspiratory muscle training, may reduce postoperative pulmonary complications among patients undergoing elective cardiac surgery. In a meta-analysis, preoperative physical therapy (mixed interventions such as aerobic exercises, breathing exercises, inspiratory muscle training) compared with no therapy or sham therapy was found to reduce postoperative atelectasis in four trials (relative risk [RR] 0.52, 95% CI 0.32-0.87) and pneumonia in five trials (RR 0.45, 95% CI 0.24-0.83), but not the need for mechanical ventilation longer than 48 hours or mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?12/51/13113/abstract/34\">",
"     34",
"    </a>",
"    ]. The duration of postoperative hospital stay was significantly shorter for those in the physical therapy groups (mean difference in three studies -3.21 days, 95% CI -5.73 to -0.69).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Patient education",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lung expansion maneuvers such as coughing, incentive spirometry, and voluntary deep breaths are best taught prior to surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?12/51/13113/abstract/35\">",
"     35",
"    </a>",
"    ]. It is more difficult to emphasize the importance of these strategies to a postoperative patient who may be in pain and sedated from analgesic medication.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     INTRAOPERATIVE STRATEGIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The selection of the type of anesthesia and neuromuscular blockade both affect the incidence of postoperative pulmonary complications. Briefer, lower risk procedures should be used whenever possible in high risk patients. Pulmonary artery catheterization does not reduce risk.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Anesthesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies evaluating the incremental risk of pulmonary complications due to general anesthesia when compared with spinal or epidural anesthesia have reported differing results [",
"    <a class=\"abstract\" href=\"UTD.htm?12/51/13113/abstract/36-38\">",
"     36-38",
"    </a>",
"    ]. However, the weight of the evidence suggests that when both general and spinal or epidural anesthesia are safe and appropriate for a particular procedure, spinal or epidural anesthesia should be favored over general for patients who are at high risk for postoperative pulmonary complications. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/8/1162?source=see_link&amp;anchor=H19#H19\">",
"     \"Evaluation of preoperative pulmonary risk\", section on 'Type of anesthesia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Neuromuscular blockade",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/33/19990?source=see_link\">",
"     Pancuronium",
"    </a>",
"    , a long-acting neuromuscular blocker, is more likely to lead to postoperative residual neuromuscular blockade than intermediate-acting agents such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/46/15079?source=see_link\">",
"     vecuronium",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/14/6374?source=see_link\">",
"     atracurium",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?12/51/13113/abstract/6,36,39-41\">",
"     6,36,39-41",
"    </a>",
"    ]. This tendency toward hypoventilation may increase the risk of postoperative pulmonary complications, as suggested by a prospective, nonrandomized study of 7029 patients, in which the incidence of pulmonary complications was 13 percent in the pancuronium group compared to 5 percent in the atracurium group [",
"    <a class=\"abstract\" href=\"UTD.htm?12/51/13113/abstract/36\">",
"     36",
"    </a>",
"    ]. A subsequent prospective, randomized study confirmed these findings [",
"    <a class=\"abstract\" href=\"UTD.htm?12/51/13113/abstract/41\">",
"     41",
"    </a>",
"    ]. In this report, 26 percent of patients treated with pancuronium showed evidence of postoperative residual neuromuscular blockade; this group was four times more likely to develop a postoperative pulmonary complication than those receiving an intermediate-acting neuromuscular blocker. Thus, short or intermediate acting neuromuscular blockers are preferred for patients at high risk for postoperative pulmonary complications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Duration of surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical procedures lasting more than three to four hours are associated with a higher risk of pulmonary complications [",
"    <a class=\"abstract\" href=\"UTD.htm?12/51/13113/abstract/6,7,42-44\">",
"     6,7,42-44",
"    </a>",
"    ]. As an example, a study of risk factors for postoperative pneumonia in 520 patients found an incidence of 8 percent for procedures lasting less than two hours versus 40 percent for those lasting more than four hours [",
"    <a class=\"abstract\" href=\"UTD.htm?12/51/13113/abstract/44\">",
"     44",
"    </a>",
"    ]. This observation suggests that, when available, a less ambitious, briefer procedure should be considered in a very high risk patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Type of surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Upper abdominal, aortic aneurysm repair, thoracic, and head and neck operations carry the greatest risk of postoperative pulmonary complications [",
"    <a class=\"abstract\" href=\"UTD.htm?12/51/13113/abstract/5,44,45\">",
"     5,44,45",
"    </a>",
"    ]. Thus, a different surgical procedure should be considered, if possible, for a very high risk patient in whom there are no opportunities to significantly reduce operative risk. As an example, percutaneous cholecystostomy could be substituted for open cholecystectomy in a critically ill, high risk patient with acute cholecystitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     PA catheterization",
"    </span>",
"    &nbsp;&mdash;&nbsp;In high-risk patients, providers frequently consider using a pulmonary artery catheter (PAC) to guide hemodynamic management in the perioperative period; however, the best performed study to date found no benefit with use of a PAC [",
"    <a class=\"abstract\" href=\"UTD.htm?12/51/13113/abstract/46\">",
"     46",
"    </a>",
"    ]. In this report, 1994 high-risk patients ages 60 years or older who were undergoing urgent or elective major surgery were randomly assigned to perioperative management with or without a PAC. There was no significant difference in in-hospital mortality between the two groups (7.8 versus 7.7 percent, respectively) in six-month mortality (12.6 versus 11.9 percent) or in the rate of postoperative pneumonia (6.7 versus 7.3 percent).",
"   </p>",
"   <p>",
"    Based on these results, we do not recommend PAC as a strategy to reduce perioperative mortality or postoperative pulmonary complications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     POSTOPERATIVE STRATEGIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Risk reduction strategies continue into the postoperative period and include lung expansion maneuvers, adequate pain control, and potentially, respiratory stimulants. Routine use of nasogastric tube decompression after abdominal surgery increases the risk of postoperative pulmonary complications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Lung expansion",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of lung expansion maneuvers reduce postoperative pulmonary complications in selected patients, including chest physical therapy, deep breathing exercises, incentive spirometry, intermittent positive pressure breathing, and continuous positive airway pressure (CPAP). These maneuvers increase lung volumes after surgery through inspiratory effort. All of these interventions are more effective if patient teaching begins before surgery.",
"   </p>",
"   <p>",
"    Deep breathing exercises or incentive spirometry should be used in patients undergoing thoracic, aortic, and upper abdominal surgery who are at higher than average risk for pulmonary complications [",
"    <a class=\"abstract\" href=\"UTD.htm?12/51/13113/abstract/35,44,45\">",
"     35,44,45",
"    </a>",
"    ]. CPAP may be beneficial in selected patients. This was illustrated by a trial that randomly chose 500 patients to receive prophylactic CPAP (CPAP at 10 cm H",
"    <sub>",
"     2",
"    </sub>",
"    O continuously for six hours) or the institution's usual care (CPAP at 10 cm H",
"    <sub>",
"     2",
"    </sub>",
"    O for 10 minutes every four hours) after cardiac surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?12/51/13113/abstract/47\">",
"     47",
"    </a>",
"    ]. Prophylactic continuous (&ge;6 hours) nasal CPAP improved oxygenation and reduced the incidence of pneumonia, reintubation, and admission to an ICU.",
"   </p>",
"   <p>",
"    Studies of these interventions have been confounded by a lack of standard definitions of complications and imprecise descriptions of the involved techniques [",
"    <a class=\"abstract\" href=\"UTD.htm?12/51/13113/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. Many trials reporting a benefit have included primarily healthy patients; those with preexisting lung disease at the highest risk of postoperative complications have been underrepresented.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Deep breathing and incentive spirometry &ndash; Deep breathing exercises and incentive spirometry appear to be equally effective and capable of reducing the risk of postoperative pulmonary complications by about one-half. Deep breathing exercises are a component of chest physical therapy. Incentive spirometry involves deep breathing facilitated by a simple mechanical device. One prospective study of 172 patients undergoing abdominal surgery found a 48 percent incidence of postoperative pulmonary complications in an untreated control group, compared with 22 percent in groups receiving either postoperative incentive spirometry or supervised deep breathing exercises [",
"      <a class=\"abstract\" href=\"UTD.htm?12/51/13113/abstract/35\">",
"       35",
"      </a>",
"      ]. A second study randomized 368 patients undergoing elective abdominal surgery to preoperative instruction in deep breathing techniques or standard care, and found a significant decrease in postoperative pulmonary complications in patients who received the educational intervention (6 versus 27 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?12/51/13113/abstract/50\">",
"       50",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      In another report of 456 patients undergoing abdominal surgery, low risk patients who practiced either incentive spirometry or deep breathing exercises had similar rates of pulmonary complications [",
"      <a class=\"abstract\" href=\"UTD.htm?12/51/13113/abstract/45\">",
"       45",
"      </a>",
"      ]. High risk patients, defined as either ASA (American Society of Anesthesiologists) Class greater than 1 or age over 60 years, all received incentive spirometry and were in addition randomized to either chest physical therapy or no additional therapy. There was an insignificant reduction in complications in the combined modality group (13 versus 19 percent).",
"      <br/>",
"      <br/>",
"      A meta-analysis of 14 studies reported similar findings; the odds ratio for postoperative pulmonary complications when compared to no intervention was 0.44 for incentive spirometry and 0.43 for deep breathing exercises [",
"      <a class=\"abstract\" href=\"UTD.htm?12/51/13113/abstract/48\">",
"       48",
"      </a>",
"      ]. Other data suggest less benefit of these interventions in low-risk individuals [",
"      <a class=\"abstract\" href=\"UTD.htm?12/51/13113/abstract/49-51\">",
"       49-51",
"      </a>",
"      ]. In a systematic review of the efficacy of incentive spirometry in reducing pulmonary complications after upper abdominal surgery, the quality of studies was felt to be only moderate and results were mixed [",
"      <a class=\"abstract\" href=\"UTD.htm?12/51/13113/abstract/49\">",
"       49",
"      </a>",
"      ]. In three eligible trials, incentive spirometry was no more effective than no respiratory treatment. On the other hand, complication rates among patients who received incentive spirometry did not differ from those who received deep breathing exercises (two trials) or chest physiotherapy (two trials).",
"      <br/>",
"      <br/>",
"      While the findings have been mixed, given the safety and low cost of this intervention, we advise using incentive spirometry after upper abdominal and thoracic surgery.",
"     </li>",
"     <li>",
"      Intermittent positive pressure breathing &ndash; Intermittent positive pressure breathing (IPPB) was used commonly in the 1960s and 1970s, but it is associated with more complications than other methods of lung expansion. This was illustrated in a prospective study which found that the rates of postoperative pulmonary complications in an IPPB-treated group were similar to those in patients receiving incentive spirometry or voluntary deep breathing exercises [",
"      <a class=\"abstract\" href=\"UTD.htm?12/51/13113/abstract/40\">",
"       40",
"      </a>",
"      ]. However, 18 percent of the IPPB-treated group required discontinuation of therapy due to abdominal distension. In addition IPPB is more costly than other methods of lung expansion. Thus, it should not be used for routine prophylaxis.",
"     </li>",
"     <li>",
"      Continuous positive airway pressure &ndash; Postoperative continuous positive airway pressure (CPAP) offers the potential advantage of being effort-independent. It appears to be as effective as other lung expansion maneuvers, and can be used intermittently or continuously. One report compared the efficacy of postoperative CPAP with positive expiratory pressure and found a similar incidence of pulmonary complications in both groups [",
"      <a class=\"abstract\" href=\"UTD.htm?12/51/13113/abstract/52\">",
"       52",
"      </a>",
"      ]. A second study, which compared CPAP, incentive spirometry, and deep breathing exercises, found the incidence of postoperative atelectasis at 72 hours to be 23, 41, and 42 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?12/51/13113/abstract/51\">",
"       51",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Intermittent CPAP may be associated with complications, including patient discomfort, gastric distension, hypoventilation, and barotrauma [",
"      <a class=\"abstract\" href=\"UTD.htm?12/51/13113/abstract/53\">",
"       53",
"      </a>",
"      ]. It also requires special equipment and is costly. A critical review of lung expansion maneuvers has recommended the use of CPAP as a secondary intervention for refractory atelectasis, but not as a primary postoperative prevention strategy [",
"      <a class=\"abstract\" href=\"UTD.htm?12/51/13113/abstract/48\">",
"       48",
"      </a>",
"      ]. Others have suggested its use for primary prevention in less cooperative patients who are unable to perform regular deep breathing exercises or incentive spirometry [",
"      <a class=\"abstract\" href=\"UTD.htm?12/51/13113/abstract/24\">",
"       24",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/62/44006?source=see_link\">",
"       \"Adherence with continuous positive airway pressure (CPAP)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Pain control",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adequate postoperative pain control may help to minimize postoperative pulmonary complications by enabling earlier ambulation and improving the patient's ability to take deep breaths. This is particularly important after thoracic and upper abdominal surgery. Studies of the effect of postoperative pain management on pulmonary complications have focused on the use of epidural analgesia and intercostal nerve blocks as alternatives to more traditional parenteral opioids.",
"   </p>",
"   <p>",
"    Postoperative pain control has been consistently improved with epidural analgesia compared with parenteral opioids, although results have been mixed with regard to reduction in postoperative pulmonary complications [",
"    <a class=\"abstract\" href=\"UTD.htm?12/51/13113/abstract/54-59\">",
"     54-59",
"    </a>",
"    ]. A systematic review and meta-analysis evaluated the impact of varied postoperative analgesia techniques on medical complication rates after surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?12/51/13113/abstract/60\">",
"     60",
"    </a>",
"    ]. The authors identified two meta-analyses, two subsequent randomized controlled trials, and two observational studies of administrative databases. The relative risks for respiratory failure for patients receiving epidural analgesia ranged from 0.5 to 0.77 among these studies. Comparable rates for postoperative pneumonia ranged from 0.38 to 1.46. The authors concluded that thoracic epidural analgesia reduces postoperative pulmonary complication rates, particularly after high-risk surgery, including abdominal aortic and coronary bypass surgeries.",
"   </p>",
"   <p>",
"    In a subsequent observational study, investigators restricted their analysis to patients with COPD undergoing major abdominal surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?12/51/13113/abstract/59\">",
"     59",
"    </a>",
"    ]. In this report, epidural analgesia was associated with a reduction in postoperative pulmonary complications (OR 0.5, 95% CI 0.3-0.9) that persisted after propensity score matching to adjust for potential confounders.",
"   </p>",
"   <p>",
"    Intercostal nerve blocks have been investigated in patients undergoing upper abdominal surgery. In a study of 417 patients, for example, intercostal blocks reduced the incidence of postoperative pulmonary complications in those who had subcostal but not midline abdominal incisions [",
"    <a class=\"abstract\" href=\"UTD.htm?12/51/13113/abstract/61\">",
"     61",
"    </a>",
"    ]. This benefit was seen only in patients under the age of 50 years. A second uncontrolled study of 76 unselected patients undergoing cholecystectomy who received a continuous postoperative intercostal nerve block reported no postoperative pulmonary complications [",
"    <a class=\"abstract\" href=\"UTD.htm?12/51/13113/abstract/62\">",
"     62",
"    </a>",
"    ]. In the above meta-analysis, intercostal nerve blocks reduced pulmonary complication rates, but the differences were not statistically significant and risk ratios overlapped one [",
"    <a class=\"abstract\" href=\"UTD.htm?12/51/13113/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Nasogastric tube",
"    </span>",
"    &nbsp;&mdash;&nbsp;A meta-analysis of studies comparing routine use of a nasogastric tube (NGT) to decompress the stomach after abdominal surgery with performing NGT placement only in patients who develop a need for decompression postoperatively concluded that the routine use of an NGT significantly increased postoperative pulmonary complications including pneumonia (relative risk [RR] 1.7) and atelectasis (RR 1.9) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/51/13113/abstract/64\">",
"     64",
"    </a>",
"    ]. A subsequent systematic review similarly found a trend toward increased pulmonary complications (combined endpoint of pneumonia and atelectasis) with routine postoperative use of an NGT (odds ratio 1.35, 95% CI 0.98-1.86) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/51/13113/abstract/65\">",
"     65",
"    </a>",
"    ]. We recommend avoiding routine use of NGT decompression after abdominal surgery to decrease the risk of pulmonary complications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients undergoing upper abdominal, thoracic, or aortic aneurysm surgery with additional risk factors for postoperative pulmonary complications are candidates for risk reduction strategies. Interventions should begin in the preoperative period and continue through the postsurgical period. Clinicians should employ multiple strategies to reduce the risk of postoperative pulmonary complications to the fullest possible extent. Patient education regarding lung expansion maneuvers should begin prior to surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Preoperative",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following preoperative interventions are definitely beneficial:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Smoking cessation as early as possible; cessation for eight weeks or longer is likely of greater benefit",
"     </li>",
"     <li>",
"      Inhaled",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/37/33360?source=see_link\">",
"       ipratropium",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/34/27173?source=see_link\">",
"       tiotropium",
"      </a>",
"      for all patients with clinically significant COPD",
"     </li>",
"     <li>",
"      Inhaled beta-agonists for patients with COPD or asthma who have wheezes or dyspnea",
"     </li>",
"     <li>",
"      Preoperative glucocorticoids for patients with COPD or asthma who are not optimized and whose airway obstruction has not been maximally reduced",
"     </li>",
"     <li>",
"      Delay elective surgery if respiratory infection present",
"     </li>",
"     <li>",
"      Antibiotics only for patients with lower respiratory tract infection",
"     </li>",
"     <li>",
"      Preoperative inspiratory muscle training",
"     </li>",
"     <li>",
"      Preoperative chest physical therapy",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Intraoperative",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following intraoperative interventions are definitely beneficial:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Choose alternative procedure lasting less than three to four hours when possible",
"     </li>",
"     <li>",
"      Surgery other than upper abdominal or thoracic when possible",
"     </li>",
"     <li>",
"      Regional anesthesia (nerve block), when this is an option, in very high-risk patients",
"     </li>",
"     <li>",
"      Avoid use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/33/19990?source=see_link\">",
"       pancuronium",
"      </a>",
"      as a muscle relaxant in high-risk patients",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Choosing laparoscopic rather than open abdominal surgery when possible may be beneficial. Epidural or spinal anesthesia may confer lower risk than general anesthesia, though this remains an area of debate. Perioperative pulmonary artery catheterization is not beneficial.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Postoperative",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following postoperative interventions are definitely beneficial:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Deep breathing exercises or incentive spirometry in high risk patients",
"     </li>",
"     <li>",
"      Epidural analgesia in place of parenteral opioids",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Continuous positive airway pressure (CPAP), intercostal nerve blocks, and selective use of nasogastric tubes (for symptoms only) after abdominal surgery are probably beneficial postoperative interventions.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/51/13113/abstract/1\">",
"      Lawrence VA, Hilsenbeck SG, Mulrow CD, et al. Incidence and hospital stay for cardiac and pulmonary complications after abdominal surgery. J Gen Intern Med 1995; 10:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/51/13113/abstract/2\">",
"      Pedersen T. Complications and death following anaesthesia. A prospective study with special reference to the influence of patient-, anaesthesia-, and surgery-related risk factors. Dan Med Bull 1994; 41:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/51/13113/abstract/3\">",
"      McAlister FA, Bertsch K, Man J, et al. Incidence of and risk factors for pulmonary complications after nonthoracic surgery. Am J Respir Crit Care Med 2005; 171:514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/51/13113/abstract/4\">",
"      Hall JC, Tarala RA, Hall JL, Mander J. A multivariate analysis of the risk of pulmonary complications after laparotomy. Chest 1991; 99:923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/51/13113/abstract/5\">",
"      Gracey DR, Divertie MB, Didier EP. Preoperative pulmonary preparation of patients with chronic obstructive pulmonary disease: a prospective study. Chest 1979; 76:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/51/13113/abstract/6\">",
"      Pedersen T, Eliasen K, Henriksen E. A prospective study of risk factors and cardiopulmonary complications associated with anaesthesia and surgery: risk indicators of cardiopulmonary morbidity. Acta Anaesthesiol Scand 1990; 34:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/51/13113/abstract/7\">",
"      Brooks-Brunn JA. Predictors of postoperative pulmonary complications following abdominal surgery. Chest 1997; 111:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/51/13113/abstract/8\">",
"      Warner DO. Preoperative smoking cessation: the role of the primary care provider. Mayo Clin Proc 2005; 80:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/51/13113/abstract/9\">",
"      Smetana GW, Lawrence VA, Cornell JE, American College of Physicians. Preoperative pulmonary risk stratification for noncardiothoracic surgery: systematic review for the American College of Physicians. Ann Intern Med 2006; 144:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/51/13113/abstract/10\">",
"      Mastracci TM, Carli F, Finley RJ, et al. Effect of preoperative smoking cessation interventions on postoperative complications. J Am Coll Surg 2011; 212:1094.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/51/13113/abstract/11\">",
"      Thomsen T, Villebro N, M&oslash;ller AM. Interventions for preoperative smoking cessation. Cochrane Database Syst Rev 2010; :CD002294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/51/13113/abstract/12\">",
"      Myers K, Hajek P, Hinds C, McRobbie H. Stopping smoking shortly before surgery and postoperative complications: a systematic review and meta-analysis. Arch Intern Med 2011; 171:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/51/13113/abstract/13\">",
"      Mills E, Eyawo O, Lockhart I, et al. Smoking cessation reduces postoperative complications: a systematic review and meta-analysis. Am J Med 2011; 124:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/51/13113/abstract/14\">",
"      Wheatley IC, Hardy KJ, Barter CE. An evaluation of preoperative methods of preventing postoperative pulmonary complications. Anaesth Intensive Care 1977; 5:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/51/13113/abstract/15\">",
"      Warner MA, Divertie MB, Tinker JH. Preoperative cessation of smoking and pulmonary complications in coronary artery bypass patients. Anesthesiology 1984; 60:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/51/13113/abstract/16\">",
"      Tarhan S, Moffitt EA, Sessler AD, et al. Risk of anesthesia and surgery in patients with chronic bronchitis and chronic obstructive pulmonary disease. Surgery 1973; 74:720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/51/13113/abstract/17\">",
"      Gourgiotis S, Aloizos S, Aravosita P, et al. The effects of tobacco smoking on the incidence and risk of intraoperative and postoperative complications in adults. Surgeon 2011; 9:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/51/13113/abstract/18\">",
"      Warner DO. Perioperative abstinence from cigarettes: physiologic and clinical consequences. Anesthesiology 2006; 104:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/51/13113/abstract/19\">",
"      Warner MA, Offord KP, Warner ME, et al. Role of preoperative cessation of smoking and other factors in postoperative pulmonary complications: a blinded prospective study of coronary artery bypass patients. Mayo Clin Proc 1989; 64:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/51/13113/abstract/20\">",
"      M&oslash;ller AM, Villebro N, Pedersen T, T&oslash;nnesen H. Effect of preoperative smoking intervention on postoperative complications: a randomised clinical trial. Lancet 2002; 359:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/51/13113/abstract/21\">",
"      Kroenke K, Lawrence VA, Theroux JF, Tuley MR. Operative risk in patients with severe obstructive pulmonary disease. Arch Intern Med 1992; 152:967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/51/13113/abstract/22\">",
"      Stein M, Cassara EL. Preoperative pulmonary evaluation and therapy for surgery patients. JAMA 1970; 211:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/51/13113/abstract/23\">",
"      Celli BR. Perioperative respiratory care of the patient undergoing upper abdominal surgery. Clin Chest Med 1993; 14:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/51/13113/abstract/24\">",
"      GOLD MI, HELRICH M. A study of complications related to anesthesia in asthmatic patients. Anesth Analg 1963; 42:238.",
"     </a>",
"    </li>",
"    <li>",
"     National Asthma Education and Prevention Program: Expert panel report III: Guidelines for the diagnosis and management of asthma. Bethesda, MD: National Heart, Lung, and Blood Institute, 2007. (NIH publication no. 08-4051) www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm (Accessed on January 05, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/51/13113/abstract/26\">",
"      Kabalin CS, Yarnold PR, Grammer LC. Low complication rate of corticosteroid-treated asthmatics undergoing surgical procedures. Arch Intern Med 1995; 155:1379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/51/13113/abstract/27\">",
"      Pien LC, Grammer LC, Patterson R. Minimal complications in a surgical population with severe asthma receiving prophylactic corticosteroids. J Allergy Clin Immunol 1988; 82:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/51/13113/abstract/28\">",
"      Oh SH, Patterson R. Surgery in corticosteroid-dependent asthmatics. J Allergy Clin Immunol 1974; 53:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/51/13113/abstract/29\">",
"      Dahl R. Systemic side effects of inhaled corticosteroids in patients with asthma. Respir Med 2006; 100:1307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/51/13113/abstract/30\">",
"      Tait AR, Knight PR. The effects of general anesthesia on upper respiratory tract infections in children. Anesthesiology 1987; 67:930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/51/13113/abstract/31\">",
"      Fennelly ME, Hall GM. Anaesthesia and upper respiratory tract infections--a non-existent hazard? Br J Anaesth 1990; 64:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/51/13113/abstract/32\">",
"      Hulzebos EH, Helders PJ, Favi&eacute; NJ, et al. Preoperative intensive inspiratory muscle training to prevent postoperative pulmonary complications in high-risk patients undergoing CABG surgery: a randomized clinical trial. JAMA 2006; 296:1851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/51/13113/abstract/33\">",
"      Valkenet K, van de Port IG, Dronkers JJ, et al. The effects of preoperative exercise therapy on postoperative outcome: a systematic review. Clin Rehabil 2011; 25:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/51/13113/abstract/34\">",
"      Hulzebos EH, Smit Y, Helders PP, van Meeteren NL. Preoperative physical therapy for elective cardiac surgery patients. Cochrane Database Syst Rev 2012; 11:CD010118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/51/13113/abstract/35\">",
"      Celli BR, Rodriguez KS, Snider GL. A controlled trial of intermittent positive pressure breathing, incentive spirometry, and deep breathing exercises in preventing pulmonary complications after abdominal surgery. Am Rev Respir Dis 1984; 130:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/51/13113/abstract/36\">",
"      Pedersen T, Viby-Mogensen J, Ringsted C. Anaesthetic practice and postoperative pulmonary complications. Acta Anaesthesiol Scand 1992; 36:812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/51/13113/abstract/37\">",
"      Lawrence VA, Cornell JE, Smetana GW, American College of Physicians. Strategies to reduce postoperative pulmonary complications after noncardiothoracic surgery: systematic review for the American College of Physicians. Ann Intern Med 2006; 144:596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/51/13113/abstract/38\">",
"      Rodgers A, Walker N, Schug S, et al. Reduction of postoperative mortality and morbidity with epidural or spinal anaesthesia: results from overview of randomised trials. BMJ 2000; 321:1493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/51/13113/abstract/39\">",
"      Bevan DR, Smith CE, Donati F. Postoperative neuromuscular blockade: a comparison between atracurium, vecuronium, and pancuronium. Anesthesiology 1988; 69:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/51/13113/abstract/40\">",
"      Andersen BN, Madsen JV, Schurizek BA, Juhl B. Residual curarisation: a comparative study of atracurium and pancuronium. Acta Anaesthesiol Scand 1988; 32:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/51/13113/abstract/41\">",
"      Berg H, Roed J, Viby-Mogensen J, et al. Residual neuromuscular block is a risk factor for postoperative pulmonary complications. A prospective, randomised, and blinded study of postoperative pulmonary complications after atracurium, vecuronium and pancuronium. Acta Anaesthesiol Scand 1997; 41:1095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/51/13113/abstract/42\">",
"      Garibaldi RA, Britt MR, Coleman ML, et al. Risk factors for postoperative pneumonia. Am J Med 1981; 70:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/51/13113/abstract/43\">",
"      Brooks-Brunn JA. Postoperative atelectasis and pneumonia. Heart Lung 1995; 24:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/51/13113/abstract/44\">",
"      Fagevik Ols&eacute;n M, Hahn I, Nordgren S, et al. Randomized controlled trial of prophylactic chest physiotherapy in major abdominal surgery. Br J Surg 1997; 84:1535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/51/13113/abstract/45\">",
"      Hall JC, Tarala RA, Tapper J, Hall JL. Prevention of respiratory complications after abdominal surgery: a randomised clinical trial. BMJ 1996; 312:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/51/13113/abstract/46\">",
"      Sandham JD, Hull RD, Brant RF, et al. A randomized, controlled trial of the use of pulmonary-artery catheters in high-risk surgical patients. N Engl J Med 2003; 348:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/51/13113/abstract/47\">",
"      Zarbock A, Mueller E, Netzer S, et al. Prophylactic nasal continuous positive airway pressure following cardiac surgery protects from postoperative pulmonary complications: a prospective, randomized, controlled trial in 500 patients. Chest 2009; 135:1252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/51/13113/abstract/48\">",
"      Thomas JA, McIntosh JM. Are incentive spirometry, intermittent positive pressure breathing, and deep breathing exercises effective in the prevention of postoperative pulmonary complications after upper abdominal surgery? A systematic overview and meta-analysis. Phys Ther 1994; 74:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/51/13113/abstract/49\">",
"      Guimar&atilde;es MM, El Dib R, Smith AF, Matos D. Incentive spirometry for prevention of postoperative pulmonary complications in upper abdominal surgery. Cochrane Database Syst Rev 2009; :CD006058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/51/13113/abstract/50\">",
"      Schwieger I, Gamulin Z, Forster A, et al. Absence of benefit of incentive spirometry in low-risk patients undergoing elective cholecystectomy. A controlled randomized study. Chest 1986; 89:652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/51/13113/abstract/51\">",
"      Stock MC, Downs JB, Gauer PK, et al. Prevention of postoperative pulmonary complications with CPAP, incentive spirometry, and conservative therapy. Chest 1985; 87:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/51/13113/abstract/52\">",
"      Ingwersen UM, Larsen KR, Bertelsen MT, et al. Three different mask physiotherapy regimens for prevention of post-operative pulmonary complications after heart and pulmonary surgery. Intensive Care Med 1993; 19:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/51/13113/abstract/53\">",
"      Scuderi, J, Olsen, GN. Respiratory therapy in the management of postoperative complications. Resp Care 1989; 34:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/51/13113/abstract/54\">",
"      Cuschieri RJ, Morran CG, Howie JC, McArdle CS. Postoperative pain and pulmonary complications: comparison of three analgesic regimens. Br J Surg 1985; 72:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/51/13113/abstract/55\">",
"      Major CP Jr, Greer MS, Russell WL, Roe SM. Postoperative pulmonary complications and morbidity after abdominal aneurysmectomy: a comparison of postoperative epidural versus parenteral opioid analgesia. Am Surg 1996; 62:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/51/13113/abstract/56\">",
"      Tsui SL, Law S, Fok M, et al. Postoperative analgesia reduces mortality and morbidity after esophagectomy. Am J Surg 1997; 173:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/51/13113/abstract/57\">",
"      Jayr C, Thomas H, Rey A, et al. Postoperative pulmonary complications. Epidural analgesia using bupivacaine and opioids versus parenteral opioids. Anesthesiology 1993; 78:666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/51/13113/abstract/58\">",
"      Hjorts&oslash; NC, Neumann P, Fr&oslash;sig F, et al. A controlled study on the effect of epidural analgesia with local anaesthetics and morphine on morbidity after abdominal surgery. Acta Anaesthesiol Scand 1985; 29:790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/51/13113/abstract/59\">",
"      van Lier F, van der Geest PJ, Hoeks SE, et al. Epidural analgesia is associated with improved health outcomes of surgical patients with chronic obstructive pulmonary disease. Anesthesiology 2011; 115:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/51/13113/abstract/60\">",
"      Liu SS, Wu CL. Effect of postoperative analgesia on major postoperative complications: a systematic update of the evidence. Anesth Analg 2007; 104:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/51/13113/abstract/61\">",
"      Engberg G, Wiklund L. Pulmonary complications after upper abdominal surgery: their prevention with intercostal blocks. Acta Anaesthesiol Scand 1988; 32:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/51/13113/abstract/62\">",
"      Hashimi H, Stewart AL, Ah-Fat G. Continuous intercostal nerve block for postoperative analgesia after surgical treatment of the upper part of the abdomen. Surg Gynecol Obstet 1991; 173:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/51/13113/abstract/63\">",
"      Ballantyne JC, Carr DB, deFerranti S, et al. The comparative effects of postoperative analgesic therapies on pulmonary outcome: cumulative meta-analyses of randomized, controlled trials. Anesth Analg 1998; 86:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/51/13113/abstract/64\">",
"      Cheatham ML, Chapman WC, Key SP, Sawyers JL. A meta-analysis of selective versus routine nasogastric decompression after elective laparotomy. Ann Surg 1995; 221:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/51/13113/abstract/65\">",
"      Nelson R, Edwards S, Tse B. Prophylactic nasogastric decompression after abdominal surgery. Cochrane Database Syst Rev 2005; :CD004929.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6970 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-8641F3AC89-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_51_13113=[""].join("\n");
var outline_f12_51_13113=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PREOPERATIVE STRATEGIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Smoking cessation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Chronic obstructive lung disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Asthma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Antibiotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Upper respiratory infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H94581694\">",
"      Inspiratory muscle training",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H94581765\">",
"      Chest physical therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Patient education",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      INTRAOPERATIVE STRATEGIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Anesthesia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Neuromuscular blockade",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Duration of surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Type of surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      PA catheterization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      POSTOPERATIVE STRATEGIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Lung expansion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Pain control",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Nasogastric tube",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Preoperative",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Intraoperative",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Postoperative",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/6970\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/6970|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?43/33/44563\" title=\"figure 1\">",
"      Stepwise asthma Rx 12 and up",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/6970|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/33/39453\" title=\"table 1\">",
"      Adjusting Rx 12 and up",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/62/44006?source=related_link\">",
"      Adherence with continuous positive airway pressure (CPAP)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/26/8618?source=related_link\">",
"      Beta agonists in asthma: Acute administration and prophylactic use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/8/1162?source=related_link\">",
"      Evaluation of preoperative pulmonary risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/26/39338?source=related_link\">",
"      Management of stable chronic obstructive pulmonary disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/35/31290?source=related_link\">",
"      Overview of control measures to prevent surgical site infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/3/23609?source=related_link\">",
"      Overview of smoking cessation management in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/2/15400?source=related_link\">",
"      Preoperative evaluation for lung resection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/62/17384?source=related_link\">",
"      The surgical patient taking glucocorticoids",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_51_13114="Management of acetaminophen (paracetamol) poisoning in children and adolescents";
var content_f12_51_13114=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of acetaminophen (paracetamol) poisoning in children and adolescents",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/51/13114/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/51/13114/contributors\">",
"     Kennon Heard, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/51/13114/contributors\">",
"     Richard Dart, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/51/13114/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/51/13114/contributors\">",
"     Michele Burns Ewald, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/51/13114/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/51/13114/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/51/13114/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 3, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since its clinical introduction in 1950,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    (N-acetyl-p-aminophenol; APAP; paracetamol) has become the most widely used analgesic-antipyretic in the United States. The popularity of acetaminophen among pediatricians increased when concerns were raised about an association between",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/10/19624?source=see_link\">",
"     aspirin",
"    </a>",
"    and Reye's syndrome.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"     Acetaminophen",
"    </a>",
"    is available in hundreds of over-the-counter and prescription medications. Although it is remarkably safe when used at therapeutic doses, overdose of acetaminophen has been recognized to cause fatal and nonfatal hepatic necrosis since 1966 [",
"    <a class=\"abstract\" href=\"UTD.htm?12/51/13114/abstract/1\">",
"     1",
"    </a>",
"    ]. In addition, repeated supratherapeutic doses can cause hepatotoxicity in children with certain risk factors, including decreased oral intake [",
"    <a class=\"abstract\" href=\"UTD.htm?12/51/13114/abstract/2-4\">",
"     2-4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The management of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    intoxication in children and adolescents will be presented here. The clinical manifestations and diagnosis of acetaminophen poisoning in children and the evaluation and management of acetaminophen poisoning in adults is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/42/22186?source=see_link\">",
"     \"Clinical manifestations and diagnosis of acetaminophen (paracetamol) poisoning in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/43/25274?source=see_link\">",
"     \"Acetaminophen (paracetamol) poisoning in adults: Pathophysiology, presentation, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/10/32937?source=see_link\">",
"     \"Acetaminophen (paracetamol) poisoning in adults: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5088338\">",
"    <span class=\"h1\">",
"     APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial management of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    poisoning in children and adolescents depends upon the type of exposure and the patient&rsquo;s clinical status:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3866170\">",
"    <span class=\"h2\">",
"     Exploratory ingestions in young children",
"    </span>",
"    &nbsp;&mdash;&nbsp;These exposures usually involve small amounts of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    in an otherwise asymptomatic child. Hepatotoxicity is rare. Treatment consists of the following (see",
"    <a class=\"local\" href=\"#H31\">",
"     'Management of acute poisoning'",
"    </a>",
"    below):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Administering",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?32/47/33525?source=see_link\">",
"       activated charcoal",
"      </a>",
"      to children who present within four hours of exposure and have ingested a potentially toxic dose or an unknown amount of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"       acetaminophen",
"      </a>",
"      . (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/42/22186?source=see_link&amp;anchor=H5084986#H5084986\">",
"       \"Clinical manifestations and diagnosis of acetaminophen (paracetamol) poisoning in children and adolescents\", section on 'Toxic dose'",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H32\">",
"       'Gastrointestinal decontamination'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Plotting a timed serum",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"       acetaminophen",
"      </a>",
"      level that is obtained a minimum of four hours after ingestion on the treatment nomogram for acetaminophen poisoning (",
"      <a class=\"graphic graphic_figure graphicRef83590 \" href=\"UTD.htm?24/56/25472\">",
"       figure 1",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/42/22186?source=see_link&amp;anchor=H5085042#H5085042\">",
"       \"Clinical manifestations and diagnosis of acetaminophen (paracetamol) poisoning in children and adolescents\", section on 'Acetaminophen level'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Administering the antidote, N-",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?15/41/16022?source=see_link\">",
"       acetylcysteine",
"      </a>",
"      to those children with an",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"       acetaminophen",
"      </a>",
"      level that indicates significant potential for toxicity. (See",
"      <a class=\"local\" href=\"#H33\">",
"       'N-acetylcysteine'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3866179\">",
"    <span class=\"h2\">",
"     Intentional ingestions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The likelihood for",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    toxicity and coingestants is much higher for these patients. Patients who present less than four hours after ingestion and who are asymptomatic may be managed as described for exploratory ingestions in young children above. Additional therapeutic considerations include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Supportive care of airway, breathing, and circulation related to toxicity of coingestants may be required. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/60/22474?source=see_link&amp;anchor=H4#H4\">",
"       \"Approach to the child with occult toxic exposure\", section on 'Initial evaluation and stabilization'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Administration of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?32/47/33525?source=see_link\">",
"       activated charcoal",
"      </a>",
"      to patients receiving treatment within four hours of ingestion. Patients who present for care after four hours are unlikely to benefit from activated charcoal unless agents that slow gastric motility, such as calcium channel blockers, anticholinergic agents, or opioids were also ingested. (See",
"      <a class=\"local\" href=\"#H32\">",
"       'Gastrointestinal decontamination'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Patients who present more than six hours after ingestion should have an",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"       acetaminophen",
"      </a>",
"      level obtained as soon as possible, but should also receive empiric treatment with N-",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?15/41/16022?source=see_link\">",
"       acetylcysteine",
"      </a>",
"      (NAC), pending these results. (See",
"      <a class=\"local\" href=\"#H33\">",
"       'N-acetylcysteine'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Patients who present more than 24 hours after acute ingestion may manifest symptoms and signs of hepatic injury or failure, such as nausea, vomiting, jaundice, abdominal pain, renal injury, coagulopathy (eg, gastrointestinal bleeding), hepatic encephalopathy, cerebral edema, or hypotension. These patients should be treated as for chronic",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"       acetaminophen",
"      </a>",
"      poisoning. Serum concentrations of acetaminophen in this setting do not correlate with toxicity and the treatment nomogram for acetaminophen poisoning should",
"      <strong>",
"       not",
"      </strong>",
"      be used. However, the presence of unmetabolized acetaminophen in patients with other findings suggestive of liver toxicity is a potential indication for NAC administration. (See",
"      <a class=\"local\" href=\"#H39\">",
"       'Management of chronic poisoning'",
"      </a>",
"      below.)",
"      <br/>",
"      <br/>",
"      These patients may also require emergent resuscitation, including airway management, intravenous fluids, vasopressors, hemodialysis, or management of cerebral edema. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/40/38538?source=see_link\">",
"       \"Acute liver failure in adults: Management and prognosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3866187\">",
"    <span class=\"h2\">",
"     Inappropriate therapeutic dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Significant hepatotoxicity and mortality have been described in children receiving inappropriately high doses of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    (&gt;90",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) for more than one day. These patients may present with clinical findings including nausea, vomiting, right upper quadrant pain, and hepatotoxicity which may include fulminant hepatic failure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/42/22186?source=see_link&amp;anchor=H5084958#H5084958\">",
"     \"Clinical manifestations and diagnosis of acetaminophen (paracetamol) poisoning in children and adolescents\", section on 'Inappropriate dosing by a caregiver'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Diagnosis of chronic",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    intoxication (repeated excessive dosing) is often difficult and requires the combination of astute history-taking and recognition of typical clinical and laboratory abnormalities. Signs and symptoms are insidious in onset, often nonspecific, and easily confused with alternative diagnoses (eg, viral syndrome). Serum concentrations of acetaminophen in this setting do not correlate with toxicity and the treatment nomogram for acetaminophen poisoning should",
"    <strong>",
"     not",
"    </strong>",
"    be used. Establishing the diagnosis of chronic acetaminophen poisoning frequently involves exclusion of other causes of clinical hepatitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/42/22186?source=see_link&amp;anchor=H5085007#H5085007\">",
"     \"Clinical manifestations and diagnosis of acetaminophen (paracetamol) poisoning in children and adolescents\", section on 'Chronic exposures'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/42/22186?source=see_link&amp;anchor=H5085049#H5085049\">",
"     \"Clinical manifestations and diagnosis of acetaminophen (paracetamol) poisoning in children and adolescents\", section on 'Differential diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is no consensus regarding the management of these children. Serum",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    level, alanine aminotransferase measurement, and prothrombin time are helpful in determining further treatment. Consultation with a regional poison control center (1-800-222-1222) or medical toxicologist is advised. (See",
"    <a class=\"local\" href=\"#H12865251\">",
"     'Additional resources'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3866195\">",
"    <span class=\"h2\">",
"     Iatrogenic intravenous overdose",
"    </span>",
"    &nbsp;&mdash;&nbsp;Until further information is available, consultation with a poison control center or medical toxicologist is strongly advised for children who have received an iatrogenic overdose of intravenous",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    . (See",
"    <a class=\"local\" href=\"#H12865251\">",
"     'Additional resources'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The approach to overdose with intravenous",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    is based upon case reports and expert opinion and is controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?12/51/13114/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Some medical toxicologists recommend treatment of all children who receive an intravenous dose &gt;60",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?12/51/13114/abstract/6\">",
"     6",
"    </a>",
"    ]. This conservative position is supported by a case of possible hepatotoxicity (elevated liver enzymes and international normalized ratio) with full recovery after a single intravenous dose of 75",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    in a five month old child with intussusception [",
"    <a class=\"abstract\" href=\"UTD.htm?12/51/13114/abstract/7\">",
"     7",
"    </a>",
"    ], as well as the consideration that IV acetaminophen is more likely to be used in children who are postoperative, fasting, and likely to have depleted glutathione stores which increases the risk for hepatotoxicity.",
"   </p>",
"   <p>",
"    However, other experts point out that the liver abnormalities in the single case report noted above occurred too quickly after the",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    overdose to be attributable to poisoning and were more consistent with hepatic injury from the underlying illness which was associated with shock and required abdominal surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?12/51/13114/abstract/5\">",
"     5",
"    </a>",
"    ]. Furthermore, critics of the conservative position note that intravenous acetaminophen administration avoids the first pass effect and is likely to result in less production of the toxic metabolite, n-amino-p-benzoquinoneimine in the liver, despite a higher peak concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?12/51/13114/abstract/5\">",
"     5",
"    </a>",
"    ]. They recommend that only children who receive &gt;150",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    of acetaminophen intravenously have a four hour serum acetaminophen level plotted on the treatment nomogram for acetaminophen (",
"    <a class=\"graphic graphic_figure graphicRef83590 \" href=\"UTD.htm?24/56/25472\">",
"     figure 1",
"    </a>",
"    ) and that antidotal therapy only be provided to children with an acetaminophen level above the treatment line.",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF ACUTE POISONING",
"    </span>",
"    &nbsp;&mdash;&nbsp;After an appropriate history is obtained, initial treatment of the child with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    exposure and \"possible hepatotoxicity\" (",
"    <a class=\"graphic graphic_figure graphicRef83590 \" href=\"UTD.htm?24/56/25472\">",
"     figure 1",
"    </a>",
"    ) is similar to that of adults. Management focuses on decontamination with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?32/47/33525?source=see_link\">",
"     activated charcoal",
"    </a>",
"    (AC) and administration of the acetaminophen antidote, N-",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?15/41/16022?source=see_link\">",
"     acetylcysteine",
"    </a>",
"    (NAC) as modified by specific types of exposure. (See",
"    <a class=\"local\" href=\"#H5088338\">",
"     'Approach'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/10/32937?source=see_link\">",
"     \"Acetaminophen (paracetamol) poisoning in adults: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Gastrointestinal decontamination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children who present soon after a potentially toxic ingestion of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    (single dose &ge;150",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    or 7.5 g) are likely to benefit from gastrointestinal decontamination. We suggest treatment with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?32/47/33525?source=see_link\">",
"     activated charcoal",
"    </a>",
"    (AC), 1",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    (maximum dose 50 g) by mouth in all patients who present within four hours of a known or suspected acetaminophen ingestion, unless there are contraindications to its administration, such as gastrointestinal obstruction or altered mental status with an unprotected airway.",
"   </p>",
"   <p>",
"    AC should be withheld in patients who are sedated and may not be able to protect their airway, unless endotracheal intubation is performed first. However, endotracheal intubation should not be performed solely for the purpose of giving AC. Asymptomatic patients who present more than four hours after reported",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    ingestions are unlikely to benefit from AC, and we do not recommend routine treatment in these patients. However, AC may be useful beyond four hours in the presence of certain coingestants that may delay absorption of acetaminophen (eg, sustained-release preparations or agents that slows gut motility such as calcium channel blockers, anticholinergic agents, or opioids).",
"   </p>",
"   <p>",
"    A number of studies using simulated overdose models in adults have shown that AC reduces",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    exposure and peak acetaminophen levels maximally when given within one hour of ingestion, and that this reduction in acetaminophen absorption is not significant when AC is given four hours after ingestion [",
"    <a class=\"abstract\" href=\"UTD.htm?12/51/13114/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several observational studies primarily performed in adult and adolescent patients with acute",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    overdose support these findings but also suggest a benefit for AC administration beyond one hour:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a retrospective study of 981 consecutive patients with an acute",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"       acetaminophen",
"      </a>",
"      overdose, patients who received AC within two hours of ingestion were less likely to require N-",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?15/41/16022?source=see_link\">",
"       acetylcysteine",
"      </a>",
"      (NAC) treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?12/51/13114/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another prospective observational study of 145 patients who presented over four hours after",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"       acetaminophen",
"      </a>",
"      ingestion and had serum levels in the probable toxicity range on the treatment nomogram for acetaminophen poisoning, administration of AC with NAC was significantly associated with fewer patients attaining peak alanine aminotransferase (ALT) concentrations &gt;1000",
"      <span class=\"nowrap\">",
"       IU/L",
"      </span>",
"      when compared to treatment with NAC alone (2 versus 36 percent, respectively). These effects were independent of the time of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?15/41/16022?source=see_link\">",
"       acetylcysteine",
"      </a>",
"      administration. While limited, this study suggests that administration of AC up to 16 hours after ingestion may be beneficial in selected patients [",
"      <a class=\"abstract\" href=\"UTD.htm?12/51/13114/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a prospective study of 122 patients with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"       acetaminophen",
"      </a>",
"      overdose, administration of AC prior to N-",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?15/41/16022?source=see_link\">",
"       acetylcysteine",
"      </a>",
"      (NAC) was associated with significantly less liver injury (AST &gt;125",
"      <span class=\"nowrap\">",
"       IU/L)",
"      </span>",
"      than treatment with NAC alone (5 versus 25 percent, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?12/51/13114/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Taken together, these studies suggest that limiting treatment with AC to one hour after",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    ingestion as indicated by volunteer studies and the simulated overdose studies may overly restrict the benefit of AC as demonstrated in observational studies of poisoned patients. However, the studies in poisoned patients have focused on liver enzyme elevation as the primary outcome which may not be clinically relevant and have evaluated a small number of patients who receive AC more than four hours after acetaminophen overdose. Thus, the true benefit of AC when administered more than four hours after acetaminophen overdose is uncertain.",
"   </p>",
"   <p>",
"    We recommend that children with a potentially toxic ingestion of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    not undergo gastric emptying with either gastric lavage or syrup of ipecac. Although these procedures have been shown to lower peak serum acetaminophen levels in adolescents and adults, they are significantly less effective than",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?32/47/33525?source=see_link\">",
"     activated charcoal",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?12/51/13114/abstract/12\">",
"     12",
"    </a>",
"    ]. Furthermore, gastric lavage can increase the risk of aspiration in poisoned patients and persistent vomiting from syrup of ipecac may delay administration of oral N-",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?15/41/16022?source=see_link\">",
"     acetylcysteine",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/1/37913?source=see_link&amp;anchor=H13#H13\">",
"     \"Decontamination of poisoned children\", section on 'Adverse effects'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/1/37913?source=see_link&amp;anchor=H3#H3\">",
"     \"Decontamination of poisoned children\", section on 'Syrup of ipecac'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     N-acetylcysteine",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend that all patients at significant risk for hepatotoxicity following",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    overdose receive N-",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?15/41/16022?source=see_link\">",
"     acetylcysteine",
"    </a>",
"    (NAC).",
"   </p>",
"   <p>",
"    There are no trials comparing NAC to supportive treatment alone. However, large cohort studies have shown that, when compared to historical control patients who received supportive care alone, administration of NAC within 8 to 10 hours of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    overdose has been associated with a significant reduction in hepatotoxicity (58.0 to 1.6 percent) and mortality (5.0 to 0.7 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/51/13114/abstract/9,13,14\">",
"     9,13,14",
"    </a>",
"    ]. Furthermore, when NAC is administered late (ie, more than 24 hours) following acetaminophen ingestion to adults with evidence of hepatic failure, it was associated with decreased the development of cerebral edema, improved hepatic function, and decreased mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?12/51/13114/abstract/15-17\">",
"     15-17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mechanism of action and efficacy of NAC in the treatment of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    intoxication are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/10/32937?source=see_link&amp;anchor=H4#H4\">",
"     \"Acetaminophen (paracetamol) poisoning in adults: Treatment\", section on 'Antidote: acetylcysteine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h3\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Indications for NAC therapy in children and adolescents include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Serum",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"       acetaminophen",
"      </a>",
"      concentration above the \"treatment\" line of the treatment nomogram for acetaminophen poisoning (",
"      <a class=\"graphic graphic_figure graphicRef83590 \" href=\"UTD.htm?24/56/25472\">",
"       figure 1",
"      </a>",
"      ) following acute ingestion of an immediate-release preparation. Some experts only treat those patients with serum acetaminophen concentrations above the \"probable hepatic toxicity\" line (",
"      <a class=\"graphic graphic_figure graphicRef83590 \" href=\"UTD.htm?24/56/25472\">",
"       figure 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?12/51/13114/abstract/18\">",
"       18",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/42/22186?source=see_link&amp;anchor=H5085042#H5085042\">",
"       \"Clinical manifestations and diagnosis of acetaminophen (paracetamol) poisoning in children and adolescents\", section on 'Acetaminophen level'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A suspected single ingestion of greater than 150",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      (7.5 g total dose regardless of weight) in a patient for whom the serum",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"       acetaminophen",
"      </a>",
"      concentration will not be available until more than eight hours from the time of the ingestion. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/42/22186?source=see_link&amp;anchor=H5084986#H5084986\">",
"       \"Clinical manifestations and diagnosis of acetaminophen (paracetamol) poisoning in children and adolescents\", section on 'Toxic dose'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with an unknown time of ingestion beyond 24 hours and a serum",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"       acetaminophen",
"      </a>",
"      concentration &gt;10",
"      <span class=\"nowrap\">",
"       mcg/mL",
"      </span>",
"      (66",
"      <span class=\"nowrap\">",
"       &micro;mol/L).",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H39\">",
"       'Management of chronic poisoning'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Patients with delayed presentation (&gt;24 hours after ingestion) consisting of laboratory evidence of hepatotoxicity (from mildly elevated aminotransferases to fulminant hepatic failure) and a history of excessive",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"       acetaminophen",
"      </a>",
"      ingestion. Children with delayed presentation and hepatic injury should be managed in consultation with a regional poison control center (1-800-222-1222 in the United States) or a medical toxicologist. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/42/22186?source=see_link&amp;anchor=H5085028#H5085028\">",
"       \"Clinical manifestations and diagnosis of acetaminophen (paracetamol) poisoning in children and adolescents\", section on 'Chronic overdoses'",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H12865251\">",
"       'Additional resources'",
"      </a>",
"      below.)",
"      <br/>",
"      <br/>",
"      The use of N-",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?15/41/16022?source=see_link\">",
"       acetylcysteine",
"      </a>",
"      (NAC) in children with delayed (&gt;24 hours) presentation of acetaminophen intoxication has not been studied. However, in a trial of 50 adults with delayed presentation and acetaminophen-induced fulminant hepatic failure, the use of intravenous NAC reduced mortality (20 versus 48 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?12/51/13114/abstract/15\">",
"       15",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Controlled studies evaluating the use of NAC in patients with delayed presentation and hepatotoxicity, but without signs of hepatic failure, have also not been performed. Nonetheless, many medical toxicologists recommend the use of NAC in patients with delayed presentation, unmetabolized acetaminophen in the serum,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      evidence of hepatic injury [",
"      <a class=\"abstract\" href=\"UTD.htm?12/51/13114/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h3\">",
"     Administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;No trials have compared the 21 hour intravenous (IV) and the 72 hour oral treatment regimens for N-",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?15/41/16022?source=see_link\">",
"     acetylcysteine",
"    </a>",
"    (NAC). Pooled data from a systematic review demonstrate efficacy for both routes of administration in the treatment of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    poisoning and minimal differences in efficacy as long as the antidote is given within 10 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?12/51/13114/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    NAC should be administered intravenously to children with any of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intractable vomiting",
"     </li>",
"     <li>",
"      Contraindications to oral administration (eg, aspiration risk due to altered mental status, pancreatitis, bowel ileus or obstruction, or bowel injury)",
"     </li>",
"     <li>",
"      Hepatic failure (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/10/32937?source=see_link&amp;anchor=H13#H13\">",
"       \"Acetaminophen (paracetamol) poisoning in adults: Treatment\", section on 'Treatment in hepatic failure'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Patients who refuse oral administration",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The regimens for oral or IV administration of NAC are as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Oral &ndash;",
"      </strong>",
"      The standard oral N-",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?15/41/16022?source=see_link\">",
"       acetylcysteine",
"      </a>",
"      treatment regimen has been regularly used in the United States for over 30 years. It consists of a 72-hour oral course given as a 140",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      loading dose followed by 17 doses of 70",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      every four hours (total dose 1330",
"      <span class=\"nowrap\">",
"       mg/kg)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?12/51/13114/abstract/13\">",
"       13",
"      </a>",
"      ]. This regimen has the theoretical advantage of delivering the antidote to the portal circulation in patients with oral ingestions. The noxious odor and taste of the preparation sometimes results in problems with vomiting and inability of children to tolerate the full oral course. (See",
"      <a class=\"local\" href=\"#H242394\">",
"       'Vomiting'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      <strong>",
"       Intravenous",
"      </strong>",
"      &ndash; The 21 hour intravenous (IV) protocol for",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?15/41/16022?source=see_link\">",
"       acetylcysteine",
"      </a>",
"      treatment has been used in the United Kingdom since the 1970s [",
"      <a class=\"abstract\" href=\"UTD.htm?12/51/13114/abstract/20\">",
"       20",
"      </a>",
"      ]. The approved IV dosing regime is complicated and requires special care in children to avoid administration of excess free water. Fluid overload and dosing errors in young children receiving IV NAC have resulted in hyponatremia, seizures, and death.",
"      <br/>",
"      <br/>",
"      A total dose of 300",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      of NAC is given intravenously over 21 hours. IV NAC is compatible with 5 percent dextrose, 0.45 percent normal saline (ie,",
"      <span class=\"nowrap\">",
"       1/2",
"      </span>",
"      normal saline), and water for injection. Detailed prescribing information, post-marketing safety data, and a dosing calculator are available from the manufacturer [",
"      <a class=\"abstract\" href=\"UTD.htm?12/51/13114/abstract/21\">",
"       21",
"      </a>",
"      ]. Children &ge;40 kg may receive IV NAC as recommended for adults. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/10/32937?source=see_link&amp;anchor=H6#H6\">",
"       \"Acetaminophen (paracetamol) poisoning in adults: Treatment\", section on '20 hour IV protocol'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      The manufacturer recommends the following weight-based dilution in children who weigh &lt;40 kg:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients &le;20 kg:",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Loading dose: 150",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      in 3 mL per kg of diluent given IV over 60 minutes",
"     </li>",
"     <li>",
"      Second dose: 50",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      in 7 mL per kg of diluent given IV over 4 hours (12.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      NAC per hour)",
"     </li>",
"     <li>",
"      Third dose: 100",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      in 14 mL per kg of diluent given IV over 16 hours (6.25",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      NAC per hour)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients &gt;20 and &lt;40 kg:",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Loading dose: 150",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      in 100 mL of diluent given IV over 60 minutes",
"     </li>",
"     <li>",
"      Second dose: 50",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      in 250 mL of diluent given IV over 4 hours (12.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      NAC per hour)",
"     </li>",
"     <li>",
"      Third dose: 100",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      in 500 mL of diluent administered over 16 hours (6.25",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      NAC per hour)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h3\">",
"     Adverse reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Non-IgE mediated anaphylaxis (previously called anaphylactoid reactions) with intravenous administration and vomiting with oral administration are the most common adverse reactions associated with N-",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?15/41/16022?source=see_link\">",
"     acetylcysteine",
"    </a>",
"    administration.",
"   </p>",
"   <p>",
"    Fluid overload and dosing errors in young children receiving IV NAC have rarely resulted in hyponatremia, seizures, and death. These severe effects can be avoided by following the manufacturer&rsquo;s guidelines for administration in children. (See",
"    <a class=\"local\" href=\"#H36\">",
"     'Administration'",
"    </a>",
"    above.) &nbsp;",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H242387\">",
"    <span class=\"h4\">",
"     Anaphylaxis (anaphylactoid reaction)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anaphylaxis that is not IgE-mediated (previously called an &ldquo;anaphylactoid reaction&rdquo;) may occur in up to 20 percent of adults and children receiving intravenous N-",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?15/41/16022?source=see_link\">",
"     acetylcysteine",
"    </a>",
"    (NAC) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/51/13114/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. Patients with a prior history of asthma appear to be predisposed. Although interruption of the IV NAC infusion is often necessary in these patients, most are able to tolerate resumption of NAC infusion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/29/35290?source=see_link&amp;anchor=H12#H12\">",
"     \"Anaphylaxis: Rapid recognition and treatment\", section on 'Triggers and mechanisms'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients receiving IV NAC warrant close monitoring and immediate availability of oxygen, antihistamine medication (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/29/34256?source=see_link\">",
"     diphenhydramine",
"    </a>",
"    1 and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/1/33815?source=see_link\">",
"     ranitidine",
"    </a>",
"    ),",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/54/39782?source=see_link\">",
"     albuterol",
"    </a>",
"    , epinephrine 1:1000 for intramuscular use, glucocorticoid medication (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/63/17401?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    ), a resuscitation cart, and appropriately sized airway equipment. Thus, NAC infusion should be initiated in clinical settings where critical care monitoring and management is immediately available. Patients who develop anaphylaxis during NAC infusion and are able to continue the infusion should be monitored in a critical care setting for the entire infusion. Patients who tolerate the initial infusion without reaction do not require critical care monitoring for the remaining doses (but may require monitoring for other conditions).",
"   </p>",
"   <p>",
"    In addition to stopping the NAC infusion, a rapid overview provides treatment recommendations for NAC-induced anaphylaxis (",
"    <a class=\"graphic graphic_table graphicRef74242 \" href=\"UTD.htm?17/50/18221\">",
"     table 1",
"    </a>",
"    ). Additional tables demonstrate a method for calculating epinephrine infusion in children with hypotension (",
"    <a class=\"graphic graphic_table graphicRef56049 \" href=\"UTD.htm?2/18/2350\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef66791 \" href=\"UTD.htm?39/39/40573\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Limited observational evidence is available regarding the continuation of intravenous NAC in patients with anaphylaxis, and we encourage consultation with a regional poison control center of medical toxicologist to determine whether NAC infusion should continue after an allergic reaction has occurred. Based upon one small case series, the following approach is suggested [",
"    <a class=\"abstract\" href=\"UTD.htm?12/51/13114/abstract/23\">",
"     23",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients who experience flushing without pruritus or urticaria do not require intervention and the infusion can be continued, unless more severe signs develop.",
"     </li>",
"     <li>",
"      Patients who develop urticaria should have the infusion stopped and be treated with intramuscular epinephrine,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/29/34256?source=see_link\">",
"       diphenhydramine",
"      </a>",
"      , and glucocorticoid medication (",
"      <a class=\"graphic graphic_table graphicRef74242 \" href=\"UTD.htm?17/50/18221\">",
"       table 1",
"      </a>",
"      ). The infusion can be restarted at the prior rate once the urticaria resolves.",
"     </li>",
"     <li>",
"      Patients with angioedema or respiratory symptoms should have the infusion stopped and be treated with epinephrine,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/29/34256?source=see_link\">",
"       diphenhydramine",
"      </a>",
"      , glucocorticoid medication and if wheezing,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/54/39782?source=see_link\">",
"       albuterol",
"      </a>",
"      (",
"      <a class=\"graphic graphic_table graphicRef74242 \" href=\"UTD.htm?17/50/18221\">",
"       table 1",
"      </a>",
"      ). In patients for whom signs and symptoms resolve, the infusion may be started at the prior rate one hour after the administration of epinephrine.",
"     </li>",
"     <li>",
"      Patients who develop hypotension or other persistent systemic anaphylaxis symptoms after IV",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?15/41/16022?source=see_link\">",
"       acetylcysteine",
"      </a>",
"      therapy should have the infusion stopped and receive treatment for anaphylaxis (",
"      <a class=\"graphic graphic_table graphicRef74242 \" href=\"UTD.htm?17/50/18221\">",
"       table 1",
"      </a>",
"      ). IV NAC should not be restarted. Oral NAC therapy should be provided as an alternative. These patients will generally tolerate oral acetylcysteine. If the patient cannot be treated with oral acetylcysteine, the clinician should consult a medical toxicologist or poison control center for guidance. (See",
"      <a class=\"local\" href=\"#H12865251\">",
"       'Additional resources'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H242394\">",
"    <span class=\"h4\">",
"     Vomiting",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 33 percent of subjects treated with oral N-",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?15/41/16022?source=see_link\">",
"     acetylcysteine",
"    </a>",
"    (NAC) develop nausea and vomiting [",
"    <a class=\"abstract\" href=\"UTD.htm?12/51/13114/abstract/24\">",
"     24",
"    </a>",
"    ]. The palatability of NAC can be improved by diluting it to a 5 percent solution in cola or juice, covering the cup, and drinking through a straw. If a patient vomits within 60 minutes of an oral dose of NAC, the dose should be repeated.",
"   </p>",
"   <p>",
"    Antiemetic therapy (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/47/759?source=see_link\">",
"     metoclopramide",
"    </a>",
"    0.1 to 1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    every two to four hours or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/40/27272?source=see_link\">",
"     ondansetron",
"    </a>",
"    0.15",
"    <span class=\"nowrap\">",
"     mg/kg,",
"    </span>",
"    maximum dose: 16 mg) often facilitates administration.",
"   </p>",
"   <p>",
"    Persistent vomiting in spite of antiemetic therapy is an indication to administer NAC intravenously. (See",
"    <a class=\"local\" href=\"#H36\">",
"     'Administration'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H243433\">",
"    <span class=\"h3\">",
"     Duration of treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;While the efficacy of IV and oral administration is similar, controversy persists about the optimal duration of N-",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?15/41/16022?source=see_link\">",
"     acetylcysteine",
"    </a>",
"    (NAC) therapy. The current commonly used treatment protocols are time-based (21 and 72 hours for IV and oral administration, respectively). While these protocols are adequate for the vast majority of patients, it is clear that the 72 hour protocol is longer than needed for many patients while the 21 hour protocol is not long enough for some others. Suggestions for the tailoring of NAC therapy to clinical endpoints based upon the type of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    exposure and clinical status of the patient is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/10/32937?source=see_link&amp;anchor=H12#H12\">",
"     \"Acetaminophen (paracetamol) poisoning in adults: Treatment\", section on 'Duration of treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20063133\">",
"    <span class=\"h3\">",
"     Monitoring during treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Guidelines disagree regarding monitoring during N-",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?15/41/16022?source=see_link\">",
"     acetylcysteine",
"    </a>",
"    treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?12/51/13114/abstract/18,25\">",
"     18,25",
"    </a>",
"    ]. We suggest that patients receiving N-acetylcysteine (NAC) for",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    overdose be monitored according to their clinical condition and the NAC regimen that they receive as follows (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/10/32937?source=see_link&amp;anchor=H14#H14\">",
"     \"Acetaminophen (paracetamol) poisoning in adults: Treatment\", section on 'Monitoring during treatment'",
"    </a>",
"    ): &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       IV NAC initiated within 8 hours of exposure",
"      </strong>",
"      &ndash; These patients typically are asymptomatic and do not have elevations in liver enzymes prior to initiation of NAC therapy. Prior to stopping NAC, we suggest that clinicians measure a serum",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"       acetaminophen",
"      </a>",
"      level and ALT. If the patient has no symptoms, the acetaminophen concentration is undetectable and the ALT is normal, then NAC can be discontinued. Otherwise, IV NAC treatment should be continued at a rate of 6.25",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per hour until these conditions are met. &nbsp;",
"      <br/>",
"      <br/>",
"      Elevation in ALT warrants additional testing as described below. Therapeutic serum concentrations of NAC and high concentrations of acetaminophen can elevate the INR. Elevations due to NAC are usually mild (INR should not be greater than 1.5), occur between 4 and 20 hours post ingestion, and resolve as treatment is continued [",
"      <a class=\"abstract\" href=\"UTD.htm?12/51/13114/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Oral NAC initiated within 8 hours of exposure",
"      </strong>",
"      &ndash; These patients typically are asymptomatic and do not have elevations in liver enzymes prior to initiation of NAC therapy. Serum",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"       acetaminophen",
"      </a>",
"      level should be measured every 12 hours until it is undetectable. ALT should also be obtained at least once prior to the end of the 72 hour course. Elevation in ALT warrants additional testing as described below.",
"     </li>",
"     <li>",
"      <strong>",
"       Elevation in ALT",
"      </strong>",
"      &ndash; We suggest measuring the ALT and INR every 12 hours for any patient who develops ALT elevation or is significantly symptomatic (",
"      <a class=\"graphic graphic_table graphicRef57032 \" href=\"UTD.htm?15/60/16332\">",
"       table 4",
"      </a>",
"      ). More frequent testing does not allow enough time to detect clinically meaningful trends. If the patient develops an ALT greater than 1000",
"      <span class=\"nowrap\">",
"       IU/L,",
"      </span>",
"      coagulopathy (ie, INR &gt;1.5), or encephalopathy, then the serum bicarbonate, glucose, and creatinine should also be measured every 12 hours. Closer monitoring (eg, ICU admission, cardiac monitor) may be indicated based upon the patient's clinical condition if a significant coingestion is known or suspected or other problems arise.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20063259\">",
"    <span class=\"h2\">",
"     Other therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although several other therapies such as",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/58/43943?source=see_link\">",
"     cimetidine",
"    </a>",
"    , methionine,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?6/61/7124?source=see_link\">",
"     cysteamine",
"    </a>",
"    , and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/32/26115?source=see_link\">",
"     dimercaprol",
"    </a>",
"    have been evaluated for treatment of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    poisoning, they have no role in its management. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/10/32937?source=see_link&amp;anchor=H16#H16\">",
"     \"Acetaminophen (paracetamol) poisoning in adults: Treatment\", section on 'Other treatments'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3866366\">",
"    <span class=\"h2\">",
"     Extracorporeal removal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    is cleared by hemodialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/51/13114/abstract/27,28\">",
"     27,28",
"    </a>",
"    ], the safety and efficacy of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?15/41/16022?source=see_link\">",
"     acetylcysteine",
"    </a>",
"    leaves no role for dialysis in the management of acetaminophen poisoning if acetylcysteine is available. Extracorporeal removal may be useful for lowering serum acetaminophen concentrations if acetylcysteine is not available, but there are no systematic studies to evaluate the effectiveness of this treatment. Hemodialysis should never be considered an alternative to acetylcysteine therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     Liver transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Liver transplantation is rarely required in children or adolescents with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    poisoning and is much less commonly employed when compared to adults with acetaminophen hepatotoxicity. The increased availability of liver transplantation has resulted in significant improvement in survival rates for adolescent and adult patients with fulminant hepatic failure as the result of acetaminophen intoxication [",
"    <a class=\"abstract\" href=\"UTD.htm?12/51/13114/abstract/8\">",
"     8",
"    </a>",
"    ]. Although there is insufficient experience with this treatment in younger patients to evaluate the impact on survival, liver transplantation should also be considered for children.",
"   </p>",
"   <p>",
"    Clinical and laboratory criteria have been developed for adults that identify patients with fulminant hepatic failure who are unlikely to survive and should therefore be considered for liver transplantation (",
"    <a class=\"graphic graphic_table graphicRef77717 \" href=\"UTD.htm?26/33/27163\">",
"     table 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/51/13114/abstract/29\">",
"     29",
"    </a>",
"    ]. A retrospective review compared these criteria with clinical and biochemical factors that correlated with significant hepatotoxicity as the result of paracetamol (",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    ) overdose in 51 children [",
"    <a class=\"abstract\" href=\"UTD.htm?12/51/13114/abstract/30\">",
"     30",
"    </a>",
"    ]. The criteria that identified patients who should be considered for liver transplantation were the same for adults and children with the exception of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Delay in treatment was a significant risk factor for children, but not for adults.",
"     </li>",
"     <li>",
"      The serum creatinine level that predicted poor prognosis was lower for children (greater than 200",
"      <span class=\"nowrap\">",
"       micromol/L",
"      </span>",
"      [2.3",
"      <span class=\"nowrap\">",
"       mg/dL])",
"      </span>",
"      than for adults (greater than 300",
"      <span class=\"nowrap\">",
"       micromol/L",
"      </span>",
"      [3.4",
"      <span class=\"nowrap\">",
"       mg/dL]).",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF CHRONIC POISONING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children who have received multiple supratherapeutic doses of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    (&gt;150",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day for more than one to two days) are at risk for hepatotoxicity. There is no consensus regarding the management of these children [",
"    <a class=\"abstract\" href=\"UTD.htm?12/51/13114/abstract/31\">",
"     31",
"    </a>",
"    ]. Consultation with a regional poison control center (1-800-222-1222) or medical toxicologist is advised. (See",
"    <a class=\"local\" href=\"#H12865251\">",
"     'Additional resources'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    One approach is to classify children with repeated overdose into one of three treatment groups based upon the results of the initial evaluation (including serum",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    concentration and aminotransferases, which should be monitored for 36 hours after the last ingested dose) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/51/13114/abstract/2,32\">",
"     2,32",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Those without hepatic injury and no unmetabolized",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"       acetaminophen",
"      </a>",
"     </li>",
"     <li>",
"      Those without liver injury but with unmetabolized",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"       acetaminophen",
"      </a>",
"     </li>",
"     <li>",
"      Those with liver injury (with or without unmetabolized",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"       acetaminophen",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Children in the first category may be discharged home. Their caregivers should receive instruction to avoid",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    for the remainder of the current illness [",
"    <a class=\"abstract\" href=\"UTD.htm?12/51/13114/abstract/2\">",
"     2",
"    </a>",
"    ]. The caregivers of these children also may benefit from education regarding future prevention of such exposures. (See",
"    <a class=\"local\" href=\"#H40\">",
"     'Prevention'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Children without liver injury, but with unmetabolized",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    , are at risk for hepatic injury because they have the potential to generate more toxic metabolite through the cytochrome oxidase system (",
"    <a class=\"graphic graphic_figure graphicRef68213 \" href=\"UTD.htm?20/49/21279\">",
"     figure 2",
"    </a>",
"    ). These patients warrant monitoring of serum alanine aminotransferase, prothrombin time, and supportive care in the hospital. Consultation with a regional poison control center or medical toxicologist should be obtained for recommendations regarding antidotal therapy with N-",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?15/41/16022?source=see_link\">",
"     acetylcysteine",
"    </a>",
"    (NAC). (See",
"    <a class=\"local\" href=\"#H12865251\">",
"     'Additional resources'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Children with a history of multiple supratherapeutic doses of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    that is associated with hepatic injury with or without unmetabolized acetaminophen should receive NAC and supportive care in the hospital. The optimal mode of delivery and the duration of NAC therapy in this setting have not been established in controlled trials [",
"    <a class=\"abstract\" href=\"UTD.htm?12/51/13114/abstract/2,32\">",
"     2,32",
"    </a>",
"    ]. The end-point of therapy in this setting is either resolution of symptoms or liver transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?12/51/13114/abstract/2\">",
"     2",
"    </a>",
"    ]. Those patients with moderate to severe hepatotoxicity at initial evaluation warrant transfer to a liver transplant center [",
"    <a class=\"abstract\" href=\"UTD.htm?12/51/13114/abstract/2,16,33-36\">",
"     2,16,33-36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5383988\">",
"    <span class=\"h1\">",
"     RESUMING ACETAMINOPHEN THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;After an",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    overdose, otherwise healthy children and adolescents may safely resume acetaminophen therapy if the following conditions are met [",
"    <a class=\"abstract\" href=\"UTD.htm?12/51/13114/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      No clinical symptoms",
"     </li>",
"     <li>",
"      Serum",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"       acetaminophen",
"      </a>",
"      level &lt;10",
"      <span class=\"nowrap\">",
"       mcg/mL",
"      </span>",
"      (66",
"      <span class=\"nowrap\">",
"       &micro;mol/L)",
"      </span>",
"     </li>",
"     <li>",
"      Normal serum alanine aminotransferase",
"     </li>",
"     <li>",
"      Normal prothrombin time",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prevention of exploratory",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    intoxication in children involves storage of medications out of the reach of children. Prevention of inappropriate dosing involves education of patients, parents, and caregivers regarding fever management and the safe and judicious use of acetaminophen and other antipyretics.",
"   </p>",
"   <p>",
"    Explicit instructions should be given regarding [",
"    <a class=\"abstract\" href=\"UTD.htm?12/51/13114/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Strictly adhering to the weight-based dosing schedules on the label, with a maximum of five doses per day and a maximum daily dose of 75",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?12/51/13114/abstract/39\">",
"       39",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Avoiding concurrent administration of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"       acetaminophen",
"      </a>",
"      with acetaminophen-containing over-the-counter medications",
"     </li>",
"     <li>",
"      Caution when administering multiple doses of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"       acetaminophen",
"      </a>",
"      to a child who has had decreased oral intake",
"     </li>",
"     <li>",
"      Caution when using rectal suppositories of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"       acetaminophen",
"      </a>",
"      because the absorption characteristics and peak concentration times vary depending upon the preparation [",
"      <a class=\"abstract\" href=\"UTD.htm?12/51/13114/abstract/40-42\">",
"       40-42",
"      </a>",
"      ]; in addition, suppository preparations should not be divided, since it is impossible to know with certainty the dose in each portion [",
"      <a class=\"abstract\" href=\"UTD.htm?12/51/13114/abstract/43\">",
"       43",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Avoidance of the use of adult",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"       acetaminophen",
"      </a>",
"      preparations (325 mg and 500 mg) in children (",
"      <a class=\"graphic graphic_table graphicRef79854 \" href=\"UTD.htm?30/9/30876\">",
"       table 6",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      The fact that there are no data about the safety or efficacy of combined therapy with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"       acetaminophen",
"      </a>",
"      and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/48/7946?source=see_link\">",
"       ibuprofen",
"      </a>",
"      in children, and there are several theoretical risks (especially that of renal injury) [",
"      <a class=\"abstract\" href=\"UTD.htm?12/51/13114/abstract/44-47\">",
"       44-47",
"      </a>",
"      ]; such therapy is not recommended",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The pathophysiology and treatment of fever in infants and children is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/8/18570?source=see_link\">",
"     \"Pathophysiology and management of fever in infants and children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12865251\">",
"    <span class=\"h1\">",
"     ADDITIONAL RESOURCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regional poison control centers in the United States are available at all times for consultation on patients who are critically ill, require admission, or have clinical pictures that are unclear (1-800-222-1222). In addition, some hospitals have clinical",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    medical toxicologists available for bedside consultation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    inpatient care. Whenever available, these are invaluable resources to help in the diagnosis and management of ingestions or overdoses. The World Health Organization provides a listing of international poison centers at its website:",
"    <a class=\"external\" href=\"file://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\">",
"     www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html",
"    </a>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?32/49/33554?source=see_link\">",
"       \"Patient information: Acetaminophen poisoning (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?23/6/23651?source=see_link\">",
"       \"Patient information: Toxic hepatitis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with acute",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"       acetaminophen",
"      </a>",
"      overdose should undergo measurement of serum acetaminophen levels between 4 and 24 hours of ingestion and plotting of the results on the treatment nomogram for acetaminophen poisoning (",
"      <a class=\"graphic graphic_figure graphicRef83590 \" href=\"UTD.htm?24/56/25472\">",
"       figure 1",
"      </a>",
"      ) to determine the poisoning severity. Additional management depends upon the type of exposure and the patient&rsquo;s clinical status. In patients who seek medical attention more than 24 hours after acute ingestion or have ongoing chronic ingestion of supratherapeutic doses of acetaminophen, serum concentrations of acetaminophen do not correlate with toxicity and the treatment nomogram should",
"      <strong>",
"       not",
"      </strong>",
"      be used. However, serum acetaminophen level, along with alanine aminotransferase measurement, and prothrombin time are helpful in determining further treatment. (See",
"      <a class=\"local\" href=\"#H5088338\">",
"       'Approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest treatment with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?32/47/33525?source=see_link\">",
"       activated charcoal",
"      </a>",
"      (AC), 1",
"      <span class=\"nowrap\">",
"       g/kg",
"      </span>",
"      (maximum dose 50 g) by mouth in all children or adolescents who present within four hours of a known or suspected",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"       acetaminophen",
"      </a>",
"      ingestion, unless there are contraindications to its administration such as gastrointestinal obstruction or altered mental status with an unprotected airway (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Asymptomatic patients who present more than four hours after reported acetaminophen ingestions are unlikely to benefit from AC unless they have ingested sustained-release acetaminophen preparations or coingested substances that delay gastrointestinal motility (eg, calcium channel blockers, anticholinergic agents, or opioids). We recommend that children with potentially toxic ingestions of acetaminophen",
"      <strong>",
"       not",
"      </strong>",
"      undergo gastric emptying with either gastric lavage or syrup of ipecac (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H32\">",
"       'Gastrointestinal decontamination'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      We recommend that all patients at significant risk for hepatotoxicity following",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"       acetaminophen",
"      </a>",
"      overdose receive N-",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?15/41/16022?source=see_link\">",
"       acetylcysteine",
"      </a>",
"      (NAC) (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). For patients who present &lt;24 hours after acetaminophen overdose, the risk of hepatotoxicity is based upon plotting of a serum acetaminophen level on the treatment nomogram (",
"      <a class=\"graphic graphic_figure graphicRef83590 \" href=\"UTD.htm?24/56/25472\">",
"       figure 1",
"      </a>",
"      ). NAC may be given intravenously (IV), or orally. Each regimen and its indications are described in the text. NAC is most effective when given within 10 hours of acetaminophen overdose, but may still be of benefit in patients who present &gt;24 hours later. (See",
"      <a class=\"local\" href=\"#H31\">",
"       'Management of acute poisoning'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H33\">",
"       'N-acetylcysteine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      NAC should be administered intravenously to children or adolescents with any of the following (see",
"      <a class=\"local\" href=\"#H36\">",
"       'Administration'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Persistent vomiting despite antiemetic therapy (see",
"      <a class=\"local\" href=\"#H242394\">",
"       'Vomiting'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Contraindications to oral administration (eg, aspiration risk due to altered mental status, pancreatitis, bowel ileus or obstruction, or bowel injury)",
"     </li>",
"     <li>",
"      Hepatic failure (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/10/32937?source=see_link&amp;anchor=H13#H13\">",
"       \"Acetaminophen (paracetamol) poisoning in adults: Treatment\", section on 'Treatment in hepatic failure'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Patients who refuse oral administration",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Anaphylaxis that is not IgE-mediated (previously called an &ldquo;anaphylactoid reaction) may occur in up to 20 percent of patients receiving intravenous (IV) NAC. Patients with asthma appear predisposed. Thus, children and adolescents receiving IV NAC warrant close monitoring and immediate availability of resuscitation drugs and equipment. In addition to stopping the NAC infusion, a rapid overview provides treatment recommendations for NAC-induced anaphylaxis (",
"      <a class=\"graphic graphic_table graphicRef74242 \" href=\"UTD.htm?17/50/18221\">",
"       table 1",
"      </a>",
"      ). Additional tables demonstrate a method for calculating epinephrine infusion in children with hypotension (",
"      <a class=\"graphic graphic_table graphicRef56049 \" href=\"UTD.htm?2/18/2350\">",
"       table 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef66791 \" href=\"UTD.htm?39/39/40573\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H242387\">",
"       'Anaphylaxis (anaphylactoid reaction)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Approximately one-third of patients treated with oral NAC develop nausea and vomiting.",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/40/27272?source=see_link\">",
"       Ondansetron",
"      </a>",
"      and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/47/759?source=see_link\">",
"       metoclopramide",
"      </a>",
"      are useful antiemetics. If the patient vomits within 60 minutes of an oral dose of NAC, the dose should be repeated. (See",
"      <a class=\"local\" href=\"#H242394\">",
"       'Vomiting'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We routinely measure the ALT prior to stopping NAC and continue treatment as long as the ALT is abnormal, as some patients will develop liver injury during the treatment period. We also suggest remeasuring the serum",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"       acetaminophen",
"      </a>",
"      concentration prior to stopping NAC to verify that the level is undetectable. (See",
"      <a class=\"local\" href=\"#H20063133\">",
"       'Monitoring during treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      While these NAC protocols are adequate for the vast majority of patients, it is clear that the 72 hour protocol is longer than needed for many patients while the 21 hour protocol is not long enough for others. Suggestions for the tailoring of NAC therapy to clinical endpoints based upon the type of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"       acetaminophen",
"      </a>",
"      exposure and clinical status of the patient is discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/10/32937?source=see_link&amp;anchor=H12#H12\">",
"       \"Acetaminophen (paracetamol) poisoning in adults: Treatment\", section on 'Duration of treatment'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Management of children with chronic",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"       acetaminophen",
"      </a>",
"      overdoses should occur in consultation with a regional poison control center or medical toxicologist (1-800-222-1222). Children with multiple supratherapeutic ingestions of acetaminophen who do not have liver injury but do have measurable serum acetaminophen levels warrant monitoring of serum alanine aminotransferase, prothrombin time, and supportive care in the hospital. Children with a history of multiple supratherapeutic doses of acetaminophen that is associated with hepatic injury with or without unmetabolized acetaminophen should receive NAC and supportive care in the hospital. Those patients with moderate to severe hepatotoxicity warrant transfer to a liver transplant center. (See",
"      <a class=\"local\" href=\"#H39\">",
"       'Management of chronic poisoning'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The increased availability of liver transplantation has resulted in significant improvement in survival rates for adolescent and adult patients with fulminant hepatic failure as the result of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"       acetaminophen",
"      </a>",
"      intoxication. Although there is insufficient experience with this treatment in younger patients to evaluate the impact on survival, liver transplantation should also be offered to children. Clinical and laboratory criteria have been developed for adults that identify patients with fulminant hepatic failure who are unlikely to survive and should therefore be considered for liver transplantation (",
"      <a class=\"graphic graphic_table graphicRef77717 \" href=\"UTD.htm?26/33/27163\">",
"       table 5",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H38\">",
"       'Liver transplantation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/51/13114/abstract/1\">",
"      Davidson DG, Eastham WN. Acute liver necrosis following overdose of paracetamol. Br Med J 1966; 2:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/51/13114/abstract/2\">",
"      Sztajnkrycer MJ, Bond GR. Chronic acetaminophen overdosing in children: risk assessment and management. Curr Opin Pediatr 2001; 13:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/51/13114/abstract/3\">",
"      Rivera-Penera T, Gugig R, Davis J, et al. Outcome of acetaminophen overdose in pediatric patients and factors contributing to hepatotoxicity. J Pediatr 1997; 130:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/51/13114/abstract/4\">",
"      Heubi JE, Barbacci MB, Zimmerman HJ. Therapeutic misadventures with acetaminophen: hepatoxicity after multiple doses in children. J Pediatr 1998; 132:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/51/13114/abstract/5\">",
"      Dart RC, Rumack BH. Intravenous acetaminophen in the United States: iatrogenic dosing errors. Pediatrics 2012; 129:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/51/13114/abstract/6\">",
"      Gray T, Hoffman RS, Bateman DN. Intravenous paracetamol--an international perspective of toxicity. Clin Toxicol (Phila) 2011; 49:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/51/13114/abstract/7\">",
"      Beringer RM, Thompson JP, Parry S, Stoddart PA. Intravenous paracetamol overdose: two case reports and a change to national treatment guidelines. Arch Dis Child 2011; 96:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/51/13114/abstract/8\">",
"      Brok J, Buckley N, Gluud C. Interventions for paracetamol (acetaminophen) overdose. Cochrane Database Syst Rev 2006; :CD003328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/51/13114/abstract/9\">",
"      Buckley NA, Whyte IM, O'Connell DL, Dawson AH. Activated charcoal reduces the need for N-acetylcysteine treatment after acetaminophen (paracetamol) overdose. J Toxicol Clin Toxicol 1999; 37:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/51/13114/abstract/10\">",
"      Spiller HA, Winter ML, Klein-Schwartz W, Bangh SA. Efficacy of activated charcoal administered more than four hours after acetaminophen overdose. J Emerg Med 2006; 30:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/51/13114/abstract/11\">",
"      Spiller HA, Krenzelok EP, Grande GA, et al. A prospective evaluation of the effect of activated charcoal before oral N-acetylcysteine in acetaminophen overdose. Ann Emerg Med 1994; 23:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/51/13114/abstract/12\">",
"      Underhill TJ, Greene MK, Dove AF. A comparison of the efficacy of gastric lavage, ipecacuanha and activated charcoal in the emergency management of paracetamol overdose. Arch Emerg Med 1990; 7:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/51/13114/abstract/13\">",
"      Smilkstein MJ, Knapp GL, Kulig KW, Rumack BH. Efficacy of oral N-acetylcysteine in the treatment of acetaminophen overdose. Analysis of the national multicenter study (1976 to 1985). N Engl J Med 1988; 319:1557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/51/13114/abstract/14\">",
"      Prescott LF. Treatment of severe acetaminophen poisoning with intravenous acetylcysteine. Arch Intern Med 1981; 141:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/51/13114/abstract/15\">",
"      Keays R, Harrison PM, Wendon JA, et al. Intravenous acetylcysteine in paracetamol induced fulminant hepatic failure: a prospective controlled trial. BMJ 1991; 303:1026.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/51/13114/abstract/16\">",
"      Harrison PM, Keays R, Bray GP, et al. Improved outcome of paracetamol-induced fulminant hepatic failure by late administration of acetylcysteine. Lancet 1990; 335:1572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/51/13114/abstract/17\">",
"      Harrison PM, Wendon JA, Gimson AE, et al. Improvement by acetylcysteine of hemodynamics and oxygen transport in fulminant hepatic failure. N Engl J Med 1991; 324:1852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/51/13114/abstract/18\">",
"      Daly FF, Fountain JS, Murray L, et al. Guidelines for the management of paracetamol poisoning in Australia and New Zealand--explanation and elaboration. A consensus statement from clinical toxicologists consulting to the Australasian poisons information centres. Med J Aust 2008; 188:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/51/13114/abstract/19\">",
"      Tucker JR. Late-presenting acute acetaminophen toxicity and the role of N-acetylcysteine. Pediatr Emerg Care 1998; 14:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/51/13114/abstract/20\">",
"      Kanter MZ. Comparison of oral and i.v. acetylcysteine in the treatment of acetaminophen poisoning. Am J Health Syst Pharm 2006; 63:1821.",
"     </a>",
"    </li>",
"    <li>",
"     www.acetadote.net (Accessed on June 04, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/51/13114/abstract/22\">",
"      Dawson AH, Henry DA, McEwen J. Adverse reactions to N-acetylcysteine during treatment for paracetamol poisoning. Med J Aust 1989; 150:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/51/13114/abstract/23\">",
"      Bailey B, McGuigan MA. Management of anaphylactoid reactions to intravenous N-acetylcysteine. Ann Emerg Med 1998; 31:710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/51/13114/abstract/24\">",
"      Yip L, Dart RC. A 20-hour treatment for acute acetaminophen overdose. N Engl J Med 2003; 348:2471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/51/13114/abstract/25\">",
"      Wallace CI, Dargan PI, Jones AL. Paracetamol overdose: an evidence based flowchart to guide management. Emerg Med J 2002; 19:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/51/13114/abstract/26\">",
"      Whyte IM, Buckley NA, Reith DM, et al. Acetaminophen causes an increased International Normalized Ratio by reducing functional factor VII. Ther Drug Monit 2000; 22:742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/51/13114/abstract/27\">",
"      Wu ML, Tsai WJ, Deng JF, Yang CC. Hemodialysis as adjunctive therapy for severe acetaminophen poisoning: a case report. Zhonghua Yi Xue Za Zhi (Taipei) 1999; 62:907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/51/13114/abstract/28\">",
"      Marbury TC, Wang LH, Lee CS. Hemodialysis of acetaminophen in uremic patients. Int J Artif Organs 1980; 3:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/51/13114/abstract/29\">",
"      O'Grady JG, Alexander GJ, Hayllar KM, Williams R. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology 1989; 97:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/51/13114/abstract/30\">",
"      Mahadevan SB, McKiernan PJ, Davies P, Kelly DA. Paracetamol induced hepatotoxicity. Arch Dis Child 2006; 91:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/51/13114/abstract/31\">",
"      Kozer E, McGuigan M. Approaches toward repeated supratherapeutic doses of paracetamol in children: a survey of medical directors of poison centres in North America and Europe. Drug Saf 2002; 25:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/51/13114/abstract/32\">",
"      Anker AL, Smilkstein MJ. Acetaminophen. Concepts and controversies. Emerg Med Clin North Am 1994; 12:335.",
"     </a>",
"    </li>",
"    <li>",
"     Smilkstein MJ. Acetaminophen. In: Goldfrank's Toxicologic Emergencies, Goldfrank LR, Flomenbaum NE, Lewin NA, et al.  (Eds), Appleton &amp; Lange, Stamford 1998. p.541.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/51/13114/abstract/34\">",
"      Bateman DN, Woodhouse KW, Rawlins MD. Adverse reactions to N-acetylcysteine. Hum Toxicol 1984; 3:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/51/13114/abstract/35\">",
"      Jones AL. Mechanism of action and value of N-acetylcysteine in the treatment of early and late acetaminophen poisoning: a critical review. J Toxicol Clin Toxicol 1998; 36:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/51/13114/abstract/36\">",
"      Kozer E, Koren G. Management of paracetamol overdose: current controversies. Drug Saf 2001; 24:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/51/13114/abstract/37\">",
"      Kearns GL, Leeder JS, Wasserman GS. Acetaminophen intoxication during treatment: what you don't know can hurt you. Clin Pediatr (Phila) 2000; 39:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/51/13114/abstract/38\">",
"      Divoll M, Greenblatt DJ, Ameer B, Abernethy DR. Effect of food on acetaminophen absorption in young and elderly subjects. J Clin Pharmacol 1982; 22:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/51/13114/abstract/39\">",
"      Heubi JE, Bien JP. Acetaminophen use in children: more is not better. J Pediatr 1997; 130:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/51/13114/abstract/40\">",
"      Birmingham PK, Tobin MJ, Henthorn TK, et al. Twenty-four-hour pharmacokinetics of rectal acetaminophen in children: an old drug with new recommendations. Anesthesiology 1997; 87:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/51/13114/abstract/41\">",
"      van Lingen RA, Deinum HT, Quak CM, et al. Multiple-dose pharmacokinetics of rectally administered acetaminophen in term infants. Clin Pharmacol Ther 1999; 66:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/51/13114/abstract/42\">",
"      Cullen S, Kenny D, Ward OC, Sabra K. Paracetamol suppositories: a comparative study. Arch Dis Child 1989; 64:1504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/51/13114/abstract/43\">",
"      Henretig FM, Selbst SM, Forrest C, et al. Repeated acetaminophen overdosing. Causing hepatotoxicity in children. Clinical reports and literature review. Clin Pediatr (Phila) 1989; 28:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/51/13114/abstract/44\">",
"      Mofenson HC, McFee R, Caraccio T, Greensher J. Combined antipyretic therapy: another potential source of chronic acetaminophen toxicity. J Pediatr 1998; 133:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/51/13114/abstract/45\">",
"      Mayoral CE, Marino RV, Rosenfeld W, Greensher J. Alternating antipyretics: is this an alternative? Pediatrics 2000; 105:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/51/13114/abstract/46\">",
"      Rosefsky JB. Alternating antipyretics: is this an alternative? Pediatrics 2001; 108:1236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/51/13114/abstract/47\">",
"      Walker RJ. Paracetamol, nonsteroidal antiinflammatory drugs and nephrotoxicity. N Z Med J 1991; 104:182.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6495 Version 18.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-213.134.24.46-F1BE05E961-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_51_13114=[""].join("\n");
var outline_f12_51_13114=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H41\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5088338\">",
"      APPROACH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3866170\">",
"      Exploratory ingestions in young children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3866179\">",
"      Intentional ingestions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3866187\">",
"      Inappropriate therapeutic dosing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3866195\">",
"      Iatrogenic intravenous overdose",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      MANAGEMENT OF ACUTE POISONING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Gastrointestinal decontamination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      N-acetylcysteine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      - Indications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      - Administration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      - Adverse reactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H242387\">",
"      Anaphylaxis (anaphylactoid reaction)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H242394\">",
"      Vomiting",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H243433\">",
"      - Duration of treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20063133\">",
"      - Monitoring during treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20063259\">",
"      Other therapies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3866366\">",
"      Extracorporeal removal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Liver transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      MANAGEMENT OF CHRONIC POISONING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5383988\">",
"      RESUMING ACETAMINOPHEN THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12865251\">",
"      ADDITIONAL RESOURCES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6495\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6495|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?24/56/25472\" title=\"figure 1\">",
"      Acetaminophen poisoning nomogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?20/49/21279\" title=\"figure 2\">",
"      Acetaminophen metabolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6495|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/50/18221\" title=\"table 1\">",
"      Rapid overview for pediatric anaphylaxis treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/18/2350\" title=\"table 2\">",
"      Example of epinephrine infusion - pediatric 10 kg",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?39/39/40573\" title=\"table 3\">",
"      Example of epinephrine infusion - pediatric 20 kg",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/60/16332\" title=\"table 4\">",
"      Acetaminophen toxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?26/33/27163\" title=\"table 5\">",
"      Kings College criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?30/9/30876\" title=\"table 6\">",
"      Acetaminophen preparations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/43/25274?source=related_link\">",
"      Acetaminophen (paracetamol) poisoning in adults: Pathophysiology, presentation, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/10/32937?source=related_link\">",
"      Acetaminophen (paracetamol) poisoning in adults: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/40/38538?source=related_link\">",
"      Acute liver failure in adults: Management and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/29/35290?source=related_link\">",
"      Anaphylaxis: Rapid recognition and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/60/22474?source=related_link\">",
"      Approach to the child with occult toxic exposure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/42/22186?source=related_link\">",
"      Clinical manifestations and diagnosis of acetaminophen (paracetamol) poisoning in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/1/37913?source=related_link\">",
"      Decontamination of poisoned children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/8/18570?source=related_link\">",
"      Pathophysiology and management of fever in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/49/33554?source=related_link\">",
"      Patient information: Acetaminophen poisoning (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/6/23651?source=related_link\">",
"      Patient information: Toxic hepatitis (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_51_13115="Termination of exercise testing in children";
var content_f12_51_13115=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F57123&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F57123&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Indications for terminating pediatric exercise testing before reaching maximal voluntary capacity level",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        The onset of serious cardiac arrhythmias (eg, ventricular tachycardia, supraventricular tachycardia)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Any appearance of potential hazard to the patient",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Failure of electrocardiographic monitoring system",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Symptoms such as pain, headache, dizziness, or syncope, precipitated by exercise",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Segmental ST depression or elevation &ge;3 mm during exercise",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Arrhythmia (over 25 percent of beats) precipitated or aggravated by exercise",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Recognized types of intracardiac block precipitated by exercise",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Inappropriate rise in blood pressure with systolic pressures exceeding 230 mmHg and diastolic pressures exceeding 120 mmHg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Inappropriate fall in blood pressure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Marked signs of cutaneous vascular insufficiency (eg, pallor)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_51_13115=[""].join("\n");
var outline_f12_51_13115=null;
var title_f12_51_13116="Specimen collection methods IV";
var content_f12_51_13116=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F82682&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F82682&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Microbiology specimen handling and collection - IV",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Specimen",
"       </td>",
"       <td class=\"subtitle1\">",
"        Method",
"       </td>",
"       <td class=\"subtitle1\">",
"        Volume",
"       </td>",
"       <td class=\"subtitle1\">",
"        Storage temperature*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Comments",
"       </td>",
"       <td class=\"subtitle1\">",
"        See UpToDate topic review",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Tissue",
"       </td>",
"       <td>",
"        Transport in sterile container. Keep moist - add sterile (non-bacteriostatic saline) if necessary.",
"       </td>",
"       <td>",
"        As much as possible",
"       </td>",
"       <td>",
"        25&ordm;C",
"       </td>",
"       <td>",
"        Tissue itself provides much better yield than swabs",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"6\" rowspan=\"1\">",
"        Urine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Clean catch or straight catheter",
"       </td>",
"       <td>",
"        Midstream urine in sterile wide-mouth container",
"       </td>",
"       <td>",
"        &ge;1 mL for routine culture (&gt;20 mL for fungal or mycobacterial culture)",
"       </td>",
"       <td>",
"        4&ordm;C",
"       </td>",
"       <td>",
"        Always send urinalysis as well",
"       </td>",
"       <td>",
"        Urine sampling and culture in the diagnosis of urinary tract infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Indwelling catheter",
"       </td>",
"       <td>",
"        Disinfect specimen port with alcohol, remove 5-10 mL of urine with needle and syringe, and transfer into sterile container",
"       </td>",
"       <td>",
"        &ge;1 mL for routine culture (&gt;20 mL for fungal or mycobacterial culture)",
"       </td>",
"       <td>",
"        4&ordm;C",
"       </td>",
"       <td>",
"        Always send urinalysis as well",
"       </td>",
"       <td>",
"        Urine sampling and culture in the diagnosis of urinary tract infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Suprapubic aspirate",
"       </td>",
"       <td>",
"        Sterile container",
"       </td>",
"       <td>",
"        &ge;1 mL for routine culture (&gt;20 mL for fungal or mycobacterial culture)",
"       </td>",
"       <td>",
"        4&ordm;C",
"       </td>",
"       <td>",
"        Always send urinalysis as well",
"       </td>",
"       <td>",
"        Urine sampling and culture in the diagnosis of urinary tract infection",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * If immediate processing is not possible.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_51_13116=[""].join("\n");
var outline_f12_51_13116=null;
var title_f12_51_13117="Staged treatment for childhood obesity";
var content_f12_51_13117=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F54846&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F54846&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Recommendations for treatment of childhood obesity",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Stage",
"       </td>",
"       <td class=\"subtitle1\">",
"        Staff and skills",
"       </td>",
"       <td class=\"subtitle1\">",
"        Nutrition goals",
"       </td>",
"       <td class=\"subtitle1\">",
"        Activity goals",
"       </td>",
"       <td class=\"subtitle1\">",
"        Behavior intervention",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1: Prevention plus",
"       </td>",
"       <td>",
"        Primary care provider",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Encourage consumption of 5 or more servings of vegetables or fruit daily",
"         </li>",
"         <li>",
"          Minimize sugared beverages",
"         </li>",
"         <li>",
"          Eat breakfast every day",
"         </li>",
"         <li>",
"          Eat most meals at home and as a family",
"         </li>",
"        </ul>",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Less than 2 hours of television or other screen time per day",
"         </li>",
"         <li>",
"          More than 1 hour of physical activity daily",
"         </li>",
"        </ul>",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Reinforce goals at each health care visit, additional visits as tolerated",
"         </li>",
"         <li>",
"          Allow child to self-regulate, avoid overly strict eating regimens",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        2: Structured weight management",
"       </td>",
"       <td rowspan=\"2\">",
"        Primary care physician or provider with additional training in nutrition or behavioral counseling (eg, dietitian)",
"       </td>",
"       <td>",
"        Stage 1 plus:",
"       </td>",
"       <td>",
"        Stage 1 plus:",
"       </td>",
"       <td rowspan=\"2\">",
"        <ul>",
"         <li>",
"          Monthly patient-provider contact",
"         </li>",
"         <li>",
"          Monitor eating and physical activities through logs",
"         </li>",
"         <li>",
"          Use positive reinforcement techniques (reward system)",
"         </li>",
"         <li>",
"          Strong parental involvement for school-aged children",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <ul>",
"         <li>",
"          Daily eating plan, with scheduled meals and snacks",
"         </li>",
"         <li>",
"          Emphasize foods with low energy density",
"         </li>",
"         <li>",
"          Reduce frequency and quantity of foods with high energy density (eg, fried foods, baked goods, fats)",
"         </li>",
"         <li>",
"          Limit portion size",
"         </li>",
"         <li>",
"          Set explicit behavior goals",
"         </li>",
"        </ul>",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Less than 1 hour of television or other screen time daily",
"         </li>",
"         <li>",
"          More than 1 hour of physical activity daily, supervised and structured",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        3: Comprehensive multidisciplinary intervention",
"       </td>",
"       <td rowspan=\"2\">",
"        Multidisciplinary team with childhood obesity expertise OR primary care-based program with counselor, dietitian, and use of structured outside activity program",
"       </td>",
"       <td>",
"        Stage 2 plus:",
"       </td>",
"       <td rowspan=\"2\">",
"        Similar to stage 2, supported by behavioral interventions",
"       </td>",
"       <td rowspan=\"2\">",
"        <ul>",
"         <li>",
"          Weekly patient-provider contact (and/or phone)",
"         </li>",
"         <li>",
"          Similar, but with increased structure and accountability",
"         </li>",
"         <li>",
"          Parent training in behavioral techniques to improve home eating and activity environment",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <ul>",
"         <li>",
"          Structured diet and physical activity designed for negative energy balance",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        4: Tertiary care intervention",
"       </td>",
"       <td>",
"        Multidisciplinary team with childhood obesity expertise, including obesity medicine physician to rigorously assess comorbidities",
"       </td>",
"       <td colspan=\"3\">",
"        As guided by established protocols. Various modalities are available, including: highly structured diets, medications, or bariatric surgery.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Most children 2 years and older who are overweight or obese start at stage 1 (Prevention plus). Those who are older than 6 years progress to higher stages if there is no improvement in BMI percentile or trend after 3 to 6 months of treatment. Initiating treatment at higher stages of intervention is appropriate for children who are older, more severely obese (BMI &gt;99th percentile) and motivated.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Based on information from: Spear BA, Barlow SE, Ervin C, et al. Recommendations for treatment of child and adolescent overweight and obesity. Pediatrics 2007; 120:S254.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_51_13117=[""].join("\n");
var outline_f12_51_13117=null;
var title_f12_51_13118="Exercise testing protocols";
var content_f12_51_13118=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F70044&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F70044&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Treadmill exercise testing protocols",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup width=\"10%\">",
"     </colgroup>",
"     <colgroup span=\"6\" width=\"15%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Protocol name",
"       </td>",
"       <td class=\"subtitle1\">",
"        Stage",
"       </td>",
"       <td class=\"subtitle1\">",
"        Grade",
"        <br/>",
"        (percent)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Speed",
"        <br/>",
"        (mph)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Total time",
"        <br/>",
"        (min)",
"       </td>",
"       <td class=\"subtitle1\">",
"        O2 uptake",
"        <br/>",
"        (mL/kg/min)",
"       </td>",
"       <td class=\"subtitle1\">",
"        METS*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Modified Bruce",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td class=\"centered\">",
"        0",
"       </td>",
"       <td class=\"centered\">",
"        0",
"       </td>",
"       <td class=\"centered\">",
"        1.7",
"       </td>",
"       <td class=\"centered\">",
"        3",
"       </td>",
"       <td class=\"centered\">",
"        9",
"       </td>",
"       <td class=\"centered\">",
"        2.3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        1/2",
"       </td>",
"       <td class=\"centered\">",
"        5",
"       </td>",
"       <td class=\"centered\">",
"        1.7",
"       </td>",
"       <td class=\"centered\">",
"        3",
"       </td>",
"       <td class=\"centered\">",
"        13",
"       </td>",
"       <td class=\"centered\">",
"        3.4",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"4\">",
"        Bruce",
"       </td>",
"       <td class=\"centered\">",
"        1",
"       </td>",
"       <td class=\"centered\">",
"        10",
"       </td>",
"       <td class=\"centered\">",
"        1.7",
"       </td>",
"       <td class=\"centered\">",
"        3",
"       </td>",
"       <td class=\"centered\">",
"        17",
"       </td>",
"       <td class=\"centered\">",
"        4.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        2",
"       </td>",
"       <td class=\"centered\">",
"        12",
"       </td>",
"       <td class=\"centered\">",
"        2.5",
"       </td>",
"       <td class=\"centered\">",
"        6",
"       </td>",
"       <td class=\"centered\">",
"        25",
"       </td>",
"       <td class=\"centered\">",
"        7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        3",
"       </td>",
"       <td class=\"centered\">",
"        14",
"       </td>",
"       <td class=\"centered\">",
"        3.4",
"       </td>",
"       <td class=\"centered\">",
"        9",
"       </td>",
"       <td class=\"centered\">",
"        35",
"       </td>",
"       <td class=\"centered\">",
"        10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        4",
"       </td>",
"       <td class=\"centered\">",
"        16",
"       </td>",
"       <td class=\"centered\">",
"        4.2",
"       </td>",
"       <td class=\"centered\">",
"        12",
"       </td>",
"       <td class=\"centered\">",
"        47",
"       </td>",
"       <td class=\"centered\">",
"        13",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"9\">",
"        Cornell",
"       </td>",
"       <td class=\"centered\">",
"        1",
"       </td>",
"       <td class=\"centered\">",
"        0",
"       </td>",
"       <td class=\"centered\">",
"        1.7",
"       </td>",
"       <td class=\"centered\">",
"        2",
"       </td>",
"       <td class=\"centered\">",
"        7",
"       </td>",
"       <td class=\"centered\">",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        2",
"       </td>",
"       <td class=\"centered\">",
"        5",
"       </td>",
"       <td class=\"centered\">",
"        1.7",
"       </td>",
"       <td class=\"centered\">",
"        4",
"       </td>",
"       <td class=\"centered\">",
"        11",
"       </td>",
"       <td class=\"centered\">",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        3",
"       </td>",
"       <td class=\"centered\">",
"        10",
"       </td>",
"       <td class=\"centered\">",
"        1.7",
"       </td>",
"       <td class=\"centered\">",
"        6",
"       </td>",
"       <td class=\"centered\">",
"        17",
"       </td>",
"       <td class=\"centered\">",
"        4.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        4",
"       </td>",
"       <td class=\"centered\">",
"        11",
"       </td>",
"       <td class=\"centered\">",
"        2.1",
"       </td>",
"       <td class=\"centered\">",
"        8",
"       </td>",
"       <td class=\"centered\">",
"        19",
"       </td>",
"       <td class=\"centered\">",
"        5.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        5",
"       </td>",
"       <td class=\"centered\">",
"        12",
"       </td>",
"       <td class=\"centered\">",
"        2.5",
"       </td>",
"       <td class=\"centered\">",
"        10",
"       </td>",
"       <td class=\"centered\">",
"        25",
"       </td>",
"       <td class=\"centered\">",
"        7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        6",
"       </td>",
"       <td class=\"centered\">",
"        13",
"       </td>",
"       <td class=\"centered\">",
"        3.0",
"       </td>",
"       <td class=\"centered\">",
"        12",
"       </td>",
"       <td class=\"centered\">",
"        30",
"       </td>",
"       <td class=\"centered\">",
"        8.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        7",
"       </td>",
"       <td class=\"centered\">",
"        14",
"       </td>",
"       <td class=\"centered\">",
"        3.4",
"       </td>",
"       <td class=\"centered\">",
"        14",
"       </td>",
"       <td class=\"centered\">",
"        35",
"       </td>",
"       <td class=\"centered\">",
"        10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        8",
"       </td>",
"       <td class=\"centered\">",
"        15",
"       </td>",
"       <td class=\"centered\">",
"        3.8",
"       </td>",
"       <td class=\"centered\">",
"        16",
"       </td>",
"       <td class=\"centered\">",
"        40",
"       </td>",
"       <td class=\"centered\">",
"        11.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        9",
"       </td>",
"       <td class=\"centered\">",
"        16",
"       </td>",
"       <td class=\"centered\">",
"        4.2",
"       </td>",
"       <td class=\"centered\">",
"        18",
"       </td>",
"       <td class=\"centered\">",
"        47",
"       </td>",
"       <td class=\"centered\">",
"        13",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"7\">",
"        Naughton",
"       </td>",
"       <td class=\"centered\">",
"        1",
"       </td>",
"       <td class=\"centered\">",
"        0",
"       </td>",
"       <td class=\"centered\">",
"        2.0",
"       </td>",
"       <td class=\"centered\">",
"        2",
"       </td>",
"       <td class=\"centered\">",
"        7",
"       </td>",
"       <td class=\"centered\">",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        2",
"       </td>",
"       <td class=\"centered\">",
"        3.5",
"       </td>",
"       <td class=\"centered\">",
"        2.0",
"       </td>",
"       <td class=\"centered\">",
"        4",
"       </td>",
"       <td class=\"centered\">",
"        10.5",
"       </td>",
"       <td class=\"centered\">",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        3",
"       </td>",
"       <td class=\"centered\">",
"        7.0",
"       </td>",
"       <td class=\"centered\">",
"        2.0",
"       </td>",
"       <td class=\"centered\">",
"        6",
"       </td>",
"       <td class=\"centered\">",
"        14",
"       </td>",
"       <td class=\"centered\">",
"        4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        4",
"       </td>",
"       <td class=\"centered\">",
"        10.5",
"       </td>",
"       <td class=\"centered\">",
"        2.0",
"       </td>",
"       <td class=\"centered\">",
"        8",
"       </td>",
"       <td class=\"centered\">",
"        17.5",
"       </td>",
"       <td class=\"centered\">",
"        5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        5",
"       </td>",
"       <td class=\"centered\">",
"        14.0",
"       </td>",
"       <td class=\"centered\">",
"        2.0",
"       </td>",
"       <td class=\"centered\">",
"        10",
"       </td>",
"       <td class=\"centered\">",
"        21.0",
"       </td>",
"       <td class=\"centered\">",
"        6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        6",
"       </td>",
"       <td class=\"centered\">",
"        17.5",
"       </td>",
"       <td class=\"centered\">",
"        2.0",
"       </td>",
"       <td class=\"centered\">",
"        12",
"       </td>",
"       <td class=\"centered\">",
"        24.5",
"       </td>",
"       <td class=\"centered\">",
"        7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        7",
"       </td>",
"       <td class=\"centered\">",
"        12.5",
"       </td>",
"       <td class=\"centered\">",
"        3.0",
"       </td>",
"       <td class=\"centered\">",
"        14",
"       </td>",
"       <td class=\"centered\">",
"        28",
"       </td>",
"       <td class=\"centered\">",
"        8",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Metabolic equivalents - 1 MET = 3.5 mL O2/kg/min.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     Stages 1 through 4 of the Modified Bruce protocol are identical to stages 1 through 4 of the standard Bruce protocol.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_51_13118=[""].join("\n");
var outline_f12_51_13118=null;
var title_f12_51_13119="Monopolar electrosurgical instrument";
var content_f12_51_13119=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F56659&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F56659&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 542px\">",
"   <div class=\"ttl\">",
"    Monopolar electrosurgical instrument",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 522px; height: 222px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted from: www.encision.com/tech.html Copyright &copy; 2006 Encision Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_51_13119=[""].join("\n");
var outline_f12_51_13119=null;
